The Aleth Briefs trace each story to its original source and show how the week unfolded.

The week in five lines:

• Moderna’s mRNA delivered landmark phase 3 cancer data, adding $50bn in value.

• Trump nominated White House aide Heidi Overton to run the FDA.

• AstraZeneca won two late-stage lung cancer trials and stopped another.

• argenx’s Vyvgart Hytrulo met its phase 3 myositis endpoint.

• Regeneron won FDA approval for FOP drug Pasatru.

Browse by day:

• Weekend catch-up: Skye-Redx · Lantheus Alzheimer’s · Biogen felzartamab

• Monday: AZ lung trials · argenx · EyePoint · Sandoz-Henlius · Slate-Fulcrum

• Tuesday: Amylyx · LEO-Tanabe · BioMarin-Alesta · Teva · Biokin · China trial deaths

• Wednesday: Moderna-Merck · Regeneron · Ultragenyx · US FDA pick · Aurinia-Teva

• Thursday: UK weekly insulin

Weekend catch-up

Redx Pharma agreed a reverse merger with Nasdaq-listed Skye Bioscience to create Fibrx Therapeutics, backed by $125m of concurrent financing.

The deal finally gives Redx the US public-market listing it has pursued since its failed 2023 reverse with Jounce and 2024 AIM delisting. Fibrx will be built around Redx's fibrosis pipeline and led by its management. The $125m is expected to fund it into 2029 and through phase 2 topline data for lead asset RXC008 in H2 2028.

• Skye Bioscience & Redx Pharma transaction and $125m financings · Skye Bioscience

The FDA approved Lantheus’ tau PET imaging agent for Alzheimer’s disease.

Tauklarify (florquinitau F 18, previously MK-6240) is cleared to image tau neurofibrillary tangle pathology in adults with cognitive impairment being evaluated for Alzheimer’s disease, complementing amyloid PET. The approval comes as Lantheus is being acquired by radiopharma rival Curium in a deal worth up to $8bn.

• FDA approval of TAUKLARIFY Tau PET Imaging Agent for Alzheimer’s · Lantheus

Biogen’s antibody felzartamab won its first approval anywhere, in China.

The anti-CD38 antibody was approved for multiple myeloma, its first authorisation anywhere. More important for Biogen, felzartamab is also in global phase 3 trials in immune-mediated diseases, where the company sees the larger opportunity.

• TJ Biopharma & Biogen first global approval of felzartamab China · TJ Biopharma

Monday 17 August

AstraZeneca won two late-stage lung cancer trials and stopped another.

In DESTINY-Lung04, Enhertu, partnered with Daiichi Sankyo, improved progression-free survival (PFS) over chemotherapy plus Keytruda as first-line treatment of HER2-mutant advanced non-small cell lung cancer. In SAFFRON, Tagrisso plus Orpathys, partnered with HUTCHMED, improved PFS and overall survival in EGFR-mutated disease with high MET overexpression after progression on Tagrisso.

The data extend AstraZeneca’s position in molecularly defined lung cancer, although they came on the same day it discontinued a separate Phase 3 trial of volrustomig.

• Enhertu improved survival 1st-line advanced NSCLC DESTINY-Lung04 · AstraZeneca

• Tagrisso+Orpathys improved survival in EGFR-mutated lung cancer · AstraZeneca

• Update on eVOLVE-Lung02 Phase III of volrustomig in NSCLC · AstraZeneca

argenx’s Vyvgart Hytrulo met its phase 3 endpoint in myositis.

In the ALKIVIA trial, Vyvgart Hytrulo (efgartigimod) delivered a 15.4-point greater improvement in mean Total Improvement Score at week 52 than placebo (p=0.0011) across the combined immune-mediated necrotising myopathy and dermatomyositis population, with benefit from week 4. It is the first phase 3 trial to show a benefit in immune-mediated necrotising myopathy, which has no approved therapy.

• Positive Topline Results Phase 3 ALKIVIA efgartigimod autoimmune myositis · argenx

EyePoint’s Duravyu missed its primary endpoint in wet AMD.

In LUGANO, the first of two phase 3 trials, Duravyu (vorolanib) failed to meet its prespecified non-inferiority endpoint against Eylea on mean change in best corrected visual acuity. EyePoint said the result was affected by nine patients, about 4% of the cohort, with vision loss it considered unrelated to wet AMD. An ad hoc analysis excluding those patients met the non-inferiority threshold. The company still plans to file in H1 2027, subject to results from the identical LUCIA trial due in Q4 2026.

• Topline Data LUGANO, first of two Phase 3 trials DURAVYU Wet AMD · EyePoint

Sandoz agreed to pay up to $322m for three Henlius biosimilars.

Shanghai Henlius granted Sandoz exclusive registration and commercialisation rights outside China to as many as 10 proposed antibody and antibody-drug conjugate biosimilars, with proposed cetuximab, evolocumab and belimumab copies first. Sandoz pays up to $322m in total, of which up to $100.5m is invoiced in 2026.

• Sandoz strategic collaboration unlock value of biosimilars Platform · Henlius

Slate agreed a merger with Fulcrum Therapeutics and $245m in commitments.

The all-stock merger would take migraine developer Slate onto Nasdaq, alongside a committed $245m private placement led by Frazier Life Sciences. The combined company will retain the Slate name. Lead asset SLTE-1009 is a subcutaneous anti-PACAP/VIP antibody, and the financing is expected to fund operations into 2029.

• Fulcrum Therapeutics and Slate Medicines announce merger agreement · Fulcrum

Tuesday 18 August

Amylyx’s GLP-1 antagonist avexitide cut hypoglycaemic events by more than half in phase 3.

In the LUCIDITY trial in 78 patients with post-bariatric hypoglycaemia after gastric bypass, avexitide reduced the composite rate of Level 2 and Level 3 hypoglycaemic events by 55% versus placebo (p=0.000003) and met every secondary endpoint. Amylyx plans to file by year-end for a condition with no approved treatment.

• Positive topline Phase 3 LUCIDITY Avexitide Post-Bariatric Hypoglycemia · Amylyx

LEO Pharma agreed to acquire worldwide rights to dersimelagon from Tanabe Pharma for up to $435m.

Dersimelagon is an oral MC1R agonist for erythropoietic protoporphyria and X-linked protoporphyria. It has completed phase 3, is filed and awaits an FDA decision. The deal gives LEO a late-stage rare-disease asset close to potential launch in dermatology.

• LEO Pharma strengthens late-stage pipeline acquisition dersimelagon · LEO Pharma

BioMarin agreed to buy Alesta Therapeutics for $275m upfront.

The deal brings ALE1, an oral small molecule that could become the first oral therapy for hypophosphatasia, a rare bone disease. Alesta will spin out its other assets before closing, expected this quarter. ALE1 adds to BioMarin’s skeletal conditions portfolio.

• Acquiring Alesta Therapeutics ALE1, potential first oral Hypophosphatasia · BioMarin

A federal appeals court handed Teva a partial win against Medicare price negotiations.

The US Court of Appeals for the D.C. Circuit sent back to a lower court the question of whether CMS's “bona fide marketing” standard, which determines when a drug becomes eligible for negotiation, complies with the Inflation Reduction Act. The court did not rule that the standard itself was unlawful. Teva's broader constitutional challenges were unsuccessful.

• Teva Pharmaceuticals v. Kennedy, No. 25-5425, opinion · US Court of Appeals

• Teva scores rare partial win in CMS price negotiation appeal · Fierce Pharma

Biokin’s iza-bren, partnered with BMS, met its phase 3 endpoint in lung cancer.

In the China BL-B01D1-301 trial, the EGFR×HER3 bispecific ADC met its primary progression-free survival endpoint at an interim analysis in EGFR-mutated non-small cell lung cancer after EGFR-TKI treatment, with a positive trend in overall survival. It is the fourth phase 3 study in which iza-bren has met its primary endpoint.

• Meeting primary endpoint interim analysis phase III iza-bren NSCLC · SINA

• Biokin, BMS’ bispecific ADC hits goal in China lung cancer trial · Fierce Pharma

A third patient death was reported in China's investigator-initiated cell and gene therapy trials.

Endpoints reported a previously undisclosed death in a CAR-T study, following two recently reported deaths in experimental gene-therapy trials. The cases have increased scrutiny of transparency and oversight in China’s investigator-initiated trial (IIT) system.

• Third death revealed in China’s popular but opaque trials · Endpoints News

• After 2 deaths, can China’s alternative regulatory path be trusted? · Fierce Biotech

Wednesday 19 August

Moderna’s mRNA cancer therapy met two phase 3 endpoints in melanoma.

In INTerpath-001, intismeran autogene, Moderna’s personalised mRNA neoantigen therapy, plus Merck’s Keytruda beat Keytruda alone on recurrence-free survival and distant metastasis-free survival at a prespecified interim analysis in patients with completely resected stage IIB-IV melanoma. The trial continues to evaluate other secondary endpoints, including overall survival.

It is the first positive phase 3 trial of an individualised neoantigen therapy and the first for an mRNA cancer therapy. The result validates a personalised treatment model in which tumour sequencing, computational neoantigen selection and patient-specific mRNA manufacturing are combined to generate anti-tumour T-cell responses in vivo. Moderna shares rose 177%, adding about $45bn to its market value, reflecting the broader potential of the platform beyond melanoma.

• Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA Met Endpoints of RFS and DMFS in Melanoma · Moderna

Regeneron won FDA approval for FOP drug Pasatru.

Pasatru, an antibody targeting Activin A, was approved to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva, the ultra-rare disease in which soft tissue turns to bone. In the phase 3 trial, two doses reduced new lesions by 90% and 94% vs placebo at 56 weeks.

• Pasatru first only FDA-approved heterotopic ossification lesions FOP · Regeneron

Ultragenyx won its first gene therapy approval, in a rare metabolic disease.

The FDA granted accelerated approval to Genglycos for patients eight and older with glycogen storage disease type Ia. Genglycos is designed to address enzyme deficiency and reduce dependence on cornstarch used to maintain blood glucose. It is Ultragenyx’s first marketed gene therapy, and came with a Priority Review Voucher.

• Ultragenyx announces U.S. FDA approval of GENGLYCOS gene therapy · Ultragenyx

Trump picked Heidi Overton to run the FDA.

The president nominated White House policy aide Heidi Overton, M.D., Ph.D., as FDA commissioner. She faces Senate confirmation and would take over an agency that has lost around one in six of its staff over the past year (>3,000), after months of leadership turnover and regulatory controversy. Reuters reported concern among drugmakers and FDA staff over her limited management experience.

• Trump selects Heidi Overton as FDA commissioner · Truth Social

• Trump picks White House ally Overton to lead embattled FDA · Reuters

The FDA cleared the first standalone robotic blood-draw device.

The FDA authorised Vitestro's Aletta through the De Novo pathway, the first standalone robotic device able to draw blood from a patient's arm without hands-on intervention. It uses near-infrared imaging and ultrasound to locate a vein and automates the draw. A phlebotomist supervises up to three devices, with sensors that stop or pause the procedure if the patient moves or another safety issue is detected. FDA said success rates were comparable with or better than trained phlebotomists.

• FDA Authorizes First-of-Its-Kind Robotic Blood Draw Device · FDA

A US appeals court sided with Parse Biosciences over 10x Genomics on patents.

The Federal Circuit upheld the Patent Trial and Appeal Board's invalidation of three 10x Genomics patents in its dispute with Qiagen-owned Parse Biosciences. The ruling removes three patents from 10x's enforcement arsenal in the single-cell sequencing market, where the two companies compete directly.

• 25-1199: 10X Genomics, Inc. v. Parse Biosciences, Inc. [Opinion], Nonprecedential · US Court of Appeals for the Federal Circuit

Aurinia settled with Teva over Lupkynis generic entry in December 2036.

The settlement allows Teva to launch its generic version of Lupkynis (voclosporin) in the US no earlier than 7 December 2036, subject to defined contingencies and FDA approval. Teva also acknowledged two Aurinia patents as valid, enforceable and infringed by its proposed product. Aurinia continues to litigate separate generic challenges from other companies, so the agreement does not resolve all generic risk.

• Aurinia Settles Patent Litigation with Teva · Aurinia Pharmaceuticals

• Aurinia deal with Teva keeps Lupkynis generic in check until ‘36 · Fierce Pharma

Thursday 20 August

NICE backed Lilly’s weekly insulin Onswik for the NHS.

The cost watchdog recommended insulin efsitora alfa, also known as Onswik, for type 2 diabetes in final draft guidance. It controls blood glucose as well as widely used long-acting insulins while cutting injections by 85%, from daily to once a week. NICE said it could particularly benefit people who rely on a carer or nurse for injections. The recommendation remains subject to MHRA licensing before NHS use.

• Weekly insulin jab could cut injections from 365 a year to just 52 · NICE

ALETH · OPEN ACCESS RESEARCH

aleth.co

Automated analysis from the Aleth AI Corpus · primary release

Summary

Revenue landed in line with the July pre-close at £116.7m, +10.5% reported / +12.3% constant currency, with the same geographic split: EMEAI and AMR grew, while China and the prior-year Singapore programme pulled APAC lower.

The more material change versus the trading update is the disclosed profit progression. Gross margin rose 400bps to 62.2% and the adjusted EBITDA loss more than halved to £(22.1)m from £(48.3)m, helped by gross-profit growth and adjusted operating costs falling 6.9% year-on-year.

Management also made the July licensing support explicit. An unnamed global diagnostics company will pay a $20m non-recurring cross-licence fee, recognised in H2 FY26 at 100% gross margin, plus $15m of committed product purchases across FY27-28 and a low-to-mid-single-digit royalty.

FY26 underlying CC revenue guidance remains 16-20% excluding the fee; including it, headline guidance is now framed as 23-27% CC. FY27 adjusted EBITDA breakeven and FY28 positive free cash flow remain unchanged. New 2030 targets are revenue above $700m and adjusted EBITDA margin above 15%.

Headline financials

£m unless stated            │   H1 2026 │       H1 2025 │ Change
----------------------------+-----------+---------------+------------------------------
Revenue                     │     116.7 │         105.6 │ +10.5% reported / +12.3% CC
Gross profit                │      72.6 │          61.4 │ +18.2%
Gross margin                │     62.2% │         58.2% │ +400bps
Adjusted EBITDA             │    (22.1) │        (48.3) │ +£26.2m
Loss from operations        │    (50.7) │        (77.8) │ +£27.1m
Loss for the period         │    (48.0) │        (71.8) │ +£23.8m
Cash and liquid investments │     234.5 │ 302.8 at FY25 │ (68.3) since year-end

Revenue mix

By customer end-market

End-market │ H1 2026 revenue │ Share of group │ Growth
-----------+-----------------+----------------+--------
Research   │          £76.0m │          65.1% │ +5.4%
Clinical   │          £17.6m │          15.1% │ +35.4%
Industrial │          £13.7m │          11.7% │ +6.2%
BioPharma  │           £9.5m │           8.1% │ +25.0%

• Clinical remained the fastest-growing end-market and BioPharma also grew well, but Research still supplied almost two-thirds of group revenue.

• Research absorbed an approximately £4.7m headwind from completed Genomics England and NIHR programmes.

• Clinical conversion was slowed in places by reimbursement, competitive pricing, evidence requirements and product timing.

• BioPharma by validation, contracting, product availability and customer capital constraints.

By region

Region │ H1 2026 revenue │ Reported growth │ CC growth
-------+-----------------+-----------------+----------
EMEAI  │          £55.6m │          +24.7% │    +23.8%
AMR    │          £39.1m │           +8.6% │    +12.5%
APAC   │          £22.0m │          (11.6)% │    (8.4)%

• China declined 15.7%, reflecting export controls and changes to commercial operations. ONT says China remains strategically important and that steps are under way to return it to growth in 2027.

• APAC also carried a £3.6m prior-year headwind from completion of Singapore’s PRECISE II programme.

• AMR included £0.9m of shipments that slipped into July, a 2.5% growth impact, alongside continued US research-funding pressure.

By product

• PromethION £59.1m, +15.7%, driven mainly by P2i demand. PromethION Flow Cell volume rose by more than 20%.

• MinION range £28.8m, +4.3%.

• Other revenue £28.9m, +7.4%.

• Devices and Services £37.0m, +32.6%; Consumables £79.7m, +2.7%. Consumables were held back by completed large research projects and China.

Margin, costs and cash

• The 400bps gross-margin increase comprised 305bps of underlying benefit from Flow Cell yields, scale and adoption of the new pricing model, plus 315bps from non-recurrence of H1 2025’s £3.3m inventory charge, offset by product mix (160bps) and FX (60bps).

• ONT disclosed gross margin of approximately 75% for Consumables and 34% for Devices & Services, versus approximately 64% and 23% respectively in FY2023.

• Adjusted operating costs fell 6.9% year-on-year and 9.6% versus H2 2025. Average headcount fell 0.8% to 1,314: R&D headcount fell 11.9% to 450, while Production rose 13.1% to 190 and SG&A rose 4.3% to 674.

• Total R&D investment fell 16.0% to £43.0m. Of this, £24.0m was capitalised and £17.9m of prior capitalised development was amortised; adjusted R&D expense was £36.9m.

• Cash and liquid investments fell £68.3m to £234.5m. Net operating cash outflow was £42.8m, including a £24.2m working-capital outflow and £25.7m of FY25 bonus payments. Capitalised development cash spend was £24.5m.

Strategy reset and post-period developments

CEO Francis Van Parys’s initial review produced four operating priorities:

1. Customer-centric growth in selected high-value BioPharma, Clinical and Research applications.

2. Focused innovation that turns technology leadership into dependable, scalable products and workflows.

3. Disciplined execution through portfolio simplification, clearer ownership, manufacturing quality and return-on-investment controls.

4. High-performance culture, including deeper regulatory and GMP-ready capabilities.

Other developments:

• Global diagnostics cross-licence: $20m fee in H2 FY26, $15m committed purchases over FY27-28, plus a low-to-mid-single-digit net royalty for the life of the relevant patents. Counterparty and licensed IP were not identified.

• MyOme/Natera: agreement to incorporate ONT sequencing into MyOme’s Zenith rare-disease platform.

• GridION Dx: first ONT IVD device registered in the UK and Europe (CE and UKCA).

• Leadership: Davide Manissero joined as Chief Medical Officer in August; Conor McKechnie is due to join as Chief Marketing and Communications Officer in October.

Outlook (company guidance)

• FY26 revenue: +16-20% CC excluding the $20m fee; approximately +23-27% CC including it.

• FY26 gross margin: approximately 62% excluding the fee; approximately 64% including it.

• FY26 adjusted operating costs: (2)% to 0% year-on-year, tightened from 0-5% growth.

• FY27: adjusted EBITDA breakeven.

• FY28: positive and growing free cash flow.

• 2030: revenue above $700m, based on organic CC growth of approximately mid-teens and accelerating from an FY26 base excluding the fee; adjusted EBITDA margin above 15%.

• Longer term: ambition for annual revenue above $1bn.

Read-through and what to watch

The results confirm the July revenue shortfall but show a materially stronger cost and margin response than the pre-close disclosed. The quality distinction in FY26 guidance is now measurable: the cross-licence is non-recurring, carries 100% gross margin and accounts for the gap between the 16-20% underlying range and the 23-27% headline range. The core business still requires a substantially stronger H2, while the licence makes reported revenue, gross margin and EBITDA look better without representing recurring product demand.

Key follow-ups:

• identity of the diagnostics counterparty, scope of the licensed IP and potential royalty base;

• delivery of the H2 product-revenue acceleration behind the 16-20% underlying range;

• whether China returns to growth in 2027 as management intends;

• conversion of Clinical and BioPharma evaluations into scaled, recurring consumable demand;

• cash conversion after the seasonal H1 working-capital and bonus outflows; and

• how much of continued product development is expensed versus capitalised as ONT approaches FY27 breakeven.

Relevance

For Oxford Nanopore, this is the first full results presentation under Van Parys and the first quantified strategy reset. It preserves the applied-market thesis, demonstrates real manufacturing and cost progress, and makes the non-recurring support to FY26 guidance explicit. The new 2030 framework raises the medium-term test from reaching breakeven to sustaining mid-teens growth while moving the mix toward Clinical and BioPharma.

Read the primary RNS release. Figures and targets are company-stated; the interim financial statements were independently reviewed, not audited. Derived interpretation is identified as such. Not investment advice.

The Aleth Briefs trace each story to its original source and show how the week unfolded.

The week in five lines:

• Anthropic withheld is most capable model ‘Model 2’ on risk grounds.

• AI agents reportedly breached Taiwanese government systems.

• xAI released Grok 4.6 drawing it level with GPT-5.6 Sol.

• Encrypted reasoning traces leak credentials and hidden reasoning.

• Z.ai pushes open models closer to the cyber frontier.

Browse by day:

• Weekend: Gym agent

• Monday: Muse Glimmer · GPT-5.6-Cyber · Nvidia · Riemann zeta · reasoning traces

• Tuesday: Claude watermarks

• Wednesday: Taiwan · Grok 4.6 · Lovable · UK gene synthesis · Google · Qwen3.8

• Thursday: DeepSeek V4-Pro · Databricks · Crouzeix · OpenAI

• Friday: Anthropic Model 2 · GLM-5.3 · SpaceX-Cursor · Apple · OpenAI

Weekend (8-9 August)

An OpenClaw agent running on Claude exploited a Melbourne gym’s booking API and cancelled a stranger’s reservation.

Asked whether it could move its user up a class waitlist, the agent found the API had no authorisation checks on cancelling bookings and removed the person in position one. It could not undo it: “The person I removed is gone from the waitlist and I have no way to restore them.“ The user had the agent email the gym’s software vendor.

• AI hacks gym website in first known Australian autonomous cyber attack · ABC

• The tech industry is buzzing after a Claude agent hacked into a gym · TechCrunch

Monday 10 August

Meta released Muse Glimmer, a 30B open-weight agentic model, and Mark Zuckerberg published the vision behind it.

The model takes text and images, and runs on a single-GPU Mac or PC at <20 GB quantised. Zuckerberg’s essay calls open source “a positive and important force for empowering people“, rejects centralised alignment as “enforcing a centralized dogma“, and asks for shared model checkpoints with government not pre-release review.

• Muse Glimmer: an open agentic model that runs on your device · Meta AI Research

• The future is for everyone - The path to a positive AI future · Mark Zuckerberg

OpenAI released GPT-5.6-Cyber and split Daybreak into defensive/specialist tiers.

Daybreak Blue gives approved defenders GPT-5.6 Sol for vulnerability discovery, malware analysis and incident response. Daybreak Red adds specialist models for authorised vulnerability research and exploit validation. GPT-5.6-Cyber completed 95% advanced cybersecurity requests in an OpenAI evaluation, against 2% for GPT-5.6 Sol, and has already identified previously unknown flaws in Chrome’s V8 engine.

• Expanding Daybreak as the cyber defence window narrows · OpenAI

Nvidia signed six partnerships aimed at mobilising >$500bn for AI infrastructure.

Apollo, BlackRock, Blackstone, Brookfield, Goldman Sachs and KKR signed MOUs to develop financing platforms for Nvidia-based AI infrastructure. The aim is to make compute an investable infrastructure asset and expand the capital available to Nvidia customers. The $500bn is a long-term mobilisation target not yet committed funding.

• Partnering Apollo, BlackRock, Blackstone, Brookfield, Goldman Sachs & KKR · Nvidia

Anthropic said an unreleased research version of Claude raised a lower bound on the Riemann zeta function from 41.6% to 67.2%.

The bound is the proportion of the function’s zeros proved to lie on the critical line. Claude worked through Claude Code over two sessions and 31 million output tokens, coordinating 60 subagents. It will not lead to a proof of the Riemann hypothesis itself. The result is evidence that LLM-based systems can move beyond interpolation over their training data into genuine knowledge production.

• Learning more about Claude’s mathematical capabilities · Anthropic

Researchers showed that encrypted AI reasoning traces can leak secrets and hidden model reasoning.

In the paper, 315,320 encrypted reasoning blocks from public agent logs were decoded recovering 182 credentials and 367 personally identifying artefacts. It showed that reasoning traces could be transferred across sessions, users and models within the same provider, allowing weaker models to expose stronger models’ hidden reasoning. This raises broader risks around privacy, model IP and security of workflows.

• Stealing reasoning traces from proprietary LLM APIs · arXiv

Tuesday 11 August

Anthropic began marking outputs from Claude models launched since 2 August.

Claude models will embed an imperceptible watermark in text and attach signed provenance metadata to .svg, .png and .jpg files, across its API, Claude, Claude Code, Cowork and Claude Tag. The method derives from Google DeepMind’s SynthID-Text approach of biasing which of several equally valid words is chosen. Anthropic says heavy editing or formatting can strip the mark and a detection API is coming.

• How Claude marks AI-generated content · Claude Support

• How Claude’s text watermark works · Anthropic

Wednesday 12 August

AI agents were used in a breach of Taiwanese government systems.

Israeli security firm Dream said attackers used open-source frameworks including Hermes and OpenClaw to run up to eight agents in parallel, mapping 21 government systems, compromising at least 85 accounts and extracting more than 2,500 personnel records before probing Taiwan’s nuclear safety agency and energy companies.

Taiwan’s government separately confirmed an overseas AI-assisted attack on its agencies. The attackers appear to have bypassed model safeguards by presenting the operation as authorised penetration testing, highlighting how freely available agent frameworks can automate substantial parts of an offensive cyber campaign.

• China-linked hackers hit Taiwan in unprecedented ‘autonomous’ AI cyber attack · FT

• Foreign hackers AI agent attacks against government agencies · MODA (gov.tw)

xAI released Grok 4.6, matching GPT-5.6 Sol at substantially lower cost.

Grok 4.6 scores 61 on the Artificial Analysis Intelligence Index, level with GPT-5.6 Sol, at $2/$6 per million input/output tokens. It is particularly competitive on agentic coding and long-running knowledge work: a frontier model at much lower cost.

• Introducing Grok 4.6 · Space xAI

• Grok 4.6 returns xAI to intelligence frontier and leads on cost · Artificial Analysis

Lovable raised $400m at a $13.3bn valuation, twice its level in December 2025.

Menlo Ventures led Series C, with EU Scaleup Europe Fund, managed by EQT, co-leading. Tencent, Balderton, Carmignac, Kaszek and Regent participated. The Swedish AI company says users have created >60m projects, generating >900m monthly visits.

• We raised $400M in Series C funding to help people run their businesses · Lovable

UK ministers are drawing up rules on the use of AI in gene synthesis.

Options under consideration include new bio weapons legislation and a regime requiring laboratories to establish the legitimacy of customers and report concerning sequence requests. Officials are also weighing whether to intervene in how closely AI firms partner with academic institutions holding large genome sequencing datasets.

UK plans safeguards to stop terrorists using AI for bioweapons · Bloomberg

Google is reorganising DeepMind around Gemini as Brin tells staff to “go all in”.

Brin made the appeal at an April town hall. Google has since delayed the next flagship Gemini by two months after internal testing showed it still trailing rivals on coding, and an all-hands on 6 August disclosed the team moves. The changes further reduce the independence DeepMind has retained within Google since its 2014 acquisition.

• Inside the Google executive moves that led to its big AI reshuffle · Reuters

Alibaba released the weights for its largest open Qwen model.

Qwen3.8-2.4T is a 2.4tn-parameter mixture-of-experts model, with 95bn parameters active and a 262k context window. Alibaba calls it its most capable open model yet, competitive with leading closed models across coding, research and long-horizon agentic tasks. Open weights make Qwen3.8 accessible to well-funded labs and startup, but the flagship 2.4T still requires datacentre-scale hardware to run seriously.

Qwen3.8-2.4T-A95B · Hugging Face

Thursday 13 August

DeepSeek released V4-Pro, open-sourced its Harness agent framework and raised API prices.

V4-Pro is now generally available, while DeepSeek Harness has been released under the MIT licence as a developer-preview framework for building tool-using agents. DeepSeek also introduced peak and off-peak API pricing, but even its new discounted rates are much higher than previous levels ($0.87/m output tokens to $3.96 peak / $1.98 off-peak). Together, the changes make DeepSeek’s agent layer easier to adopt while increasing the cost of using the underlying model.

• DeepSeek-V4-Pro release and new API pricing · DeepSeek API Docs

• DeepSeek Harness · GitHub

Databricks closed $5bn at a $190bn valuation and said it has passed a $7bn revenue run rate.

Coatue led, with Blackstone, MGX and T. Rowe Price alongside. Growth was >80% YoY, and the company counts >1,000 customers at a $1m run rate and >100 at $10m. Six months ago, Databricks raised the same amount at a $134bn valuation (37% step-up).

Databricks grows >80% YoY and surpasses a $7B revenue run rate · Databricks

A neurosurgery resident used GPT-5.6 Sol to help prove Crouzeix’s conjecture.

Shanmu Jin, a neurosurgery resident at Peking Union Medical College Hospital and largely self-taught in mathematics, posted a preprint on 27 July claiming a proof of Crouzeix’s conjecture. In SIAM News, Alex Townsend and Anne Greenbaum said Jin credited GPT-5.6 Sol with a substantial role and that they had found the proof sound.

• The Numerical Range Is a 2-Spectral Set · Preprints.org

• The neurosurgery resident who proved Crouzeix’s conjecture · Alex Townsend

OpenAI employees told Wired that pressure to ship cut into time for safety work.

They link that pressure to the May incident in which OpenAI agents escaped a restricted test environment and breached Hugging Face to read cybersecurity evaluation answers. One former employee called it the biggest safety incident in the company’s history. Boaz Barak, who co-leads OpenAI’s safety advisory group, said the response required “not just fixing some issues but also changing our culture“.

• The Safety Reckoning Inside OpenAI · Wired

Friday 14 August

Anthropic withheld an internal model more capable than Mythos 5.

In its August risk report, Anthropic raised its estimate of the risk of catastrophic harm from misalignment in high-stakes settings from very low to low. The same document discloses an internal model it calls ‘Model 2’, that is “somewhat more capable than Mythos 5” and scores 62.8% on Anthropic’s CoBench against 50.3%. Mythos 5 is available to vetted partners, while there are no plans to release Model 2 externally.

OpenAI had paused some work on its unreleased Astra model on cyber-capability grounds a week earlier, so Anthropic is not alone in withholding frontier capability. What is unusual here is that Anthropic disclosed the decision in a published risk reassessment and quantified the capability gap.

Risk report: August 2026 · Anthropic

Z.ai’s GLM-5.3 pushed open models closer to the cyber frontier.

GLM-5.3 scores 84.5% on CyberGym, notably slightly ahead of Anthropic’s Mythos 5 on vulnerability discovery, while more than doubling its predecessor on the harder ExploitBench to 54.4%. It still trails Mythos 5 substantially on exploit generation, but the results show advanced cyber capability spreading beyond closed frontier models. The planned open-weight release is notable as US frontier labs are simultaneously restricting models over rising cyber capability.

• GLM-5.3: Frontier coding with emergent cyber capabilities · Z.ai

SpaceX completed its acquisition of Cursor at a $60bn implied equity value.

Cursor is now a SpaceX subsidiary, with its equity now to SpaceX shares at the $60bn valuation. Cursor says the combination gives it access to SpaceX’s GPU infrastructure to train stronger models at lower cost. The deal brings one of the leading AI coding platforms together with SpaceX’s rapidly expanding compute operation.

• Cursor is now a part of SpaceX · Cursor

• Form 8-K, 14 August 2026 · SpaceX

Apple trained its own AI model for China with Alibaba’s support.

Reuters reported that Apple has developed a China-specific LLM with Alibaba, alongside plans to integrate Qwen and other local technology into Apple Intelligence. China’s regulator registered Apple Intelligence in July, clearing the way for launch. If deployed as planned, Apple would become the first foreign company to offer its own proprietary AI model in China, rather than relying entirely on domestic models.

• Apple trains its own AI model for the China market with Alibaba’s support · Reuters

OpenAI’s enterprise business has overtaken consumer revenue.

CFO Sarah Friar told investors that enterprise customers rose 32% in July and now generate more revenue than OpenAI’s consumer business. The crossover shows how quickly the company is shifting from a consumer chatbot-led business towards selling AI as core enterprise infrastructure.

• OpenAI CFO Friar tells investors that enterprise is bigger than consumer · CNBC

ALETH · OPEN ACCESS RESEARCH

aleth.co

The Aleth Briefs trace each story to its original source and show how the week unfolded.

The week in five lines:

• The White House ordered an overhaul of US childhood vaccination schedules.

• The FDA proposed 50% fee cuts for US-run trials.

• Jazz and Actio agreed a $1.3bn rare-epilepsy deal.

• Sionna dropped SION-719 after a phase 2 miss.

• Definium’s LSD pill cleared a second phase 3.

Browse by day:

• Weekend catch-up: WuXi ruling

• Monday: US vaccines · Jazz-Actio · Sionna · UK Foundayo · MoonLake · Sobi-Innate

• Tuesday: Autolus · Vaderis · Vykat XR

• Wednesday: Definium · Cullinan-Taiho · MMR pushback · Sangamo auction

• Thursday: US user fees · Tavneos

Weekend catch-up

A US federal judge blocked the Pentagon from enforcing WuXi AppTec’s designation as a Chinese military company.

A US District Court granted a preliminary injunction barring the Department of Defense from effecting the Section 1260H listing while WuXi’s challenge runs, finding the company likely to show the designation was arbitrary and capricious. WuXi had documented clients cancelling and moving work to rivals since the June listing.

• WuXi AppTec Co., Ltd. v. US Department of Defense, 1:26-cv-02069 · CourtListener

• Judge blocks listing of WuXi AppTec as ‘Chinese military’ · Pharma Manufacturing

Monday 10 August

The White House ordered a rewrite of US childhood vaccine schedules.

The executive order, “Delivering Gold Standard Childhood Vaccine Recommendations for Americans”, cuts the universally recommended childhood vaccinations from 17 to 11, moves shots including hepatitis B, rotavirus, influenza and COVID-19 to high-risk or shared decision-making categories, and directs that the MMR vaccine be given as three separate shots once single-disease versions exist in the US.

• Gold standard childhood vaccine recommendations for Americans · White House

Jazz agreed to buy Actio Biosciences for up to $1.32bn.

Jazz Pharmaceuticals will pay $820m upfront and up to $500m in contingent consideration for the private biotech, whose lead asset ABS-1230 is a potential first-in-class KCNT1 ion channel inhibitor for a rare genetic epilepsy affecting 2,500 in the US. The deal extends the epilepsy business built on Epidiolex (cannabidiol, GW Pharma).

• Acquiring Actio Biosciences, expanding rare epilepsy portfolio · Jazz Pharmaceuticals

Sionna’s cystic fibrosis add-on failed.

In the phase 2a PreciSION CF trial, SION-719 added to Trikafta shifted sweat chloride by a placebo-adjusted -1.0 mmol/L (p=0.7). Sionna Therapeutics will not take the NBD1 stabiliser forward as an add-on to standard of care. Sionna named SION-451 plus SION-2222 as its preferred pairing while it weighs next steps.

• Topline data from two development programs in CF · Sionna Therapeutics

The MHRA authorised Lilly’s orforglipron, the first regulator in Europe to clear it.

Foundayo (orforglipron) is authorised for weight loss in adults with obesity or overweight plus a comorbidity, and separately for inadequately controlled type 2 diabetes. It is the second oral GLP-1 cleared for weight loss in the UK in two months, after Novo Nordisk’s oral Wegovy in June. NHS use will require NICE evaluation first.

• UK first in Europe to authorise orforglipron for weight loss and diabetes · MHRA

MoonLake’s sonelokimab met its endpoints in first phase 3 in psoriatic arthritis.

In IZAR-1, 42.1% of biologic-naive patients on the nanobody’s 60 mg induction regimen reached ACR50, with wins across key secondary endpoints and no new safety signals. The trial runs to week 52, reading out fully in H1 2027; IZAR-2, in TNF-inadequate responders with a Skyrizi reference arm, completes enrolment in Q3 2026.

• Positive topline results phase 3 of sonelokimab · MoonLake Immunotherapeutics

Sobi licensed Innate Pharma’s lacutamab in a deal worth up to $580m.

Sobi pays $75m at closing for global rights to commercialise the anti-KIR3DL2 antibody on any accelerated approval in Sézary syndrome, with up to $40m in near-term milestones and up to $465m tied to an option over full development rights.

• Partnership with Innate Pharma to license lacutamab in T-cell lymphoma · Sobi

The FDA rejected ITM’s radiopharmaceutical over manufacturing issues.

The complete response letter for 177Lu-edotreotide (ITM-11) in gastroenteropancreatic neuroendocrine tumours rests on chemistry, manufacturing and controls (CMC) deficiencies and unresolved conditions at a third-party facility. It raised no clinical or safety concerns and asks for no new trials. The phase 3 COMPETE trial had beaten everolimus on progression-free survival. ITM intends to resubmit.

• ITM Receives Complete Response Letter for 177Lu-edotreotide (ITM-11) · ITM

Revolution Medicines and BeOne Medicines agreed a RAS collaboration.

BeOne takes exclusive rights to Revolution’s four clinical RAS(ON) inhibitors in selected Asian markets ex-Japan and South Korea and will fund a global registrational phase 3. The pair will also test combinations pairing daraxonrasib and zoldonrasib with BeOne’s PRMT5 inhibitor and its EGFR x MET x MET trispecific antibody.

• BeOne clinical and regional commercialization collaboration · Revolution Medicines

Silence Therapeutics’ divesiran hit in phase 2 and it priced a $175m offering.

In the 48-patient SANRECO polycythaemia vera trial, 88% on the siRNA responded against 19% on placebo, while phlebotomies fell to 0.2 against 2.1 (per pt, p<0.0001). Phase 3 starts H1’27. Silence priced an upsized $175m offering at $13.50 the next day.

• Positive topline results for divesiran & $175m offering · Silence · Silence

AbCellera’s mAb cut hot flushes 83% in phase 2 and it priced a $200m offering.

A single 600 mg dose of ABCL635 cut daily moderate-to-severe hot flushes by 83% reduction against 33% placebo, with no serious adverse events among 92 postmenopausal women. AbCellera priced an oversubscribed $200m offering at $9.75.

• Positive topline results for ABCL635 & $200m offering · AbCellera · AbCellera

Quanterix cut its 2026 revenue guidance by 15% and its shares fell about 40%.

Q2 revenue of $32.9m came in 9% below the company’s own May guidance, with pro forma revenue down 23% YoY, and the full-year range falls to $142m-$148m from $169m-$174m on weak academic and government demand and execution challenges.

• Quanterix releases financial results for the second quarter of 2026 · Quanterix

Tuesday 11 August

Autolus confirmed Q2 Aucatzyl revenue of $45.7m, up 119% YoY.

Q2 net revenue for Aucatzyl reached $45.7m, up 119% YoY, taking H1 to $71.9m; the London-based company guides 2026 sales of $140-$150m. Enrolment continues in lupus nephritis, paediatric acute lymphoblastic leukaemia and multiple sclerosis.

• Second quarter 2026 financial results and business updates · Autolus Therapeutics

Vaderis raised a $152m series B and started a phase 3 in a rare vascular disorder.

The Swiss biotech’s engasertib, an oral allosteric AKT inhibitor, enters the global phase 3 HEROIC study in hereditary haemorrhagic telangiectasia, which has no approved treatment anywhere. Goldman Sachs Alternatives and TCGX co-led the round.

• Oversubscribed $152m Series B financing & Phase 3 study · Vaderis Therapeutics

Prader-Willi organisations flagged serious adverse events reported on Neurocrine’s Vykat XR.

A joint statement from PWSA USA, the Foundation for Prader-Willi Research and IPWSO urges careful patient selection and monitoring after post-marketing reports of oedema, respiratory and cardiac complications. Fierce Pharma reported seven deaths and >100 serious adverse events in the FDA’s adverse event system. Neurocrine, which took on Vykat XR (diazoxide choline) in its $2.9bn Soleno purchase, says the drug has “a compelling risk-benefit profile in the context of a very serious disease.”

• PWS organizations share joint statement on VYKAT XR adverse events · PWSA USA

• Neurocrine stands by blockbuster hopeful as docs raise safety flags · Fierce Pharma

Wednesday 12 August

Definium’s LSD pill cleared its second phase 3.

In the Voyage trial in generalised anxiety disorder, DT120 (lysergide) 100 µg cut the Hamilton Anxiety score by 11.6 points against 6.2 on placebo at week 12 (p<0.0001). It is the second positive phase 3 for the orally disintegrating tablet after June’s Emerge readout in major depression. The FDA has granted breakthrough therapy designation in anxiety. A second trial, Panorama, reads out in September.

• Topline results from Phase 3 Voyage study of DT120 ODT · Definium Therapeutics

Taiho and Cullinan’s zipalertinib met its phase 3 goal in first-line lung cancer.

In a planned interim analysis of the 285-patient REZILIENT3 trial, the EGFR inhibitor plus chemotherapy improved progression-free survival in untreated EGFR exon 20 insertion non-small cell lung cancer. Pending FDA discussions, the partners plan to pursue US approval, which would take the drug into Rybrevant’s (J&J) territory.

• Zipalertinib meets primary endpoint of PFS in Phase 3 REZILIENT3 · Taiho Oncology

Merck and GSK pushed back on splitting the MMR vaccine.

Both makers of the US combination shot told Reuters there is no published evidence to support separating it, and neither set out plans to. Merck said single-disease approvals could take “as many as 10“ years. No standalone measles, mumps or rubella shot has been sold in the US since Merck stopped making them in 2008.

• Goal to split MMR vaccine could take a decade, experts say · Reuters via KFGO

Sangamo selected PTC and Lilly as winning bankruptcy-auction bidders.

PTC bid $111m at closing plus up to $100m in approval milestones for the Fabry disease gene therapy isaralgagene civaparvovec. Lilly takes the capsid, zinc finger and MINT platforms and the prion disease programme for $50m. Winning bids total $163.6m in cash, subject to approval by the US Bankruptcy Court (Delaware) in Q3.

• Sangamo selects successful bidders following asset auction · Sangamo Therapeutics

Thursday 13 August

The FDA proposed a 50% fee cut for US-based phase 1 trials.

The proposed PDUFA VIII commitment letter, covering fiscal years 2028 to 2032, would halve the application fee where a filing includes clinical data from at least one phase 1 trial run in the US and begun after 1 October 2027.

• PDUFA VIII: Fiscal Years 2028-2032 · FDA

EMA says Tavneos approval relied on “incorrect and misleading” trial data.

The CHMP recommended revoking Tavneos (avacopan) in June, with the European Commission making that decision legally binding across the EU on 4 August. The EMA has now published the grounds for that decision, concluding that the ADVOCATE trial supporting approval breached good clinical practice and that its data could no longer be relied on to demonstrate effectiveness. CSL’s Vifor unit is managing the withdrawal.

• Tavneos: Article 20 referral · European Medicines Agency

• EC adopts decision to revoke marketing authorisation for TAVNEOS (avacopan) · CSL

ALETH · OPEN ACCESS RESEARCH

aleth.co

The Aleth Briefs trace each story to its original source and show how the week unfolded.

The week in five lines:

• Demis Hassabis stepped down as Google DeepMind CEO.

• UK AISI tests recorded 19 unsanctioned model actions against real targets.

• Google lined up $200bn to fund Anthropic’s chips.

• The EU AI Act obligations became enforceable.

• Stanford and Arc scientists built 16 AI-designed bacteriophages.

Browse by day:

• Weekend: OpenAI Astra · EU AI Act

• Monday: Qwen3.8-Max · US AI framework · Olix

• Tuesday: UK AISI · Google-Anthropic $200bn · Anthropic-Volta

• Wednesday: DeepMind shake-up · Jeff Dean · Meta Muse Code

• Thursday: AI-designed bacteriophages

• Friday: ByteDance 10T · Kimi K3 escape · Anthropic biology safeguards

Weekend (1-2 August)

OpenAI said its Astra model produced results on ten open problems in mathematics, quantum complexity and theoretical computer science.

OpenAI published a 249-page paper sharing a selection of ten results, each of which resolves or makes progress on long-standing open problems, together with machine-checkable proofs on GitHub. The results came at compute costs of c.$2,000 at Sol API rates. OpenAI showed the same model family privately to US policymakers days earlier.

• Ten advances in mathematics and theoretical computer science · OpenAI

EU AI Act obligations for general-purpose models became enforceable.

From 2 August the European Commission’s AI Office can investigate providers of general-purpose AI models, demand access for evaluations, order risk mitigations and fine up to 3% of global turnover. Separate transparency rules took effect requiring chatbots to disclose they are AI and synthetic images, audio and video to be labelled.

• Commission starts enforcing AI Act & transparency rules · European Commission

Monday 3 August

Alibaba said its 2.4-trillion-parameter Qwen3.8-Max tops Moonshot’s Kimi K3 and will publish the weights of Qwen3.8-Max and Qwen3.8-27B next week.

The model activates only 95B parameters per query through a mixture-of-experts design and carries a 1M-token context window. Open weights at that scale would be among the largest sets of frontier weights released.

• Qwen3.8-Max: a new bar for coding and cowork · Alibaba Cloud

• Alibaba adds to China AI breakthroughs with new Qwen model · Bloomberg

The White House said it met its deadline to establish a voluntary framework for evaluating advanced AI models, without publishing what it contains.

Details are being provided only to the companies taking part. Axios reported the next day that the text defined a covered frontier model as closed-source with state-of-the-art capabilities and national-security risks, leaving open-weights outside the perimeter.

• White House AI framework & Inside Trump’s AI framework · Axios · Axios

London chip startup Olix raised $312m led by Fundomo at a $3.3bn valuation, with Arm and the UK’s sovereign AI fund among the backers.

Up from just over $1bn when it raised $220m in February, a tripling inside six months. Olix is building optical AI-inference silicon aimed at Nvidia’s territory. Arm’s investment secures it a strategic foothold in a rising competitor’s hardware roadmap.

• OLIX raises $312m at a $3.3bn valuation & appoints Nick McKeown to board · OLIX

• UK AI chip startup Olix raises $312m at a $3.3bn valuation · Financial Times

Tuesday 4 August

The UK AI Security Institute recorded 19 unsanctioned actions against real people and organisations.

During a cyber evaluation between 25 and 28 July, the Institute found that agents under test took 19 unsanctioned actions against real people and organisations: 17 by Anthropic’s Mythos 5 and two by OpenAI’s GPT-5.6 Sol with its safety filters disabled.

One agent tried to insert malicious code into a public open-source project and used fake identities to socially engineer a maintainer to approve it. The reviewer refused the code, the AISI isolated its systems, notified GitHub, and no real-world harm resulted.

• Incident report: unsanctioned agent behaviour during testing · AI Security Institute

Google assembled a $200bn financing programme for Anthropic.

Google has arranged $200bn of financing to supply Anthropic, >$150bn of it tied to its own TPUs, together with Broadcom, Blackstone, Apollo and Morgan Stanley. A vehicle will buy the chips and lease them to Anthropic, moving it off Google’s balance sheet. This deepens Anthropic’s dependence on Google rather than Nvidia silicon.

• Inside Google’s $200bn Wall Street machine for Anthropic · Financial Times

Anthropic signed a $10bn, six-year deal for computing capacity with Volta Infra, an Nvidia-backed cloud startup founded only this year.

The capacity sits at a 133 MW site in Norway operated by crypto miner Bitdeer, running on hydroelectric power and Nvidia’s Vera Rubin chips, with delivery phased into early 2027. It puts a sizeable share of Anthropic’s compute outside the US.

• Volta launches: the utility of compute · Volta

• Anthropic signs a $10bn deal with cloud startup Volta · TechCrunch

SpaceX reported Q2 capital spending of $18.4bn, with $15.8bn of it going to its AI segment, and booked a $1.3bn AI operating loss.

The figure puts SpaceX among the largest single-quarter AI-infrastructure spenders anywhere, and SPCX fell >7% after hours. The next day Elon Musk said SpaceX will build exclusively on Nvidia, citing the Vera Rubin architecture, one of the larger single-buyer commitments Nvidia has won this year.

• SpaceX reports second quarter 2026 results · SpaceX

• SpaceX and Nvidia are taking their relationship exclusive · Business Insider

An internal TikTok document shows it withheld a safety-tuned version of its recommendation algorithm from 10% of US users as a control group.

One of those users was a 16-year-old who was served self-harm content and later died by suicide. A deliberate, documented withholding of a safety intervention is evidence that may drive litigation and legislation.

• TikTok withheld a safety feature from millions. One died by suicide · Bloomberg

Wednesday 5 August

Demis Hassabis stepped down as CEO of Google DeepMind.

Hassabis becomes chair of Deepmind and Alphabet chief scientist, allowing him to “put his full attention on actively shaping the future of AGI” and will lean into to his role at Isomorphic, noting “It’s time for AI to prove its unequivocal value to the world, and what better way to demonstrate that than to help finally cure diseases like cancer”.

CTO Koray Kavukcuoglu takes over day-to-day leadership as SVP, reporting to Sundar Pichai. Hassabis has run DeepMind since co-founding it in London. GOOG fell >3% on the news. Google has been moving AI decision-making towards Mountain View.

• The next chapter of our AI momentum · Google

Jeff Dean is leaving Google as chief scientist to co-found Discovery Loop, a startup chasing AI-driven breakthroughs in drug discovery and chip design.

Leaving after 27 years, he is joined by longtime collaborator Sanjay Ghemawat. Google is a founding investor and cloud partner in Discovery Loop. The move brings two of AI’s most influential pioneers further into life sciences.

• The next chapter of our AI momentum · Google

• Four top Google AI researchers form new startup · The New York Times

Meta released Muse Code in beta, a terminal coding agent running on a new model, Muse Spark 1.2.

Muse Spark 1.2 is priced at $1.25/m input tokens and $4.25/m output, undercutting coding offerings from Anthropic and OpenAI. The agent installs from the terminal and works across large repos with background sub-agents and a crash-safe event log.

• Introducing Muse Code and Muse Spark 1.2 · Meta AI Research

A filing shows Microsoft recorded $24.1bn from commercial arrangements with OpenAI, including revenue-sharing payments, in the year ended June.

Bloomberg estimated it represented more than half of Microsoft’s AI sales. The concentration cuts both ways: it quantifies how much of Microsoft’s AI business rests on one customer, and how much of OpenAI’s spending flows back to its own investor.

• Form 10-K for the fiscal year ended 30 June 2026 · Microsoft

• Microsoft’s AI sales mostly come from OpenAI, disclosures show · Bloomberg

Thursday 6 August

Stanford and Arc Institute scientists designed 16 viable bacteriophages with AI.

Writing in Science, the team used the Evo genome language model to generate whole bacteriophage genomes letter by letter, synthesised hundreds of candidates and found 16 that were viable. All 16 infect E. coli and pose no threat to humans. A cocktail of them overcame bacteria that had resisted a natural phage. The research highlights the need for biosecurity governance guardrails to be properly established.

• Generative design of bacteriophages with genome language models · Science

Two more frontier models breached real systems during safety testing.

OpenAI said the agents behind an earlier Hugging Face breach had built a covert message board to coordinate, sharing exploits through a package manager for months without anyone noticing. Separately, Meta’s Muse Spark 1.1 broke into another company after its evaluation partner Irregular left a sandbox misconfigured. In both cases the escape traced to the test harness, not the model, but a frontier system still ran an unsanctioned intrusion against a live target.

• OpenAI’s agents used a message board to plan their hacking spree · Wired

• A Meta AI model hacked another company during testing · The Information

Friday 7 August

ByteDance is pretraining a model with up to 10 trillion parameters.

Roughly three times the size of Moonshot’s Kimi K3 and above the 8T estimate for Anthropic’s Mythos 5, would make it one of the largest reported pretraining runs. Whether it yields a usable competitive frontier model is a separate question.

• ByteDance pretrains a model of up to 10T parameters · Financial Times

Moonshot’s Kimi K3 got outside its sandbox during a defensive cybersecurity evaluation and read the answers to the test.

Frontier Security ran the evaluation on the UK AI Security Institute (AISI) benchmark. It found the sandbox had left outbound HTTPS and DNS open. The model probed the settings, resolved github.com, cloned the benchmark’s own repository and read the solutions off disk rather than solving the tasks. Not a hack but specification gaming.

• Chinese model Kimi K3 breaks UK AISI benchmark evaluations · Frontier Security

• One of China’s most powerful AI models has also escaped containment · Wired

Anthropic loosened Claude Fable 5’s biology safeguards, cutting biology-related fallbacks by about 85%.

The company retrained the classifier that sits on biosecurity-relevant queries to cut false positives on everyday health, educational and clinical questions, while keeping blocks on dual-use areas such as virology and toxicology. Anyone using the model for life-sciences work should expect noticeably different behaviour.

• Improving Fable 5’s biology safeguards · Anthropic

ALETH · OPEN ACCESS RESEARCH

aleth.co

The Aleth Briefs trace each story to its original source and show how the week unfolded.

The week in five lines:

• AstraZeneca and Bristol Myers Squibb merger talks were reported, then denied.

• Curium and Lantheus agreed an $8bn radiopharma deal.

• Supernus and Indivior agreed a $7.5bn all-stock merger

• Moderna secured approval for the first mRNA flu vaccine.

• Latigo and BlossomHill closed a four-IPO week in the US.

Browse by day:

• Monday: Curium-Lantheus · Supernus-Indivior · KKR-Integer · BioNTech · Gilead

• Tuesday: Pfizer · Novo Nordisk · Merck TL1A · Pathos AI · P&G-Thorne

• Wednesday: Takeda US approval · Eli Lilly · Attovia · PacBio · GRAIL · LifeMine

• Thursday: Replimune · Moderna · Tarsus-Alkeus · Braveheart · Intellia · FDA pilot · AI

• Friday: Latigo · BlossomHill

Story of the week

The FT reported that AstraZeneca and BMS had held talks about a $400bn merger which if true would create the world’s fourth-largest drugmaker by value

The weekend report triggered sharp market reactions on Monday, despite neither company issuing official comment. AZ shares fell as much as 9% in early trading, its worst move since 2020, while BMS gained 6% in US pre-market trading.

In a Reuters article on Wednesday, an insider dismissed the speculation entirely. “There is no deal between AstraZeneca and BMS. There never was a deal to be done, and there are no discussions between the companies,” the source stated.

• AstraZeneca holds talks with BMS over $400bn tie-up · Financial Times

• Exclusive: ‘No discussions’ over AstraZeneca-BMS deal, senior source says · Reuters

Weekend catch-up

Monday 3 August

Curium agreed to buy Lantheus in a deal worth up to $8bn.

Curium, which is PE backed, will pay $102.50/share in cash plus contingent value rights (CVRs) worth up to $12.00/share on commercial milestones to 2030. The CVRs split $6.00 to prostate cancer diagnostics, $3.00 neurology and $1.00 the DEFINITY imaging agent. The combination would put diagnostic and therapeutic radioligand assets under one owner across more than 70 countries. Expects to close H1 2027.

Curium Announces Definitive Agreement to Merge with Lantheus · Curium

Supernus and Indivior agreed an all-stock merger to create a $7.5bn in value and $2.2bn in revenue central nervous system drugmaker.

Each Supernus share converts into 1.54 Indivior shares, leaving Indivior holders with about 56.5% and Supernus holders 43.5%. Indivior shareholders also take a $1bn special cash dividend before closing, funded partly by a $650m Citibank term loan. The combined company keeps the Supernus name and Jack Khattar as CEO. It targets $888m of adjusted EBITDA including $125m cost synergies. Expects to close Q4 2026.

• Supernus and Indivior to Merge · Supernus Pharmaceuticals

KKR is taking US device maker Integer private at an enterprise value of $5.7bn.

Integer shareholders get $127.00/share in cash, 51.8% above the 29 April close, the day before it announced a strategic review, and 28.8% above the 30-day volume-weighted price to 31 July. There is no financing condition. Expects to close end 2026

Integer to Be Acquired by KKR in Transaction Valued at $5.7 Billion · Integer Holdings

BioNTech named Sobi chief executive Guido Oelkers as its next chief executive.

Oelkers takes office by 1 February 2027 and succeeds co-founder Ugur Sahin, who leaves with CMO Ozlem Tureci to run a new next-gen mRNA company. Oelkers more than quadrupled revenue at Sobi over 2017 to 2026. He will prioritise BioNTech’s evolution into a global biopharma firm with multiple approved products by 2030.

• Appointment of Guido Oelkers to Board as Chief Executive Officer · BioNTech

The Supreme Court of California ruled that drugmakers owe no duty to bring a safer alternative to market sooner, ending class action litigation against Gilead.

Justice Groban wrote manufacturers “do not owe a duty of care to users of a nondefective drug when making decisions about whether and when to commercialize an allegedly safer alternative.” The plaintiffs took Viread and argued Gilead had held back Vemlidy to protect revenue. It reverses and earlier Court of Appeal decision.

• Gilead Tenofovir Cases, S283862 · Supreme Court of California

Tuesday 4 August

Pfizer added $2.5bn to its cost-cutting programme.

The new reductions run from 2027 to 2029 and take targeted net savings to $9.7bn through 2029. Q2 revenue was $15.0bn, up 1%, with adjusted earnings of $0.77 a share. Pfizer lifted its 2026 revenue guidance by $500m to $60.5-$62.5bn.

Pfizer Reports Q2 Results And Raises Midpoint of 2026 Revenue Guidance · Pfizer

Novo Nordisk raised its 2026 guidance driven by GLP-1 volumes.

Adjusted sales grew 7% at CER to DKK 78.5bn and adjusted operating profit 11% to DKK 33.4bn. Full-year adjusted sales and operating profit growth is now guided at 0% to -6%, against -4% to -12% before. The Wegovy pill has passed 5m prescriptions since launch and was running above 265,000 a week in mid-July.

• Novo Nordisk reports Q2 2026 and raises full-year outlook · Novo Nordisk

Merck’s anti-TL1A antibody tulisokibart met its endpoints in hidradenitis suppurativa and missed in a rare lung disease.

The systemic sclerosis-associated interstitial lung disease programme is discontinued, and the full hidradenitis results go to a medical meeting. Merck paid $10.8bn for Prometheus Biosciences to acquire the antibody. Q2 sales were $16.6bn, up 5%, with $8.4bn from Keytruda and a $2.31/share charge tied to the Terns Pharma purchase.

Q2 2026 Financial Results; Key Regulatory & Clinical Milestones · Merck & Co

Pathos AI licensed Alphamab Oncology’s TROP2/HER3 bispecific antibody-drug conjugate in a deal worth up to $2.2bn.

Pathos pays $125m upfront for rights outside mainland China, Hong Kong, Macau and Taiwan, with up to $2.09bn in milestones and tiered royalties. JSKN016 is already in phase 3 in triple-negative breast cancer in China. Pathos also named AZD4241, an oestrogen-receptor PROTAC licensed from AstraZeneca, in its pipeline.

• Global Licensing Agreement with Alphamab Oncology on JSKN016 · Pathos AI

P&G agreed to buy US supplements maker Thorne from L Catterton for $3.8bn.

L Catterton bought into the vitamins, minerals and supplements firm in October 2023.

Sale of Thorne to The Procter & Gamble Company for $3.8 Billion · L Catterton

Wednesday 5 August

Takeda won US approval for the first orexin agonist for narcolepsy.

The FDA cleared Orzeyful, an oral orexin receptor 2 agonist, for narcolepsy type 1 in adults. It is the first disease modifying medicine directed at orexin deficiency and improved excessive daytime sleepiness, cataplexy and quality of life in phase 3 trials.

• FDA Approves ORZEYFUL for Adults With Narcolepsy Type 1 · Takeda

Eli Lilly raised guidance as tirzepatide neared two-thirds of revenue.

Q2 revenue was $23.0bn, up 48%: Mounjaro (tirzepatide for type 2 diabetes) took $9.9bn, up 91%, and Zepbound (for weight loss) $4.9bn, up 46%. The newly launched oral GLP-1 Foundayo (orforglipron) took $98m. Lilly raised 2026 revenue guidance +3% to $85-$87bn from $82-$85bn and narrowed EPS guidance to $35.50-$36.50.

• Lilly reports second-quarter 2026 financial results, raises full-year guidance · Eli Lilly

Attovia Therapeutics priced an upsized $289m Nasdaq IPO.

The company sold 17m shares at $17.00 and began trading as ATTO. Proceeds fund three immunology candidates, led by the anti-IL-31 antibody ATTO-1310 in chronic itch, which is positioned against Sanofi and Regeneron’s Dupixent (dupilumab).

• Pricing of Upsized Initial Public Offering · Attovia Therapeutics

PacBio replaced its chief executive, cut its revenue guidance and restructured.

COO Mark Van Oene became president and CEO with immediate effect, succeeding Christian Henry after six years; Henry stays on the board and will advise to end 2026. 2026 revenue guidance fell $10m (6%) to $155-$165m. Q2 revenue was $39.0m vs $39.8m, the net loss widened to $44.7m, and cash fell to $236.9m from $314.7m.

• PacBio Second Quarter 2026 Financial Results · Pacific Biosciences

• PacBio Appoints Mark Van Oene as President and CEO · Pacific Biosciences

GRAIL expects an FDA advisory committee this autumn on Galleri, its multi-cancer early detection (MCED) blood test.

The premarket approval application rests on 25,000 PATHFINDER 2 participants with a year of follow-up and on the first screening round of the 140,000-participant NHS-Galleri trial in England. Q2 revenue rose 26% to $44.7m and Galleri volume 35% to >61,000 tests, against a net loss of $110.2m and cash of $861.6m. GRAIL also closed a $110m equity financing with Samsung to sell Galleri in South Korea.

• GRAIL Reports Second Quarter 2026 Financial Results · GRAIL

LifeMine raised a $188m series E to take transplant drug into later trials.

A $75m series D from Q4 2025 and an oversubscribed $188m series E led by Milky Way Investments, with Bezos Expeditions, Gates Frontier, RA Capital, GV and ARCH Venture Partners, fund LIFE-001. The molecule came out of mining fungal genomes, is given as a long-acting injection and does not enter the brain.

• $263m raise to Accelerate Clinical Development of LIFE-001 · LifeMine Therapeutics

Thursday 6 August

Stanford and Arc Institute scientists designed 16 viable bacteriophages with AI.

Writing in Science, the team used the Evo genome language model to generate whole bacteriophage genomes letter by letter, synthesised hundreds of candidates and found 16 that were viable. All 16 infect E. coli and pose no threat to humans. A cocktail of them overcame bacteria that had resisted a natural phage. The research highlights the need for biosecurity governance guardrails to be properly established.

• Generative design of bacteriophages with genome language models · Science

FDA approved Replimune’s Tudriqev for advanced melanoma at the 3rd attempt.

The accelerated approval covers Tudriqev with Opdivo in unresectable advanced cutaneous melanoma that has progressed on an anti-PD-1 regimen. About a quarter of evaluable patients in the single-arm trial responded, for a median of just over 14 months. Continued approval depends on the confirmatory phase 3 IGNYTE-3 trial.

• FDA Accelerated Approval of TUDRIQEV with Nivolumab · Replimune

Moderna won US approval for the first mRNA flu vaccine.

mFLUSIVA (mRNA-1010) is cleared for adults 50 and over: a standard approval for those 50-64 based on a 40,805-participant phase 3 in 11 countries, and accelerated approval for those 65 and over based on immunogenicity data from 2,992 US adults, with a confirmatory study required. This reverses a refusal to file the agency issued on the same application earlier this year. Supply is expected for the 2026-27 season.

• Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA · Moderna

Tarsus Pharmaceuticals agreed to buy Alkeus Pharmaceuticals for $450m up front, taking it into inherited retinal disease.

Tarsus pays $270m in cash and $180m in stock, with up to $350m on regulatory approval and first commercial sale plus tiered royalties. Alkeus’s gildeuretinol is in the 230-patient phase 3 NORTHSTAR trial in Stargardt disease, which affects >36,000 Americans and has no approved treatment; topline data are due in H2 2029.

Tarsus to Acquire Alkeus and Advance Eye Care Leadership · Tarsus Pharmaceuticals

Braveheart Bio priced an upsized $382.5m IPO above its range.

The company sold 21.25m shares at $18.00, against a marketed $15 to $17, and began trading as BRVE. Proceeds fund phase 3 work on a cardiac myosin inhibitor licensed from Jiangsu Hengrui for hypertrophic cardiomyopathy, against BMS’s Camzyos.

• Braveheart Bio Announces Pricing of Upsized Initial Public Offering · Braveheart Bio

Intellia linked the liver enzyme spikes in its CRISPR trials to a single HLA allele.

A genomic analysis of >600 patient samples across the nex-z programme found the highest transaminase elevations in carriers of one HLA allele. Intellia is discussing the finding with regulators and will screen patients entering its phase 3 trials.

• Intellia Announces Q2 2026 Results and Business Updates · Intellia Therapeutics

The FDA set out how its proposed expedited investigational new drug (IND) pilot would work.

Qualified research institutions, CROs and other third parties would help sponsors prepare and pre-review IND material on a rolling basis, shortening the time from picking a molecule to a first-in-human trial. The FDA would keep full authority over regulatory decisions, including the power to place a trial on clinical hold.

• Expedited IND Pilot Program Educational Webinar for Stakeholders · FDA

• Expedited IND Pilot Program; Request for Information · Federal Register

Friday 7 August

Latigo and BlossomHill priced IPOs to close four biotech IPOs this week.

Latigo Biotherapeutics sold 19.2m shares at $18.00 for $345.6m, funding LTG-001, an oral NaV1.8 painkiller positioned against Vertex Pharmaceuticals’ Journavx.

BlossomHill Therapeutics sold 9.375m shares at $16.00 for $150m, funding: BH-30643 in EGFR-mutant lung cancer, a would-be rival to AstraZeneca’s Tagrisso; and BH-30236 in acute myeloid leukaemia and higher-risk myelodysplastic syndrome.

Both begin trading today, taking the week’s US biotech IPOs to four and $1.2bn raised.

• Latigo Announces Pricing of Upsized $345.6m IPO · Latigo Biotherapeutics

• BlossomHill Announces Pricing of Upsized $150m IPO · BlossomHill Therapeutics

ALETH · OPEN ACCESS RESEARCH

aleth.co

The Aleth Briefs trace each story to its original source and show how the week unfolded.

The week in five lines:

• Moonshot released Kimi K3 as open weights.

• Anthropic found three of its models had breached outside organisations.

• Google DeepMind introduced Gemini Robotics 2.

• Nvidia is in talks to backstop $250bn for OpenAI.

• Hugging Face mapped the agent that hacked it.

Browse by day:

• Weekend: chatbot bioweapon answers

• Monday: Kimi K3 · Nvidia-OpenAI · CXMT · Hugging Face breach

• Tuesday: Claude cryptanalysis · Pacing the Frontier · Amazon Nova

• Wednesday: Big Tech earnings · Moonshot raise

• Thursday: Gemini Robotics 2 · Anthropic breaches · GPT-5.6

• Friday: DeepSeek V4 Flash

Weekend (25-26 July)

Users have been coaxing chatbots into giving accurate guidance on mass-casualty attacks and bioweapons, the Wall Street Journal reported.

Staff at AI labs are among its sources, which allege that safeguards have failed in practice and answers to highly sensitive material come back correct rather than as garbled refusals. Biosecurity policy has been written around this failure mode and the burden is back on the labs to show their mitigations hold.

• Chatbots coaxed into bioweapon guidance · The Wall Street Journal

Monday 27 July

Moonshot released Kimi K3 as open weights.

Kimi K3 is Moonshot’s most capable model to date: a native multimodal, agentic mixture-of-experts system of 2.8T parameters (104B active), released under a bespoke license. Moonshot reports scores of 93.5 on GPQA Diamond and 88.3 on Terminal-Bench, at maximum reasoning. Releasing weights on this scale publicly puts the China lab at the centre of an intense US debate over whether to ban foreign AI models.

• Kimi K3 model card · Hugging Face

Nvidia is in talks to backstop $250bn of OpenAI financing.

The Wall Street Journal reported that Nvidia was in talks to guarantee roughly $250bn of financing for OpenAI, tied to a 10 GW data centre SoftBank is developing in Ohio. Separately, Bloomberg put Nvidia’s cheque to Ilya Sutskever’s Safe Superintelligence at about $5bn, larger than everything the lab had raised before.

• Nvidia to guarantee OpenAI financing · The Wall Street Journal

• Nvidia to invest $5bn in Safe Superintelligence · Bloomberg

Anthropic set out its position on open-weights models, with Dario Amodei writing that the company has never advocated a ban.

Amodei calls for chip-export controls, a crackdown on industrial-scale distillation, and mandatory safety testing for sufficiently capable models, open or closed. A direct answer to claims Anthropic had been lobbying against open models.

• Anthropic’s position on open weights · Anthropic

CXMT closed 466% above its offer price on its Shanghai debut, making it the most valuable China-listed company.

The listing raised 57.9bn yuan ($8.6bn). Memory is a key constraint for AI servers right now and the listing gives China’s largest DRAM maker capital to serve this demand.

• CXMT surges on Shanghai debut · CNBC

Hugging Face traced the OpenAI agent that breached it.

Hugging Face published a step-by-step forensic timeline of the July intrusion, reconstructing about 17,600 actions the rogue OpenAI agent took across a 4.5 day window from 9-13 July: an initial sandbox escape, lateral movement through Kubernetes clusters on stolen service-account tokens, and data exfiltration. The analysis used open-weight GLM-5.2 after Claude models declined on safety grounds.

• Technical timeline of the agent intrusion · Hugging Face

Tuesday 28 July

More than 1,100 staff at AI companies signed a letter asking the US government to help pace AI development, Bloomberg reported.

Signatories include OpenAI’s Jakub Pachocki and Thinking Machines’ John Schulman, putting research leaders on record asking for constraints on their own labs. OpenAI and Anthropic later attached themselves to the effort, branded Pacing the Frontier .

• Statement from 1,367 employees of AI companies · Pacing the Frontier

• Staff letter asks Washington to pace AI · Bloomberg

Wednesday 29 July

Google DeepMind has broken up the team behind AlphaFold, the FT reported, reassigning most of the original authors.

Roughly a quarter of the authors have now left DeepMin, including John Jumper, who shared the 2024 Nobel Prize with Demis Hassabis and David Baker and has left to join Anthropic. This raises questions about the direction of DeepMind’s scientific mission.

• GDM dismantles Nobel-winning AlphaFold team in strategy shift · Financial Times

Meta and Microsoft quarterly results revealed rising AI capex.

Meta’s Q2 revenue rose 28% YoY to $60.8bn, but free cash flow fell to $784m as capital spending climbed, and it lifted its full-year expense outlook to $165bn-$169bn. Microsoft’s Q4 revenue rose 18% to $90bn with net income up 31% to $35.8bn, and it said Azure revenue passed $100bn for the first time, with Azure up 43% in the quarter.

• Meta second-quarter results · Meta

• Microsoft fiscal fourth-quarter results · Microsoft

Moonshot AI closed a $3.5bn round at a $35bn valuation, Bloomberg reported, well past its $1bn-$2bn target, and plans a Hong Kong IPO as soon as 2026.

Raising double its target ahead of an IPO demonstrates that non-US frontier labs can mobilise significant amounts of capital independent of American venture networks.

• Moonshot passes funding goal · Bloomberg

Thursday 30 July

Google DeepMind introduced Gemini Robotics 2.

DeepMind describes it as three models working together: a vision-language-action (VLA) controller, an embodied-reasoning planner, and an on-device variant that adapts to a new robot body in a few hours. Together they give intelligent whole-body control across humanoid and bi-arm robots, including the Apptronik Apollo 2, and support multi-robot collaboration. Available in AI Studio and Gemini Enterprise Agent Platform, the VLA and On-Device models are available to early-access partners.

• Gemini Robotics 2 brings whole body intelligence to robots · Google DeepMind

Anthropic found three of its models had breached outside organisations.

Anthropic said a review after the OpenAI-Hugging Face incident turned up three cases where Claude reached real systems it should not have: extracting credentials and production data from one company, publishing malicious code to PyPI that hit 15 real systems, and compromising an internet-facing application. The models involved were Opus 4.7, Mythos 5 and an internal research model. The company framed it as a harness and operational failure. Containment failures were not unique to one lab.

• Investigating three real-world incidents in our cybersecurity evaluations · Anthropic

OpenAI announced price cuts for two of its GPT-5.6 models.

The company said it was lowering the price of GPT-5.6 Luna by 80% and GPT-5.6 Terra by 20% after efficiency gains in serving. OpenAI is now competing directly on cost per unit of intelligence, with major implications for enterprise inference budgets.

• Advancing the price-performance frontier with GPT‑5.6 · OpenAI

AI hedge fund Situational Awareness sold the bulk of its stock portfolio to Citadel after deep losses, the Wall Street Journal reported.

Leopold Aschenbrenner’s fund was among the most concentrated bets on the AI trade. Its assets fell to about $10bn after it liquidated positions to meet margin calls, and its forced unwind is now itself a factor in AI equity prices.

• Citadel buys Situational Awareness portfolio after AI losses · The Wall Street Journal

Friday 31 July

DeepSeek released its V4 Flash model in public beta.

The company said the update improves agent capabilities over the V4 Pro Preview while keeping the same architecture, re-post-trained rather than rebuilt. Artificial Analysis scored it 52 on its Intelligence Index and classifies it as a large open-weights model, at $0.14 per million input tokens and $0.28 per million output tokens.

• DeepSeek V4 Flash release notes · DeepSeek

• V4 Flash intelligence and price analysis · Artificial Analysis

Chinese military researchers distilled OpenAI and Anthropic models to train domestic systems for defence work, Reuters reported.

Distillation uses a frontier model’s outputs as synthetic training data to instruct smaller student models, side-stepping the massive pre-training compute targeted by US export controls. The findings coincided with state media reporting a fresh call from Xi Jinping for the military to accelerate its deployment of AI and autonomous systems.

• Chinese military researchers tap US AI models to train defence systems · Reuters

ALETH · OPEN ACCESS RESEARCH

aleth.co

The Aleth Briefs trace each story to its original source and show how the week unfolded.

The week in five lines

• Biopharma dealmaking hit a record $170bn in H1 2026.

• GSK chose Cambridge for its new R&D HQ.

• Novo Nordisk‘s ziltivekimab failed its heart trial.

• Johnson & Johnson offered $5.5bn to settle talc claims.

• argenx agreed to buy Forte Biosciences for $2.2bn.

In this edition

• Monday: argenx-Forte deal; AstraZeneca Q2; Otsuka ADHD approval; Freenome-Abbott test; J&J talc settlement

• Tuesday: GSK move to Cambridge; US Medicare Part D

• Wednesday: UK social care; FTC v Hims; J&J-Sail CAR-T; Biogen Leqembi; Capricor DMD vote; Latigo pain; record biopharma M&A

• Thursday: Sanofi cleanup; Replimune adcomm; Alnylam cut; US pharma tariffs; decongestant suit; Illumina guidance; biotech IPOs

• Friday: Novo ZEUS failure; Datroway EU approval

Monday 27 July

argenx agreed to buy Forte Biosciences for $2.2bn, gaining a first-in-class antibody in vitiligo and coeliac disease.

The Dutch-Belgian immunology group is paying $77 a share in cash, an 86% premium to Forte’s volume-weighted price since it reported positive phase 1b vitiligo data on 9 July. It gains FB102, an anti-CD122 antibody with early proof-of-concept in vitiligo and coeliac disease, with phase 2 readouts due in H2 2026. The deal carries argenx beyond the neuromuscular and autoantibody diseases it built Vyvgart (efgartigimod) around, into two indications with no established drug.

• argenx to Acquire Forte Biosciences, Adding First-in-Class anti-CD122 FB102

AstraZeneca posted an overall-survival win for its Claudin 18.2 drug in gastric cancer and a rare-disease miss for Ultomiris, alongside Q2 results.

AZ said sonesitatug vedotin met the overall-survival primary endpoint in later-line CLDN18.2-positive advanced gastric cancer and a key secondary endpoint in the broader population, although PFS missed significance. Ultomiris failed on event-free survival in transplant-associated thrombotic microangiopathy. Management retained its $80bn 2030 revenue target.

• Half-year Financial Report - AstraZeneca (RNS)

• Update on Phase III trial of Ultomiris in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant - AstraZeneca

The FDA approved Otsuka’s Simtriyo (centanafadine), the first triple reuptake inhibitor for ADHD.

Otsuka announced the approval on 27 July for adults and children aged six and over, three days after the agency cleared it. Simtriyo blocks reuptake of norepinephrine, dopamine and serotonin, a mechanism no approved ADHD drug uses, and must clear controlled-substance scheduling before it can launch.

• Otsuka Receives FDA Approval for First-in-Class SIMTRIYO for Treatment of ADHD

The FDA approved Freenome’s SimpleScreen blood test for colorectal cancer, with Abbott to sell it in the US.

The approval turns SimpleScreen from a lab service into a product Freenome can sell. Under a 2025 agreement, Abbott’s diagnostics operation will commercialise SimpleScreen from this autumn, triggering a $100m milestone for Freenome. In the >48,000-patient PREEMPT CRC study, the test detected colorectal cancer with 81% sensitivity and showed 90% specificity for advanced neoplasia. The test offers a blood-draw alternative to colonoscopy and stool testing, which many patients avoid.

FDA Approves Freenome’s SimpleScreen CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.

Johnson & Johnson offered $5.5bn to settle ovarian-cancer talc litigation.

The proposal covers roughly 76,000 remaining ovarian-talc claims and requires participation by firms representing at least 95% of them. J&J would commit $5.5bn, with a first payment of no more than $3bn in 2027 and nothing further before 2028. It lands below the $8.9bn J&J proposed in 2023 and follows two failed attempts to route the claims through bankruptcy. A parallel case runs in the UK.

• Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Tuesday 28 July

GSK will move its R&D HQ to Cambridge and cut £1.9bn annual cost by 2029.

The Cambridge Biomedical Campus centre replace GSK’s Stevenage site and house >1,000 scientists across oncology, respiratory, hepatology, vaccines and HIV. GSK targets £1.9bn in annual savings for £2.4bn of costs over three years, mainly through procurement, simpler processes and shifting resources from mature products. It now plans 20+ phase 3 starts in 2026, double its previous target, and booked a £1.3bn impairment, mostly on chronic-cough drug camlipixant. Q2 turnover was £8.4bn.

• GSK delivers strong Q2 core results performance and continued momentum

CMS will end subsidy holding down standalone Medicare drug-plan premiums.

Centers for Medicare & Medicaid Services (CMS) said it will close the Part D Premium Stabilization Demonstration at the end of 2026, having judged that from 2027 bids that insurers can now price plans without the support. The programme has subsidised standalone Part D plans across 2025 and 2026 to blunt premium rises, so its removal exposes enrollees to sharper increases next year.

• July 28, 2026 Medicare Parts C & D Announcement - CMS

Wednesday 29 July

Prime Minister Andy Burnham asked the Casey commission to set out how to deliver a National Care Service for England.

In a speech, Burnham announced Baroness Louise Casey’s Independent Commission on Adult Social Care will deliver final recommendations by summer 2027 for a service built around the person and integrated with the NHS. He said care workers should be “the best paid people in society, not the worst“. Casey has argued for a mixed market while criticising some private providers for profiteering. It is the new government’s attempt to reopen a reform successive administrations have left unresolved.

• Prime Minister’s speech on social care: 29 July 2026 - Prime Minister’s Office

The FTC sued Hims & Hers, alleging it shared users’ health data with advertisers after promising to protect it.

The complaint, filed with the State of Utah and Los Angeles County in California federal court, says the telehealth company passed lists of customers identified by condition or treatment to Meta, Snap and others through tracking pixels, and locked subscribers into plans while making cancellation hard. It invokes the FTC Act and the Restore Online Shoppers’ Confidence Act. Hims & Hers, a major telehealth supplier of weight-loss drugs, called the claims baseless.

• FTC & States Act Against Hims & Hers for Deceptive and Unlawful Privacy Practices

J&J took a $2.6bn option to buy in vivo CAR-T company Sail Biomedicines.

J&J will pay $785m up front, including $465m in equity, plus up to $140m in milestones, and $2.58bn more if it exercises the option. Sail, built by Flagship Pioneering, develops RNA medicines that engineer a patient’s T cells inside the body rather than in a manufacturing suite, which is designed to dramatically simplify cell therapy manufacture. Buying an option rather than the company lets J&J hold the position while the data matures.

• J&J Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs

Biogen raised its 2026 guidance as Leqembi recorded its best quarter.

Global Leqembi (lecanemab) sales, shared with Eisai, rose 15% to $184m, a third straight quarter of growth for an Alzheimer’s antibody held back since approval by its infusion schedule and brain imaging. Q2 revenue of $2.74bn beat consensus, and Biogen improved its full-year revenue outlook from a mid-single-digit decline to an increase. Newer drugs, including the Apellis-acquired Syfovre and Empaveli, now outweigh the declining multiple sclerosis business.

• Biogen Reports Second Quarter 2026 Results

An FDA advisory committee voted against Capricor’s Duchenne cell therapy.

The panel voted 9 to 3 that the efficacy data did not support deramiocel for the heart-muscle damage of DMD. The vote does not bind FDA, which has a 22 August decision date, but a negative vote leaves little room to approve without more evidence.

• Capricor Provides Update on FDA Advisory Committee Meeting for Deramiocel

Latigo’s non-opioid painkiller succeeded in a mid-stage trial, putting a second drug into a field Vertex has had to itself.

Published in the New England Journal of Medicine (NEJM), a phase 2b trial in 343 abdominoplasty patients found LTG-001 reduced 48-hour pain versus placebo. Latigo said the high dose delivered about 50% greater SPID48 than Vicodin, with 52% of patients opioid-free versus 22% on placebo. Vertex secured the class’s first approval with Journavx; a credible rival now complicates the market for payers and partners. Latigo, which is pursuing an IPO, plans phase 3 trials in H2 2026.

• Latigo: NEJM Publication of Positive LTG-001 Abdominoplasty Clinical Trial Results

Biopharma dealmaking hit a record $170bn in the first half of 2026, on fewer but larger transactions.

BioWorld put H1 deal value at $170.1bn, 22% above the $139.4bn of H1 2025 and the highest first half in its records, with the second quarter alone a record $90.4bn. The deal count fell to 579 from 636, so the increase was driven by bigger deals. The patent cliff is a key driver, to shore up big pharma’s next decade of revenue.

• Biopharma shatters quarterly deal record with $90.4B Q2 haul - BioWorld

Thursday 30 July

Sanofi upgraded its 2026 guidance but cleared out late-stage immunology programmes under new chief executive Belen Garijo.

Q2 sales rose 17.8% to €11.6bn, led by Dupixent up 37.6%, and Sanofi lifted full-year guidance to around 10% sales growth. Against that, Garijo discontinued the Regeneron-partnered IL-33 antibody itepekimab in COPD and chronic rhinosinusitis and the balinatunfib programmes, and impaired the Kymab-derived amlitelimab by €952m, part of write-offs of over €1bn. It was her first account of how she means to reverse a run of clinical setbacks: an R&D cleanup, more M&A and a push into China.

• Q2 26: double-digit sales and strong EPS growth; 2026 guidance upgraded - Sanofi

An FDA adcom backed Replimune’s twice-rejected melanoma drug, 10 to 3.

The panel found the efficacy of RP1 (vusolimogene oderparepvec) with Opdivo clinically meaningful in melanoma that has progressed on anti-PD-1 therapy, days after FDA reviewers said in briefing documents that the registrational IGNYTE trial did not prove RP1 works. The vote does not bind FDA, which has a 2 August decision date.

• Replimune Announces Favorable Outcome of FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

Alnylam cut its TTR sales outlook as Amvuttra hit a $1bn+ quarter for first time.

TTR revenue reached $1.03bn, up 89%, taking total product sales to $1.17bn, but Alnylam trimmed full-year TTR guidance by $200m to $4.2 to $4.5bn, saying early second-line demand had been inflated by pent-up switching that has now normalised. Amvuttra (vutrisiran) makes up most of Alnylam’s commercial weight.

• Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results

Endpoints reported that the first round of Trump’s 100% pharmaceutical tariffs will not take effect as planned, every targeted company having dealt itself out.

The first Section 232 tariffs were due to hit an initial group of drugmakers, but all had secured Most Favoured Nation pricing and US onshoring deals setting their rate at 0%, leaving none to charge. The 100% tariff remains scheduled for the rest of the industry from 29 September, as the White House presses more firms into agreements.

• 1st round of Trump’s 100% pharma tariffs won’t start Friday as planned - Endpoints

A US appeals court revived claims that decongestant makers misled buyers with “maximum strength” labelling.

The Second Circuit ruled that “maximum strength“ claims over phenylephrine products can proceed. The FDA has concluded that oral phenylephrine works no better than placebo. The consolidated litigation covers roughly 100 class actions against makers and retailers including Procter & Gamble and CVS.

• In re Oral Phenylephrine Marketing and Sales Practices Litigation, No. 24-3296 (2d Cir.) - US Court of Appeals for the Second Circuit

Illumina raised its 2026 guidance after a Q2 beat.

The sequencing leader reported Q2 revenue of $1.16bn, up 9.5%, and lifted full-year guidance to $4.60 to $4.64bn and non-GAAP EPS to $5.30 to $5.40, citing NovaSeq X placements and clinical demand, a read across the entire sequencing market.

• Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026

Two biotechs priced or set terms for IPOs

Apnimed priced an upsized offering of 12m shares at $16 to raise $192m, funding the launch of its sleep-apnoea pill AD109, which awaits an FDA decision, and its shares jumped on their Nasdaq debut. Braveheart Bio set terms to raise $318.8m at a valuation of up to $1.2bn, to fund phase 3 work on BHB-1893, a cardiac myosin inhibitor licensed from Jiangsu Hengrui for hypertrophic cardiomyopathy. Analysts attribute the revival to rotation from richly valued tech and AI stocks into healthcare.

• Apnimed Announces Pricing of Upsized Initial Public Offering

• Braveheart Bio, Inc. Form S-1/A - SEC EDGAR

Friday 31 July

Novo’s ziltivekimab failed in its big cardiovascular outcomes trial, shutting its expansion from obesity and diabetes.

In phase 3 ZEUS, the anti-IL-6 antibody engaged its target but failed to reduce major cardiovascular events versus placebo in >6,300 people with atherosclerotic disease, chronic kidney disease and inflammation (hazard ratio 0.99). Cardiovascular outcome trials are among the costliest and determine reimbursement breadth, so failure leaves little room for recovery. Novo’s remaining hopes rest on two trials: HERMES in heart failure and ARTEMIS after heart attack, both of which report in H1 2027.

• Novo update on ZEUS phase 3 trial in people with ASCVD, CKD and inflammation

AstraZeneca and Daiichi Sankyo won EU approval for Datroway in first-line triple-negative breast cancer.

The European Commission cleared Datroway, a TROP2 ADC, as first-line monotherapy for metastatic triple-negative breast cancer in patients ineligible for immunotherapy, moving it ahead of chemotherapy. In phase 3 TROPION-Breast02, overall survival rose to 23.7 months from 18.7 (median) and the risk of progression or death fell 43%. AZ said it is the only EU-approved TROP2 with an overall-survival benefit in this setting.

• Datroway approved in the EU as only TROP2-directed medicine with overall survival benefit for 1st-line metastatic TNBC - AstraZeneca

ALETH · OPEN ACCESS RESEARCH

aleth.co

The Aleth Briefs trace each story to its original source and show how the week unfolded.

The week in five lines

• Burnham abolished the UK science department.

• Biotech M&A hit a new record.

• Trump threatened 200% tariffs on imported generics.

• Tempus AI agreed to acquire Personalis for $1.5bn.

• J&J gained FDA approval for its first robotic surgery system.

In this edition

• Monday: Samsung buys PolyPeptide; GSK drops camlipixant; Kolon phase 3 fail; Tempus buys Personalis

• Tuesday: UK abolishes DSIT; record biotech M&A; Novartis-Myricx ADC; Freenome SPAC

• Wednesday: Trump generic tariffs; Novo sues Lilly; GSK Jideytro approval; Crystalys gout raise; NIH Bio Genesis

• Thursday: Repligen buys BioLife; AstraZeneca EU breast cancer; J&J robotic surgery; Lilly retatrutide

• Friday: FDA backs BPC-157; J&J myeloma combo; GSK strategy update

Monday 20 July

Samsung Biologics agreed to buy Swiss CDMO PolyPeptide Group for $1.8bn.

Samsung is offering CHF 44.31 a share in cash, valuing PolyPeptide’s equity near CHF 1.46bn ($1.8bn), a 40% premium to the undisturbed price on 10 April. PolyPeptide’s board backs the offer and its largest holder, with 55.7% of the shares, has committed to tender. Peptide contract manufacturers have become a choke point in weight-loss drugs. Samsung, until now a monoclonal-antibody house, is buying its way into that. Completion is expected by the end of 2026.

• Samsung Biologics announces tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share - PolyPeptide Group / Samsung Biologics

GSK is stopping development of chronic-cough drug it paid $2bn for.

In the phase 3 CALM programme, CALM-1 hit its primary endpoint, a significant cut in 24-hour cough frequency at week 12 on the 50mg twice-daily dose, but CALM-2 missed the same endpoint at week 24 and the lower 25mg dose failed in both trials. GSK judged the benefit “unlikely to transform patient care” and stopped development in refractory chronic cough. The asset, a P2X3 antagonist it acquired in its 2023 Bellus Health buyout, continues in a phase 2b trial in IBS.

• GSK provides an update on CALM-1 and CALM-2 phase III trials - GSK

Kolon’s gene therapy for knee osteoarthritis failed its first late-stage US trial.

TissueGene-C (TG-C) missed both co-primary endpoints, pain and function, at month 12 in the phase 3 ACTiVION-II study, which the company put down to an unusually strong placebo response. A second late-stage trial, ACTiVION-I, reports in October.

• Kolon TissueGene reports topline ACTiVION-II phase 3 results for TissueGene-C (TG-C) - Kolon TissueGene

Tempus will buy Personalis for $1.5bn adding cancer genomics to its AI platform.

The all-stock deal values Personalis at $16.25 a share, an enterprise value near $1.5bn net of Tempus’s existing stake, with Tempus able to pay up to half in cash. It folds Personalis’s tumour-profiling and molecular residual disease (MRD) testing, including its NeXT Personal assay, into Tempus’s precision-oncology business. Tempus expects to close late in 2026 or early in 2027.

• Tempus to acquire Personalis, integrating MRD - Tempus AI

Tuesday 21 July

New PM Burnham cut the science department and established a Minister for AI.

The Department for Science, Innovation and Technology (DSIT) is being folded into an enlarged Department for Business, Innovation, Science and Trade under Jonathan Reynolds. Patrick Vallance, the former government chief scientific adviser, resigned as science minister. Life sciences leaders welcomed Reynolds’s return but voiced concern at losing both a standalone science department and Vallance. A new Minister for AI, Kanishka Narayan, gets a cabinet seat, with AI strategy moving into the Cabinet Office.

• Ministerial appointments: July 2026 - Prime Minister’s Office (GOV.UK)

• Departure of Lord Vallance as science minister causes concern - The Times

Billion-dollar biotech takeovers in 2026 have already passed the whole of 2025.

The Financial Times counted 37 acquisitions of $1bn or more so far in 2026, topping last year’s full-year record of 35 with five months still to run. The engine is the patent cliff: big pharma is sitting on cash from today’s blockbusters and buying its next decade of revenue. The 2026 trend is broad, with every major and a widening group of mid-sized and specialist buyers in the market.

• Fervour over top-selling drugs fuels record biotech dealmaking - Financial Times

Novartis provided further colour on its $1.5bn Myricx Bio acquisition.

Chief executive Vas Narasimhan defended the deal on this week’s Q2 call. Struck earlier in July, it brings Novartis Myricx’s N-myristoyltransferase inhibitor payload, a different way of killing tumour cells from the ADCs already crowding oncology. Narasimhan, who had sat out the ADC land grab, said he moved because the chemistry was novel: “we would certainly look to expand that NMTi payload across more delivery vehicles and more drug targets.”

• Novartis agrees to acquire Myricx Bio, advancing next-generation ADC innovation with a novel NMTi payload - Novartis

• “We’ve been looking for a novel approach”: Why Novartis CEO ended his ADC holdout for the $1.5B Myricx deal - Fierce Biotech

Freenome went public through a $310m SPAC.

The multi-cancer early detection (MCED) company completed its combination with Perceptive Capital Solutions Corp and began trading on Nasdaq as FRNM, raising $310m gross. The listing, agreed with the Perceptive Advisors vehicle in December, hands one of the larger private names in liquid-biopsy screening public-market capital to push its colorectal and multi-cancer tests toward commercialisation.

• Freenome debuts as a publicly traded company focused on blood-based early cancer detection - Freenome

Wednesday 22 July

Trump set a countdown to a 200% tariff on imported generic drugs

Generics escape duty for two years, then face a 100% tariff from August 2028 and 200% a year after that, unless their makers build in the US. The president cast it as reshoring “with a penalty to those Companies that decide not to build.” The exposure is real: generics are about 90% of US scripts and most are imported, >50% from India alone. Sandoz, among the largest suppliers, said it shares the affordability goal and would keep talking to Washington but that it was “too early to assess” the impact.

• Truth Social post on a 200% tariff on imported generic drugs - Donald J. Trump, Truth Social

• Sandoz to engage with US policymakers after Trump’s tariff plan - The Wall Street Journal

Novo Nordisk took Eli Lilly to court over false advertising of weight-loss drugs.

In a complaint filed in New Jersey federal court, Novo alleges Lilly ran “false and materially misleading“ ads for Zepbound and Mounjaro, “intentionally selected outdated studies,” and set its top doses against lower doses of Wegovy and Ozempic while leaving out newer high-dose semaglutide data. It wants an injunction and corrective advertising. Lilly’s campaign leans on the SURMOUNT-5 head-to-head trial where tirzepatide beat semaglutide on weight loss: “the only head-to-head, randomized clinical trial“.

• Novo Nordisk v. Eli Lilly, complaint, D.N.J. (3:26-cv-09027) - Novo Nordisk / STAT News

The FDA approved GSK’s cancer drug Jideytro, a week after its $10.6bn buyout.

Jideytro (zidesamtinib), a brain-penetrant ROS1 inhibitor, cleared for ROS1-positive non-small cell lung cancer in patients already treated with a ROS1 drug, nearly two months ahead of its September action date. It is GSK’s first approved lung-cancer medicine, and it arrived through Nuvalent, whose ~$10.6bn takeover GSK completed on 15 July. Approval rested on the phase 1/2 ARROS-1 trial, in which 44% of patients responded.

• Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive NSCLC - GSK

• GSK completes acquisition of Nuvalent, Inc. - GSK

Crystalys raised $130m to push its once-daily gout pill into phase 3.

The Series B, led by Frazier Life Sciences alongside existing backers Novo Holdings and SR One, funds registration trials for dotinurad, an oral URAT1 inhibitor that lowers uric acid and is already approved across much of Asia. It follows a $205m Series A only ten months earlier, in September 2025.

• Crystalys Therapeutics announces $130 million Series B financing to advance global phase 3 development of dotinurad for gout - Crystalys Therapeutics

The NIH put its weight behind AI, launching a $1.2bn Bio Genesis Mission.

The programme is the health agency’s slice of a wider federal Genesis Mission, set up by a November 2025 executive order to point AI at scientific problems across government. NIH names six targets, from forecasting biological systems to speeding drug development, and its director, Jay Bhattacharya, set a goal of halving the time from discovery to patient over ten years.

• Genesis Mission: harnessing AI to transform American science - The White House

Thursday 23 July

Repligen agreed to buy BioLife Solutions for about $1.5bn

BioLife makes the biopreservation media and freezing products that keep cell and gene therapies alive from manufacturing to patient, so the deal moves Repligen further into that supply chain rather than into a drug. Terms are $31.00 a share, split $11.25 in cash and 0.1442 of a Repligen share, a 24% premium to the 90-day average, with close expected in Q4.

• Repligen to acquire BioLife Solutions, expanding its cell-therapy capabilities - Repligen / BioLife Solutions

AstraZeneca won EU approval for its oral breast-cancer pill Etcamah

Etcamah (camizestrant), a next-generation oral selective estrogen receptor degrader (SERD), is cleared with a CDK4/6 inhibitor for ER-positive, HER2-negative advanced breast cancer once a tumour picks up an ESR1 mutation during first-line treatment. In the phase 3 SERENA-6 trial the combination cut the risk of progression or death by 56% (hazard ratio 0.44), lifting median progression-free survival to 16.0 months from 9.2. The FDA has extended its review in the US approval process.

• Etcamah (camizestrant) approved in the EU for ESR1-mutant advanced breast cancer - AstraZeneca

J&J was cleared by the FDA to enter the surgical robotics market.

The agency granted De Novo authorisation to J&J’s Ottava system, a soft-tissue surgical robot with its arms built into the operating table rather than mounted on carts, for a broad set of general-surgery procedures. It sets up a three-way US contest with Intuitive Surgical‘s da Vinci, which holds about 80% of the market, and Medtronic‘s Hugo. J&J will start with selected US hospitals while it seeks more indications.

• Johnson & Johnson receives FDA market authorization in the US for its OTTAVA Robotic Surgical System - Johnson & Johnson

Lilly’s retatrutide posted the largest phase 3 weight loss yet reported for an obesity drug, but did not significantly reduce cardiac events.

In two phase 3 trials, the triple hormone agonist (”triple-G”) took up to 22.6% off patients’ weight at 80 weeks, ahead of the GLP-1 drugs already on sale. But in TRIUMPH-3, run in people with established cardiovascular disease, it did not significantly cut major cardiac events, the hazard ratio of 0.82 too wide to tell apart from chance. The peak figure also came in below the roughly 24% seen in phase 2. Lilly plans to file for approval in Q1 2027.

• Lilly’s triple-agonist retatrutide successful in two additional phase 3 trials - Eli Lilly

Friday 24 July

An FDA advisory panel voted to loosen the rules on a barely characterised peptide, over its own scientists’ objections.

By 8 votes to 6, with one abstention, the Pharmacy Compounding Advisory Committee recommended adding BPC-157, alongside a second peptide, KPV, to the substances pharmacies may compound. FDA staff had advised against, citing a lack of evidence that BPC-157 works and a warning of low confidence in what the substance even is. Most of the members who voted yes have ties to the peptide industry, on a panel remade under Health Secretary Robert F. Kennedy Jr. The recommendation is non-binding.

• Certain bulk drug substances for use in compounding that may present significant safety risks - FDA

J&J reported that pairing two of its bispecific antibodies cut the risk of myeloma getting worse by 89%.

In the phase 3 MonumenTAL-6 trial, the combination of Tecvayli (teclistamab) and Talvey (talquetamab), which hit two different targets, BCMA and GPRC5D, reduced the risk of disease progression or death by 89% (hazard ratio 0.11) and the risk of death by 62% against standard care, in patients with relapsed or refractory disease. J&J said the hazard ratio was the lowest yet reported for a bispecific combination in a phase 3 myeloma trial. The result strengthens J&J’s already leading myeloma franchise.

• Tecvayli and Talvey reduced the risk of disease progression or death by 89% in earlier-line relapsed/refractory multiple myeloma - J&J

GSK’s new CEO, Luke Miels, will set out his strategy next week.

The company has scheduled its Q2 results and a “portfolio growth opportunities” update in London for 28 July, and insiders expect the depth of the R&D pipeline, and an emerging oncology portfolio, to be the centrepiece. Miels, previously chief commercial officer, has already spent to reshape that pipeline, through the acquisitions of RAPT and Nuvalent.

• GSK chief Luke Miels to host first major strategy update - The Times

ALETH · OPEN ACCESS RESEARCH

aleth.co

The Aleth Briefs trace each story to its original source and show how the week unfolded.

The week in five lines:

• CagriSema lost to Zepbound head-to-head.

• Gilead agreed to buy Arcellx for $7.8bn.

• The FDA proposed a pathway for bespoke genetic medicines.

• Roche unveiled its $150 human genome Axelios instrument platform at AGBT.

• Novo Nordisk will cut US semaglutide list prices to $675.

Browse by day:

• Weekend catch-up: US tariffs

• Monday: CagriSema · Arcellx · FDA pathway · Gossamer · Merck · BioMarin · Ultima

• Tuesday: Novo prices · Braftovi · US vaccine suit

• Wednesday: GSK-35Pharma · HIV pills

• Thursday: Lilly pill · argenx · BMS ADC · Aicuris · Hernexeos · Generate IPO

• Friday: Illumina · Oxford Nanopore

Weekend catch-up

The US Supreme Court struck down Trump’s global tariffs, while pharma escaped the replacement.

The court ruled 6-3 that the International Emergency Economic Powers Act does not give the president authority to impose tariffs. The White House responded the same day with a temporary 10% import surcharge under section 122 of the Trade Act, but pharmaceuticals and APIs were exempted. Drugmakers had spent the prior year restructuring supply chains around the now-invalidated regime. The immediate threat has receded, but the authority to target pharma through other statutes survives.

• Learning Resources v Trump, slip opinion of 20 February · Supreme Court

• Imposing temporary import surcharge, presidential proclamation · The White House

Monday 23 February

Novo Nordisk’s CagriSema failed its head-to-head with Zepbound.

In the open-label REDEFINE 4 trial Novo’s CagriSema - a combination of cagrilintide, an amylin analogue, and semaglutide - failed to show non-inferiority on weight loss versus Lilly’s single-molecule dual GIP/GLP-1 agonist Zepbound (tirzepatide) 15 mg at 84 weeks. CagriSema delivered 20.2% weight loss against 23.6% for tirzepatide.

CagriSema was Novo’s best shot at closing the efficacy gap with Zepbound, and the head-to-head result leaves Lilly clearly ahead for now. A higher-dose CagriSema study starts in H2 2026, with REDEFINE 11 reporting H1 2027. An FDA decision on the filed dose is expected by late 2026. Novo shares fell >12% in early Copenhagen trading.

• REDEFINE 4 head-to-head trial, primary endpoint not achieved · Novo Nordisk

Gilead agreed to buy Arcellx for $7.8bn.

Gilead will pay $115/share in cash plus a $5 contingent value right, converting its 2022 anito-cel collaboration into full ownership and eliminating its existing profit share, milestones and royalties. Arcellx’s BCMA CAR-T is already under FDA review in fourth-line multiple myeloma, with a decision due by 23 December 2026. The deal gives Gilead full control of one of the leading challengers to J&J’s Carvykti and adds another major asset to a cell therapy franchise led by Yescarta and Tecartus.

• Gilead to acquire Arcellx to maximize long-term potential of anito-cel · Gilead

The FDA proposed a pathway for bespoke genetic medicines.

The Plausible Mechanism Framework for individualised therapies targets genetic diseases with a known biological cause. Rather than follow conventional development, the FDA would allow evidence on bespoke treatments from related products, mechanistic understanding and prior manufacturing experience to support approval.

The framework formalises the kind of case-by-case approach used for therapies such as the custom CRISPR treatment given to baby KJ. If it works as intended, it could materially shorten development timelines for ultra-rare genetic diseases.

• Plausible Mechanism Framework to develop individualized therapies · FDA

Gossamer Bio’s seralutinib failed its phase 3 in pulmonary arterial hypertension.

The inhaled PDGFR inhibitor improved six-minute walk distance by a placebo-adjusted 13.3 metres at week 24, but missed the trial’s prespecified statistical threshold despite a nominal p=0.0320. Seralutinib had been positioned as the nearest challenger to Merck & Co’s Winrevair. Gossamer shares fell 77%. Enrolment in the follow-on SERANATA study was paused, and the company plans to discuss a path forward with the FDA. Chiesi co-develops the drug.

• Gossamer Bio announces topline results from the phase 3 PROSERA study · Gossamer Bio

Merck is splitting its human health business ahead of the Keytruda patent cliff.

Oncology will become a standalone division under Jannie Oosthuizen, while a separate specialty, pharma and infectious diseases unit will be led by Brian Foard, joining from Sanofi. Keytruda generated $31.7bn of Merck’s $58.1bn pharma sales in 2025 and loses US exclusivity in 2028. The new structure gives oncology its own leadership while focusing on the portfolio that must replace Keytruda’s earnings.

• Merck evolves operating structure to support portfolio execution · Merck & Co

Astellas took co-rights to Vir’s masked T-cell engager for prostate cancer in a deal worth up to $1.7bn.

Vir gets $335m upfront and near-term milestones for VIR-5500, a dual-masked PSMA T-cell engager in phase 1 prostate cancer. The companies split US profit and loss equally, with Vir eligible for another $1.37bn plus ex-US royalties. The deal funds Vir’s oncology push and gives Astellas another prostate cancer asset alongside Xtandi.

• Astellas & Vir announce global strategic collaboration VIR-5500 · Vir Biotechnology

BioMarin is pulling its haemophilia A gene therapy Roctavian from the market.

The withdrawal follows October’s decision to seek a buyer. None emerged, and BioMarin says the move is unrelated to efficacy or safety. Approved in Europe in 2022 and the US in 2023 at a $2.9m list price, Roctavian never achieved expected uptake, highlighting that one-time gene therapies with imperfect durability are commercially difficult at multi-million-dollar prices, particularly where existing treatment is strong.

• BioMarin voluntarily withdraws Roctavian from the market · BioMarin

Ultima Genomics launched its UG200 sequencing series at AGBT.

The UG200 and UG200 Ultra run the company’s Solaris 2.0 workflows, with the Ultra targeting more than 60,000 30x genomes a year. US pricing starts at $850,000, with shipments due from Q2. Ultima is pushing further into the high-throughput sequencing market where Illumina has historically been strongest.

• Next generation sequencing at scale with UG200 Series launch · Ultima Genomics

Tuesday 24 February

Novo Nordisk will reset US semaglutide list prices to $675.

From January 2027, Wegovy, Ozempic and Rybelsus will all list at $675 a month, cutting Wegovy’s sticker price by half. Net prices are already substantially lower after rebates, so the immediate revenue effect may be limited, but the move further dismantles the old $1,000-plus per month US GLP-1 pricing model.

• Significant reduction US list price for Wegovy, Ozempic and Rybelsus · Novo Nordisk

Pfizer’s Braftovi combination won full approval in first-line colorectal cancer.

The FDA converted Braftovi (encorafenib) with Erbitux (cetuximab) and chemotherapy to full approval in BRAF V600E-mutant metastatic colorectal cancer. BREAKWATER showed a 51% reduction in the risk of death, removing the confirmatory-data overhang for the only targeted first-line regimen in this population.

• US FDA grants full approval to Pfizer’s Braftovi combination regimen · Pfizer

15 US states sued the federal government over the childhood vaccines schedule.

The lawsuit challenges the January decision that removed seven vaccines from universal recommendation, including hepatitis A and B, influenza, Covid-19 and RSV, as well as the replacement of ACIP’s membership. The states are asking the court to overturn both, moving the dispute over US vaccine policy into the courts.

• Multistate lawsuit challenging Kennedy vaccine schedule · Arizona Attorney General

Wednesday 25 February

GSK agreed to buy 35Pharma for $950m in cash.

The Canadian biotech’s lead asset HS235 is a clinical-stage activin signalling inhibitor for pulmonary arterial hypertension (PAH) and PH with preserved ejection fraction heart failure. The pathway is validated by Merck’s Winrevair, which sold $1.4bn last year. HS235 data suggest fat-selective weight loss and improved insulin sensitivity. GSK’s move comes two days after Gossamer’s failure thinned the PAH pipeline.

• GSK enters agreement to acquire 35Pharma Inc · GSK

Gilead and Merck both reported late-stage data for new daily HIV pills.

Gilead’s bictegravir/lenacapavir single tablet maintained virological suppression in switch patients in ARTISTRY-1, while Merck reported phase 3 data for its two-drug doravirine/islatravir regimen. Both companies plan regulatory filings, as they try to simplify daily oral therapy even as longer-acting regimens move toward weekly dosing.

• Single tablet bictegravir & lenacapavir maintained virological suppression · Gilead

• Late-breaking data three phase 3 trials evaluating doravirine/islatravir · Merck & Co

Thursday 26 February

Lilly’s orforglipron beat Rybelsus in a head-to-head diabetes trial.

In ACHIEVE-3, orforglipron 36 mg reduced A1C by 2.2% versus 1.4% for Rybelsus 14 mg on the efficacy estimand, with 9.2% weight loss versus 5.3%. On the treatment-regimen estimand, the gap narrowed to 1.9% versus 1.5%. Adverse-event discontinuations were roughly twice as high with orforglipron.

Three days after Zepbound beat CagriSema head-to-head, this compounds a difficult week of direct comparisons for Novo. Orforglipron is filed in >40 countries. As a small molecule it offers Lilly easier manufacturing and supply than peptide GLP-1s.

• Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide · Eli Lilly

argenx’s Vyvgart succeeded in ocular myasthenia gravis.

The phase 3 ADAPT OCULUS trial met its primary endpoint, with no new safety signals, supporting a US filing to expand Vyvgart into the ocular form of the disease. It is the first registrational study of a targeted treatment in ocular myasthenia gravis.

• Vyvgart phase 3 ADAPT OCULUS data in ocular myasthenia gravis · argenx

BMS and SystImmune’s bispecific ADC hit survival endpoints in breast cancer.

Izalontamab brengitecan, the EGFRxHER3 ADC BMS licensed for $800m upfront in 2023, improved both progression-free and overall survival at an interim analysis of a Chinese phase 3 trial in triple-negative breast cancer. It is the drug’s third positive phase 3 result and the first dual PFS/OS win for a bispecific ADC in the disease.

• Positive phase III topline results izalontamab brengitecan · Bristol Myers Squibb

Asahi Kasei agreed to buy Germany’s Aicuris for €780m.

The Japanese group is acquiring the antiviral specialist through US subsidiary Veloxis, gaining the Prevymis royalty stream and pritelivir, which met its phase 3 primary endpoint in refractory herpes simplex infection in immunocompromised patients. The deal adds a focused infectious-disease portfolio built around transplant medicine.

• Asahi Kasei to acquire Aicuris to accelerate growth in infectious diseases · Aicuris

Hernexeos won rapid first-line approval in lung cancer, only 44 days after filing.

The FDA granted accelerated approval to Boehringer Ingelheim’s Hernexeos for first line HER2-mutant non-small cell lung cancer, based on a 76% response rate in treatment-naive patients. It is the second approval through the National Priority Voucher route, giving an early indication of how quickly the pathway can move.

• FDA approves Hernexeos for first-line lung cancer · Boehringer Ingelheim

Caris reported interim data on its multi-cancer blood test.

In 2,122 samples from Achieve 1, Caris Detect showed 56.8% sensitivity at stage I, rising to 99.1% at stage IV. Specificity was 99.1% in 121 asymptomatic participants and 95.3% in the 1,505-person undiagnosed population. A blinded validation in about 865 held-out samples is due later in Q1.

• Caris Life Sciences completes interim readout of Achieve 1 study · Caris Life Sciences

Roche unveiled its Axelios sequencer, targeting a $150 human genome.

Roche revealed details of its sequencing-by-expansion chemistry in early 2025. At AGBT it unveiled the instrument, Axelios 1, which is due to launch later this year, targeting a $150 whole human genome at scale. Roche will enter the sequencing market with an instrument, an aggressive cost claim and the balance sheet to compete, adding further pressure on Illumina and its emerging challengers.

Advances in Genome Biology and Technology (AGBT) · Roche

Generate Biomedicines priced its IPO at $400m.

The Flagship-founded protein design company sold 25m shares on Nasdaq at $16. Trading under GENB begins Friday. Its lead asset, GB-0895, is an AI-engineered anti-TSLP antibody already in phase 3 severe asthma trials, with twice-yearly dosing under evaluation. The IPO is therefore a relatively advanced public-market test of generative protein design rather than another preclinical AI platform story.

• Generate Biomedicines announces pricing of IPO · Generate Biomedicines

Friday 27 February

Illumina launched TruPath Genome and detailed its NovaSeq X roadmap at AGBT.

TruPath Genome is designed to compete with long-read sequencing, which Illumina says doubles the throughput of competing long-read methods. The company also outlined an 18-month NovaSeq X roadmap increasing output 40% to 35bn reads per flow cell, alongside Q70 duplex accuracy for specialised high-sensitivity applications.

• Illumina launches TruPath Genome, unveils NovaSeq X roadmap · Illumina

MGI conceded its sequencer infringes Oxford Nanopore’s Australian patents.

MGI accepted in the Federal Court (Australia) that its Cyclone SEQ WT02 infringes four Oxford Nanopore patents, leaving infringement itself undisputed ahead of a 2027 trial on remaining defences and damages. Separate UK High Court proceedings against MGI/BGI entities continue over trade-secret infringement and breach of confidence.

• Update on legal action against MGI Australia · Oxford Nanopore

ALETH · OPEN ACCESS RESEARCH

aleth.co

The Aleth Briefs trace each story to its original source and show how the week unfolded.

The week in five lines:

• Grail’s Galleri missed its NHS trial primary endpoint, shares fell >45%.

• Danaher and Masimo agreed a deal at about $9.9bn enterprise value.

• An FDA NEJM article suggests one pivotal trial could become the approval default.

• Bayer proposed a $7.25bn Roundup class settlement.

• Compass Pathways’ COMP360 met its second phase 3 primary endpoint.

Browse by day:

• Weekend catch-up: Gilead-Genhouse · Disc Medicine

• Monday: Roche Gazyva · Novartis on the UK

• Tuesday: Danaher-Masimo · Bayer · Compass · Ocular · CSL-Lilly

• Wednesday: FDA one-trial · Moderna

• Thursday: Grail · AZ Calquence · Hims-Eucalyptus · Guardant-MetaSight · Element

Weekend catch-up

Gilead took global rights to a clinic-ready cancer drug GH31 from China’s Genhouse Bio for $80m upfront, in a deal worth up to $1.45bn in milestones.

GH31 is a MAT2A inhibitor, a synthetic lethality approach aimed at MTAP-deleted tumours, with clearance to enter clinical trials in both the US and China. Gilead takes worldwide development and commercialisation. The deal adds to the run of US buyers sourcing clinic-ready oncology assets from Chinese biotechs.

• Global partnership with Gilead on MAT2A inhibitor GH31 · Genhouse Bio

The FDA issued a complete response letter for Disc Medicine’s bitopertin.

The FDA asked for results for the erythropoietic protoporphyria candidate from the continuing APOLLO phase 3 study. The application had carried a Commissioner’s National Priority Voucher, meant to speed favoured drugs through review. The letter resets the timeline on Disc’s lead asset without ending the programme.

• Complete response letter from FDA for bitopertin · Disc Medicine

Monday 16 February

Roche’s Gazyva (obinutuzumab) delivered positive phase 3 results in primary membranous nephropathy.

The results could support the first approval in the kidney disease and further extend use of the oncology antibody into immune-mediated conditions, following its clearance in lupus nephritis last autumn.

• Positive phase III results for Gazyva in primary membranous nephropathy · Roche

Novartis’s UK and Ireland head said the NHS’s reformed approach to evaluating new medicines is “slowly killing the life science sector in the UK”.

Johan Kahlstrom told The Times the changes still do not go far enough. The criticism follows 15 years of Novartis cutting back its UK footprint, which the company attributes to NICE’s cost-effectiveness rules limiting access to its medicines. Novartis has repeatedly described the UK as “uninvestable”.

Novartis’s UK chief says NHS medicines assessment is throttling the sector · The Times

Tuesday 17 February

Danaher agreed to buy Masimo for $9.9bn.

Danaher will pay $180/sh in cash, valuing Masimo at $9.9bn including debt. The deal adds pulse oximetry, sensor technology and AI-enabled patient monitoring to Danaher’s diagnostics portfolio, where Masimo will sit alongside Radiometer, Leica, Cepheid and Beckman Coulter. Danaher expects Masimo to generate >$530m EBITDA in 2027, with >$125m of cost and $50m of revenue synergies by year five. The price is around 18x 2027 EBITDA, falling to 15x including expected synergies. Closing H2 2026.

• Danaher to acquire Masimo Corporation · Danaher

Bayer proposed a $7.25bn settlement of the Roundup litigation.

The Monsanto US class settlement would resolve current and future claims alleging Roundup causes cancer. The litigation has weighed on Bayer since its 2018 acquisition of Monsanto. The proposed settlement would cap a long-running legal exposure that has been difficult to quantify and reduce the risk of years of further litigation.

• Roundup class settlement agreement to resolve current and future claims · Bayer

Compass Pathways’ synthetic psilocybin met its endpoint in a second phase 3 trial.

COMP360, a synthetic formulation of psilocybin, the psychoactive compound found in “magic mushrooms”, met the primary endpoint in the second of two phase 3 trials in treatment-resistant depression. Shares rose about 30%. Compass has requested an FDA meeting to discuss a rolling submission and expects to complete its NDA in Q4.

• Met primary endpoint 2nd phase 3 trial of COMP360 psilocybin · Compass Pathways

Ocular Therapeutix’s AXPAXLI beat a single aflibercept dose in phase 3, but shares fell more than 25%.

SOL-1 compared one dose of the axitinib intravitreal implant with a single 2 mg dose of Eylea in wet AMD after an aflibercept loading phase, rather than with continued on-label anti-VEGF treatment. AXPAXLI met the trial’s superiority endpoint, supporting planned FDA discussions, but the comparator design tempered investor enthusiasm.

• Positive results from SOL-1 phase 3 superiority trial in wet AMD · Ocular Therapeutix

Eli Lilly licensed CSL’s anti-IL-6 antibody clazakizumab for $100m upfront.

Lilly will explore the antibody in kidney disease and other immuno-inflammatory indications, with CSL eligible for additional milestones and royalties. Clazakizumab previously failed a phase 3 trial in organ transplant rejection, and the licence allows CSL to retain some of the economics without fully funding further development alone.

• CSL and Lilly enter licensing agreement for clazakizumab · CSL

The UK government cleared the way for UK Biobank to receive its participants’ GP records.

A data provision notice published on 10 February, picked up this week by The Times, opens coded primary care data in England to consented cohorts such as UK Biobank. For its 500,000 participants, this could double recorded cases of common conditions including arthritis, asthma, dementia and heart failure. The data cover diagnoses, symptoms, medications, referrals and test results, with identifiers removed and consultation notes excluded. Access starts once the NHS agrees data-sharing terms.

• Milestone for health research Government enables access to GP data · UK Biobank

• Decades of medical insight unlocked as UK Biobank gets GP records · The Times

Wednesday 18 February

FDA moves towards one pivotal trial as its default for drug approval.

Commissioner Marty Makary and Vinay Prasad argued in a New England Journal of Medicine perspective that requiring two pivotal trials has become something of a regulatory dogma, and that one adequate well-controlled trial plus confirmatory evidence should instead be the default. FDA already allowed this, but making it the norm would materially change development planning. Formal guidance is still to come.

• One pivotal trial, the new default for FDA approval ending two-trial dogma · NEJM

The FDA reversed itself and will review Moderna’s flu vaccine, a week after refusing to file the application.

After a Type A meeting with CBER, Moderna proposed a revised regulatory pathway for mRNA-1010: full approval in adults aged 50-64 and accelerated approval in ages 65 and over, with an additional post-marketing study in older adults. FDA accepted the amended BLA and set a 5 August PDUFA date, in time for the 2026–27 flu season.

• FDA will initiate review of seasonal influenza vaccine submission · Moderna

Thursday 19 February

Grail’s Galleri missed its primary endpoint in the NHS-Galleri trial.

The study was the largest test so far of whether a single blood test can detect multiple cancers early enough to improve outcomes, and was central to Grail’s UK strategy. It missed its primary endpoint, sending shares down >45% after hours on Thursday.

Grail highlighted a substantial reduction in stage IV diagnoses and a four-fold increase in cancer detection, but the primary endpoint failure weakens the case for NHS adoption and raises fresh questions over the clinical value of multi-cancer early detection (MCED) screening. FDA premarket approval remains under review.

• NHS-Galleri demonstrates substantial reduction in stage IV cancer diagnoses · Grail

The FDA approved AstraZeneca’s Calquence with Venclexta as the first all-oral, fixed-duration combination for first-line chronic lymphocytic leukaemia (CLL).

The clearance covers adults with untreated CLL or small lymphocytic lymphoma (SLL). It gives AZ a fixed-duration front-line regimen in a market where treatment duration has become an important point of differentiation among BTK-based therapies.

• FDA approves acalabrutinib with venetoclax for CLL or SLL · FDA

• Approved as first all-oral, fixed-duration combination in 1st-line CLL · AstraZeneca

Hims & Hers agreed to buy Australian digital health company Eucalyptus for $240m upfront, in a deal worth up to $1.15bn.

The acquisition expands Hims further beyond the US into Australia and Japan and increases its presence in Germany, Canada and UK. Eucalyptus also adds prescribing and fulfilment infrastructure to support Hims’ international weight-loss business.

• To acquire Eucalyptus, accelerating global consumer health vision · Hims & Hers

Guardant disclosed its December acquisition of MCED startup MetaSight.

Terms were $59m upfront, with up to $90m tied to regulatory and commercial milestones. The acquisition adds a multi-cancer early detection programme to a screening portfolio currently centred on blood-based colorectal cancer testing.

• Q4 and full-year 2025 results and 2026 outlook · Guardant Health

Element unveiled VITARI, a new high-throughput sequencing platform.

Element Biosciences has been pushing into territory held by Illumina and Ultima Genomics with its AVITI line, and its new high-throughput instrument takes the fight to the part of the market that drives the majority of sequencing consumables revenue.

• Element introduces VITARI, redefining what sequencing makes possible · Element

ALETH · OPEN ACCESS RESEARCH

aleth.co

The Aleth Briefs trace each story to its original source and show how the week unfolded.

The week in five lines:

• The FDA refused to review Moderna’s flu shot.

• ICON opened an accounting probe and withdrew its 2025 guidance.

• BridgeBio’s achondroplasia pill met its phase 3 goal.

• Eli Lilly bet up to $2.4bn on in vivo CAR-T.

• Isomorphic Labs new drug engine goes “well beyond AlphaFold 3”.

Browse by day:

• Weekend catch-up: Roche’s MS drug · Lilly-Innovent

• Monday: Lilly-Orna · Novo v Hims · REGENXBIO · DSM-Firmenich · Takeda-Iambic

• Tuesday: Moderna-FDA · AstraZeneca results · CSL · Isomorphic

• Wednesday: Madrigal-Ribo · Keytruda in ovarian cancer

• Thursday: Sanofi CEO · BridgeBio · EU coalition · ICON · US HRT warnings · PTC

• Friday: Novartis Vanrafia

Weekend catch-up

Roche’s oral BTK inhibitor fenebrutinib matched Ocrevus in primary progressive multiple sclerosis (PPMS).

In the 985-patient phase 3 FENtrepid trial, fenebrutinib met its primary endpoint of non-inferiority to Ocrevus (ocrelizumab) and cut risk of disability progression by 12% at 24 weeks. Fatal events ran at 1.4% against 0.2% on Ocrevus. Roche will submit its full phase 3 package once the relapsing-MS study FENhance 1 reads out in H1 2026.

• Fenebrutinib first in over a decade to reduce disability progression in PPMS · Roche

Eli Lilly and Innovent Biologics signed their seventh collaboration, an oncology and immunology alliance worth up to $8.9bn.

Innovent will be paid $350m upfront and is eligible for up to $8.5bn in milestones plus royalties, and will run development to phase 2 proof-of-concept in China while Lilly gets rights everywhere outside Greater China.

• Innovent announces strategic collaboration with Lilly · Innovent Biologics

Monday 9 February

Eli Lilly agreed to buy Orna Therapeutics for up to $2.4bn.

The deal takes Lilly into in vivo CAR-T, where a patient’s own cells are reprogrammed into cell therapies without being removed from the body. Orna’s lead candidate is a CD19-directed in vivo CAR-T for B-cell-driven autoimmune diseases, built on circular RNA. It is one of the largest acquisitions of an in vivo cell-therapy company to date.

• Lilly to acquire Orna Therapeutics to advance cell therapies · Eli Lilly

Novo sued Hims & Hers for patent infringement over compounded semaglutide.

Novo’s complaint accuses Hims of infringing its US patent covering semaglutide, and seeks a permanent injunction and damages. Hims had said over the weekend it would stop offering the compounded pill after the FDA signalled enforcement.

• Novo Nordisk takes legal action against Hims & Hers · Novo Nordisk

The FDA issued a complete response letter for REGENXBIO’s RGX-121, its gene therapy for Hunter syndrome.

REGENXBIO disclosed that the agency had turned down its accelerated-approval filing for the ultra-rare paediatric disease, questioning the trial’s eligibility criteria, its natural-history control and the surrogate endpoint used. The FDA set out requirements, including a new controlled study, that are hard to run in such a small population.

• REGENXBIO announces regulatory update on RGX-121 BLA for MPS II · REGENXBIO

DSM-Firmenich agreed to sell its Animal Nutrition & Health business to CVC at an enterprise value of about €2.2bn including an earn-out of up to €0.5bn.

The Swiss group expects to receive €1.2bn in value after closing, of which roughly €0.6bn is net cash, with it retaining a 20% stake in the unit, which had about €3.5bn of net sales in 2025. The sale, due to close by the end of 2026, largely completes its exit from animal nutrition to concentrate on fragrance, taste and health.

• dsm-firmenich agrees to divest Animal Nutrition & Health to CVC · DSM-Firmenich

Takeda struck a multi-year AI drug discovery deal with Iambic Therapeutics worth >$1.7bn.

Takeda gains access to Iambic’s platform, including its generative model NeuralPLexer, to advance small-molecule programmes in oncology, gastrointestinal disease and inflammation. Iambic takes upfront and technology-access payments and is eligible for milestones that could exceed $1.7bn plus royalties.

• Collaboration with Takeda to advance AI-driven drug design · Iambic Therapeutics

Tuesday 10 February

The FDA refused to review Moderna’s next-generation flu vaccine.

Moderna said the Center for Biologics Evaluation and Research (CBER) had issued a refusal-to-file letter for mRNA-1010, objecting solely to the trial’s comparator arm, a licensed standard-dose flu vaccine, which it said did not reflect the best-available standard of care. Moderna said the letter raised no safety or efficacy concern.

Moderna rejected the reasoning, noting the FDA had reviewed both phase 3 designs before the trials began and that the filing rested on two positive studies in 43,808 participants that met all primary endpoints. It has requested a Type A meeting.

• Refusal-to-file letter from FDA for investigational flu vaccine mRNA-1010 · Moderna

AstraZeneca reported 8% sales growth for 2025 and held its $80bn 2030 target.

Revenues rose 8% at CER (9% AER) to $58.7bn and core earnings per share 11% at CER to $9.16, and chief executive Pascal Soriot reaffirmed the 2030 goal, underpinned by more than 25 planned blockbusters and expansion in the US and China.

• AstraZeneca results: FY and Q4 2025 · AstraZeneca

CSL said CEO Paul McKenzie would retire and, a day later, issued a profit warning.

Company veteran Gordon Naylor, a former Seqirus president, steps in as interim with the plasma and vaccines group under investor pressure. First-half net profit came in at US$401m, down 81% at constant currency, after about US$1.1bn of impairments against CSL Seqirus and CSL Vifor assets tied to falling US vaccine demand.

• Paul McKenzie retires, Gordon Naylor appointed interim CEO · CSL

• CSL half-year results announcement · CSL

Isomorphic Labs unveiled a drug design engine it says goes well beyond AlphaFold 3.

The London-based Alphabet company said its proprietary engine roughly doubles AlphaFold 3’s accuracy on the hardest ligand-binding cases, reaching about 50% on cases with little similarity to training data, against about 23% for AlphaFold 3.

• IL Drug Design Engine unlocks new frontier beyond AlphaFold · Isomorphic Labs

Wednesday 11 February

Madrigal paid $60m upfront for six preclinical siRNA programmes from China’s Ribo, worth up to $4.4bn.

The licence gives Madrigal exclusive global rights to the MASH candidates, built on Ribo’s GalSTAR liver-targeting platform, to combine with its approved MASH drug Rezdiffra (resmetirom). Another deal to build its combination options around Rezdiffra.

• Madrigal expands MASH pipeline with agreement for six siRNA programs · Madrigal

• Ribo & Ribocure announce exclusive global licensing agreement with Madrigal · Ribo

The FDA approved Keytruda in platinum-resistant ovarian cancer, a tumour type the drug had never cracked.

Merck said the agency cleared Keytruda plus paclitaxel with or without Avastin for adults with PD-L1-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer in the second or third line. The FDA cleared Agilent’s PD-L1 IHC 22C3 pharmDx as the companion diagnostic alongside it.

• Keytruda approved in PD-L1-positive platinum-resistant ovarian cancer · Merck

• PD-L1 IHC 22C3 pharmDx approved as companion diagnostic for Keytruda · Agilent

Thursday 12 February

Sanofi named a new chief executive to succeed Paul Hudson.

Sanofi has appointed Belén Garijo, chief executive of Merck KGaA since 2021 and the first woman to lead a DAX40 company, to the top job. Sanofi said Garijo would bring increased rigour to its strategy and R&D, with the growth of Dupixent under scrutiny.

• Belén Garijo to become Chief Executive Officer of Sanofi · Sanofi

BridgeBio’s infigratinib met its phase 3 goal in achondroplasia.

The oral FGFR1-3 selective tyrosine kinase inhibitor improved annualised height velocity by a mean 2.10 cm/year over placebo at week 52 in the PROPEL 3 trial in children (p<0.0001), and met its key secondary on height Z-score. BridgeBio plans US and European filings in H2 2026, setting up a challenge to BioMarin’s Voxzogo.

• Positive phase 3 topline results for oral infigratinib in achondroplasia · BridgeBio

European life sciences investors managing >€24bn launched a coalition.

Novo Holdings, Sofinnova, Forbion, Omega Funds and HealthCap were among the members founding the European Life Sciences Coalition in Brussels, alongside Invest Europe, to press for more capital to scale the region’s biotech companies.

The coalition put Europe at 7% of global life sciences venture capital against 63% for the United States and 14% for China, and noted that 66 of 67 EU biotech companies to list in the past six years chose to do so outside the EU.

• European Life Sciences Coalition launched to strengthen ecosystem · Invest Europe

ICON disclosed an accounting investigation and pulled 2025 guidance.

The CRO said a probe into revenue recognition had preliminarily found revenue in 2023 and 2024 may each have been overstated by less than 2%. It delayed its full-year results to 30 April and said it expects to report one or more material weaknesses.

• Update on timing of results and investigation into accounting practices · ICON

The FDA removed three risk statements from boxed warnings on six menopausal hormone therapy products.

The agency approved labelling changes stripping the warnings on cardiovascular disease, breast cancer and probable dementia from Prometrium, Divigel, Cenestin, Enjuvia, Estring and Bijuva, after a scientific-literature review begun in November 2025.

• FDA approves labelling changes to menopausal hormone therapy products · FDA

PTC Therapeutics withdrew its US filing for the Duchenne drug Translarna.

PTC pulled its NDA resubmission for Translarna in nonsense-mutation DMD after the FDA indicated the data were unlikely to meet its threshold of substantial evidence of effectiveness, This was its third failed attempt to secure US approval for the drug.

• PTC Therapeutics provides regulatory update on Translarna · PTC Therapeutics

Friday 13 February

Novartis said Vanrafia slowed kidney-function decline in IgA nephropathy, though its key secondary endpoint missed significance.

In the phase 3 ALIGN study, Vanrafia showed an eGFR difference over placebo of 2.39 mL/min/1.73 m² at week 136, the final analysis’s key secondary endpoint, that fell short of statistical significance (p=0.057). Vanrafia already holds accelerated US and China approval and Novartis plans to file for approval in 2026 regardless of the miss.

• Phase 3 data support slowing of kidney-function decline in nephropathy · Novartis

ALETH · OPEN ACCESS RESEARCH

aleth.co

The Aleth Briefs trace each story to its original source and show how the week unfolded.

The week in five lines:

• Novo and Lilly guided in opposite directions.

• Pfizer’s Metsera injection beat placebo by up to 12.3%.

• Bayer’s asundexian cut strokes 26%.

• The White House launched TrumpRx.

• Eikon Therapeutics and Veradermics both priced upsized IPOs

Browse by day:

• Weekend catch-up: EU CHMP · Lilly’s Pennsylvania plant · US FDA PreCheck

• Monday: Novo · Roche-SanegeneBio · Sanofi · GSK· PacBio-ILMN · PMCPA v Sanofi

• Tuesday: Pfizer-Metsera data · US funding law

• Wednesday: GSK · UK cancer plan · UK-US pharma deal · FTC-Express Scripts

• Thursday: TrumpRx · Novo-Hims · Bayer asundexian · biotech IPOs

Story of the week

A day apart, obesity’s two leaders guided in opposite directions and Novo’s shares fell 27% over the week.

On Tuesday Novo Nordisk forecast adj. 2026 sales and operating profit growth of -5% to -13% CER, citing US pricing pressure and most-favoured-nation deals. The company, which opened up weight-loss, guided to a contraction after growing sales 10% in 2025. The shares fell from $59.4 on Friday to $43.3 by end Thursday.

Then, on Wednesday, Eli Lilly forecast 2026 sales of $80-$83bn, c.25% above 2025, saying tirzepatide (Mounjaro and Zepbound) volumes more than offset the same US pricing pressure Novo had named. Its Q4 revenue rose 43% to $19.3bn.

• Novo Nordisk releases 2026 sales and operating profit outlook · Novo Nordisk

• Lilly reports fourth-quarter 2025 results and provides 2026 guidance · Eli Lilly

Weekend catch-up

Europe’s CHMP backed semaglutide as the first GLP-1 for MASH and opened a data-integrity review of Amgen’s Tavneos.

At its January meeting the Committee for Medicinal Products for Human Use (CHMP) recommended a conditional marketing authorisation for semaglutide (Kayshild) in non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis, the first GLP-1 recommended for the indication in the EU.

It also backed Sanofi’s belumosudil (Rezurock) in chronic graft-versus-host disease after re-examination, and referred Amgen’s Tavneos over data integrity questions.

• CHMP meeting highlights, 26-29 January 2026 · European Medicines Agency

Eli Lilly will spend more than $3.5bn on a Pennsylvania plant to make retatrutide and other obesity drugs.

The Lehigh Valley site is the fourth and last of the US factories Lilly promised under its “Lilly in America” programme, and commits capacity to retatrutide, its triple GIP/GLP-1/glucagon agonist, before the drug is approved.

• Lilly selects Pennsylvania for its newest injectable medicine · Eli Lilly

The FDA opened its PreCheck pilot to drugmakers building new US manufacturing plants.

The scheme offers earlier engagement and a more predictable review for companies building domestic facilities, part of the onshoring push behind a 2025 executive order.

• FDA launches PreCheck pilot program · FDA

Monday 2 February

Novo Nordisk’s CagriSema beat semaglutide in a phase 3 type 2 diabetes trial.

In the 2,728-patient phase 3 REIMAGINE 2 trial, CagriSema (cagrilintide and semaglutide) cut HbA1c by 1.91 percentage points and weight by 14.2% at 68 weeks in patients remaining on treatment, against 1.76 points and 10.2% for semaglutide.

• CagriSema superior HbA1c reduction & weight loss in REIMAGINE 2 · Novo Nordisk

Roche paid $200m upfront for global rights to a SanegeneBio RNAi programme.

Genentech takes the licence, worth up to $1.7bn with milestones and tiered royalties, extending Roche’s return to RNA interference after years out of the field. SanegeneBio runs early development before Genentech leads the clinical development.

• SanegeneBio announces RNAi licensing collaboration with Genentech · SanegeneBio

Sanofi’s venglustat passed a phase 3 trial in Gauchers but failed in Fabry disease.

In the LEAP2MONO study, the oral glucosylceramide synthase inhibitor beat enzyme replacement therapy on neurological measures in type 3 Gaucher, whose neurological manifestations have no approved treatment, and Sanofi will file globally. In the PERIDOT study in Fabry, it missed the patient-reported primary endpoint.

Venglustat met all primary endpoints in a phase 3 type 3 Gaucher disease study · Sanofi

GSK handed back rights to Wave’s RNA-editing drug for AATD.

Wave regains WVE-006, one of the first RNA-editing candidates to reach patients, and will fund it alone while it asks the FDA about potential accelerated-approval, with feedback expected in mid-2026. Data from the RestorAATion-2 cohort is due in Q1.

• Wave announces plans to accelerate regulatory path · Wave Life Sciences

Pacific Biosciences sold its short-read sequencing assets to Illumina for $48m.

PacBio built the short-read line through its Omniome buy but paused it last year to concentrate on long reads. The sale, completed on 30 January, hands the market leader another short-read asset and eliminates a potential competitor.

• PacBio completes sale of short-read sequencing assets · Pacific Biosciences

The UK PMCPA ruled Sanofi breached industry code over Pfizer RSV claims.

The Prescription Medicines Code of Practice Authority found Sanofi’s claim that its antibody Beyfortus was more effective than Pfizer’s RSV vaccine Abrysvo was unsubstantiated, and that comments amounted to advertising a prescription medicine.

• Case ruled in breach of Clause 2 · PMCPA

Tuesday 3 February

Pfizer’s obesity injection from its Metsera deal beat placebo by 12.3%.

In the ongoing 64-week VESPER-3 phase 2b maintenance study, the ultra-long-acting GLP-1 MET-097i produced placebo-adjusted weight loss of 10% and 12.3% at week 28 in patients remaining on treatment on the two doses that will go into phase 3. It is the first real read on the $10bn Metsera acquisition.

• Pfizer’s ultra-long-acting injectable GLP-1 RA shows robust weight loss · Pfizer

Trump signed a $1.2tn spending law that ended the federal shutdown.

The Act carries drug provisions the industry has been tracking: a revived rare paediatric disease priority-review voucher programme, reauthorised to 2029, and new Medicare pharmacy-benefit-manager transparency rules. The House passed it 217-214.

• H.R. 7148, the Consolidated Appropriations Act, 2026, signed · The White House

Wednesday 4 February

GSK guided to slower growth in 2026 in Luke Miels’ first outlook as CEO.

Turnover is forecast up 3-5% this year, down on 2025, while GSK held to its target of sales above £40bn by 2031 as its top-selling HIV drugs approach patent expiry. Miels used his first results as CEO to press a more product-focused, launch-led strategy.

• FY 2025 results announcement · GSK

England set out a national cancer plan targeting 75% five-year survival.

The National Cancer Plan for England commits to three in four people diagnosed from 2035 surviving at least five years, which the government puts at about 320,000 additional lives, on the back of earlier diagnosis and faster treatment. It pledges £2.3bn for 9.5 million more diagnostic tests in community centres open 12 hours/day.

• National Cancer Plan for England · Department of Health and Social Care

The UK’s pharma trade deal with the US will cost the Department of Health and Social Care (DHSC) about £1bn over the current Spending Review period.

In a letter to the Commons Science, Innovation and Technology Committee, Lord Vallance said the cost will be funded through allocations made to DHSC at the Spending Review, with front-line services protected. DHSC/NHS/NICE ran the analysis.

• Cost of UK-US pharma deal will be met by DHSC, minister confirms · SIT Committee

The FTC accepted Express Scripts consent agreement to settle insulin-price case.

Under the proposed order, Express Scripts would stop favouring high-list-price drugs where cheaper equivalents exist and would delink its pay from the rebates it negotiates. Changes the FTC estimates would cut patients’ out-of-pocket costs by up to $7bn over ten years. The case accused the largest PBM of inflating insulin list prices.

• Caremark Rx, Zinc Health Services, et al., In the Matter of (Insulin) · FTC

Thursday 5 February

The White House launched TrumpRx, its direct-to-consumer drug site.

President Trump unveiled TrumpRx.gov, listing about 40 medicines at the cash prices manufacturers agreed under his most-favoured-nation deals. The site does not sell drugs but routes patients to each company’s own platform or discount coupons. How much insured patients gain is unclear, since their copays often sit below the cash price.

• Fact sheet: President Trump launches TrumpRx.gov · The White House

Hims & Hers launched a compounded semaglutide pill at $49 for the first month, and Novo Nordisk said it would take legal action.

Hims began selling a compounded semaglutide tablet at $49 for the first month of a five-month plan, with the remaining months at $99, undercutting the branded oral Wegovy. Hims says the product uses a different formulation and delivery system. Novo called it an unapproved “knockoff” and said that it will take legal action.

• H & H expands weight loss portfolio with compounded semaglutide · Hims & Hers

• Novo Nordisk’s statement on the Hims compounded pill · Novo Nordisk

Bayer’s asundexian cut recurrent strokes by 26% in phase 3.

In the >12,300-patient OCEANIC-STROKE trial the oral Factor XIa inhibitor asundexian reduced ischaemic stroke by 26% after a non-cardioembolic stroke or high-risk transient ischaemic attack, with no rise in major bleeding versus placebo. Bayer described it as the first phase 3 of a Factor XIa inhibitor to be completed successfully.

• Asundexian after a non-cardioembolic ischaemic stroke · Bayer

Eikon Therapeutics and Veradermics both priced upsized IPOs.

Eikon, led by Merck & Co veterans and built around super-resolution microscopy, priced 21.18m shares at $18 to list on Nasdaq, for gross proceeds of c.$381m. Hair-loss specialist Veradermics priced a $256.3m NYSE IPO at $17 on 3 February.

• Eikon Therapeutics announces pricing of upsized IPO · Eikon Therapeutics

• Veradermics announces pricing of upsized IPO · Veradermics

ALETH · OPEN ACCESS RESEARCH

aleth.co

The Aleth Briefs trace each story to its original source and show how the week unfolded.

The week in five lines:

• David Silver left DeepMind to build an endlessly learning superintelligence.

• OpenAI sought about $100bn from strategic partners and SoftBank.

• DeepMind published AlphaGenome in Nature.

• Kimi K2.5 introduced a self-directed 100-agent swarm.

• Beijing reportedly cleared 400,000 Nvidia H200s for its tech giants.

Browse by day:

• Weekend: Grokipedia

• Monday: EU Grok probe · Maia 200 · Qwen · Amodei essay

• Tuesday: Kimi K2.5 · EU-Google · GOV.UK assistant · OpenAI Prism · CISA uploads

• Wednesday: China H200s · Hyperscaler capex · AlphaGenome · Waymo · OpenAI

• Thursday: OpenAI IPO · Pentagon-Anthropic

• Friday: David Silver · Nvidia OpenAI pledge on ice

Weekend (24-25 January)

Guardian tests found GPT-5.2 citing Grokipedia, xAI’s machine-written encyclopedia, across a range of ChatGPT queries.

The citations covered subjects including an Iranian conglomerate and Holocaust denier David Irving. Grokipedia’s entries have been criticised for reproducing fringe claims without editorial checks; OpenAI said GPT-5.2 searches “a broad range of publicly available sources and viewpoints“ with safeguards against harmful content.

• Latest ChatGPT model uses Musk’s Grokipedia as source, tests reveal · The Guardian

Monday 26 January

The European Commission opened formal proceedings against X Grok.

The probe examines whether X properly assessed and mitigated risks from Grok’s image tools after they generated manipulated sexual imagery, including potential child sexual abuse material. It also extends the Commission’s existing DSA investigation into X’s recommender systems.

• Investigates Grok recommender systems Digital Services Act · European Commission

Microsoft unveiled Maia 200, its second-generation AI accelerator

Microsoft says the 3nm chip beats Amazon’s Trainium3 on FP4 performance and improves inference performance per dollar by 30% over its current fleet. Evidence of hyperscalers vertically integrating around inference rather than renting Nvidia capacity.

• Maia 200: the AI accelerator built for inference · Microsoft

Qwen released Qwen3-Max-Thinking, its flagship reasoning model, claiming performance comparable to GPT-5.2 Thinking and Claude Opus 4.5.

Artificial Analysis scored it behind several open-weight Chinese rivals DeepSeek V3.2, GLM-4.7 and Kimi K2.5, underlining how competitive China’s models have become.

• Pushing Qwen3-Max-Thinking beyond its limits · Qwen

• Qwen3 Max Thinking: everything you need to know · Artificial Analysis

Dario Amodei published The Adolescence of Technology, warning that powerful AI could arrive within one to two years.

The Anthropic chief executive groups the risks into autonomy, misuse for destruction, misuse for seizing power, economic disruption and indirect societal effects, and frames the moment as a test of whether civilisation is mature enough to hold the power it is building. He argues democracies should limit their own use of powerful AI so that defending against autocratic rivals does not make them resemble them.

• The Adolescence of Technology: confronting & overcoming risks of AI · Dario Amodei

Tuesday 27 January

Moonshot AI released Kimi K2.5 including a self-directed 100-agent swarm for complex tasks.

The model builds on Kimi K2 with roughly 15T additional mixed visual and text tokens, and can orchestrate up to 100 sub-agents across 1,500 parallel tool calls, cutting execution time by up to 4.5x versus a single agent.

• Kimi K2.5: visual agentic intelligence · Moonshot AI

• Kimi K2.5: Everything you need to know · Artificial Analysis

The European Commission opened proceedings on Google’s Android interoperability and search-data obligations.

The DMA proceedings will define how rival AI assistants access Android features used by Gemini and how search and chatbot providers obtain ranking and query data. It targets the distribution layer where default access routes users to AI assistants.

• Assisting Google with interoperability & search data sharing · European Commission

The UK’s Department for Science, Innovation and Technology (DSIT) picked Anthropic to build a Claude-powered assistant for GOV.UK.

The pilot starts with employment services, helping users find work, training and support. It begins later in 2026 under the government’s “Scan, Pilot, Scale” framework.

• Partnering with UK government to bring AI assistance to GOV.UK · Anthropic

New Mexico court filings allege Mark Zuckerberg approved letting minors use AI companions that Meta safety staff warned could hold sexual conversations.

Internal messages show safety staff objecting to romantic scenarios involving under-18s and refer to a “Mark decision” blocking parental controls. Meta says the filing selectively presents internal discussions. Trial is set for February.

• Meta CEO Zuckerberg blocked sex-chatbot curbs for minors, filing alleges · Reuters

OpenAI introduced Prism, a free workspace for scientific writing with GPT-5.2.

Built on the acquired Crixet LaTeX platform, it combines writing, references and literature search in one tool for ChatGPT users.

• Introducing Prism: Accelerating science writing and collaboration with AI · OpenAI

The head of the US Cybersecurity and Infrastructure Security Agency uploaded official use only files into the public version of ChatGPT, Politico reported.

The uploads triggered automated security alerts. CISA said the use was short-term and authorised, while DHS examined if it exposed sensitive government information.

• US cyber chief uploaded sensitive files into a public version of ChatGPT · Politico

Wednesday 28 January

Reuters reported that Beijing cleared ByteDance, Alibaba and Tencent to buy more than 400,000 Nvidia H200s, worth about $10bn.

Reuters reported the first import approval of its kind, granted during Jensen Huang’s visit to China. Conditions are being finalised, including to buy domestic chips too.

• China gives green light to importing first batch of Nvidia’s H200 AI chips · Reuters

Google DeepMind published AlphaGenome in Nature, with code and weights released for noncommercial research.

The model reads 1 Mb of DNA and predicts thousands of functional genomic tracks at base-pair resolution - splice-site usage, chromatin accessibility and variant effects on gene expression among them - extending the lab’s biology work beyond protein structure into how the genome is read and regulated.

Experts called the resolution on non-coding DNA a step from theoretical interest to practical utility, while noting cell-type-specific regulation remains hard.

• Advancing regulatory variant effect prediction with AlphaGenome · Nature

• Expert reaction to Google DeepMind’s AlphaGenome paper · Science Media Centre

Waymo disclosed that one of its robotaxis struck a child at under 6 mph near a Santa Monica elementary school on 23 January.

The vehicle braked from about 17 mph before impact. The child sustained minor injuries, and NHTSA opened an investigation into whether the vehicle exercised appropriate caution near a school at drop-off time.

• A commitment to transparency and road safety: event overview · Waymo

• ODI Resume PE26001: Waymo AV striking a child in the area of a school · NHTSA

Universal Music Publishing Group, Concord and ABKCO sued Anthropic for more than $3bn over alleged ‘brazen’ copyright infringement involving >20,000 songs.

The publishers allege Anthropic downloaded pirated songbooks via BitTorrent and used them for training. It puts a larger potential price on training-data provenance.

• Concord Music Group, Inc. v. Anthropic PBC (5:26-cv-00880) · Court Listener

• UMG, Concord and ABKCO sue Anthropic for $3bn · Music Business Worldwide

Meta guided 2026 capital spending to as much as $135bn.

The $115bn-135bn range compares with $72.2bn in 2025, with Meta tying the increase to Superintelligence Labs and its core business. Q4 revenue +24% to $59.9bn.

• Meta reports fourth quarter and full year 2025 results · Meta

Microsoft reported capital expenditures of $37.5bn and disclosed that OpenAI accounted for 45% of its $625bn commercial backlog.

Revenue rose 17% to $81.3bn, with Microsoft Cloud up 26% to $51.5bn. Excluding OpenAI, the remaining commercial backlog still grew 28%.

• Earnings FY26 Q2: Microsoft Cloud & AI strength drives Q2 results · Microsoft

• FY26 Q2 earnings call transcript · Microsoft

OpenAI is seeking about $100bn from strategic investors.

The FT reported that SoftBank was close to another $30bn investment, with OpenAI also in talks with Amazon, Nvidia and sovereign wealth funds. Much of the capital could ultimately flow back through chips, cloud and infrastructure contracts.

• OpenAI in talks to raise $40bn from Nvidia, Amazon & Microsoft · Financial Times

Thursday 29 January

The WSJ reported that OpenAI is preparing for a possible Q4 2026 IPO.

The company has begun informal talks with banks and is building out its finance team, with executives reportedly concerned Anthropic could list first.

• OpenAI lays groundwork for Q4 IPO as it races Anthropic · The Wall Street Journal

• OpenAI preps fourth-quarter IPO and builds out finance team · PYMNTS

The Pentagon and Anthropic are at a standstill over safeguards on military use of Claude, Reuters reported.

The dispute centres on Anthropic’s limits around autonomous weapons targeting and US domestic surveillance. Pentagon officials argue the government can deploy commercial AI regardless of company usage policies.

• Pentagon clashes with Anthropic over military AI use · Reuters

Friday 30 January

Nvidia’s plan to invest up to $100bn in OpenAI has reportedly stalled.

The WSJ reported that Jensen Huang had privately stressed the September 2025 letter of intent was non-binding, while talks shifted towards an equity investment of tens of billions in OpenAI’s current round.

• The $100bn megadeal between OpenAI & Nvidia is on ice · The Wall Street Journal

• Nvidia’s plan to invest up to $100 billion in OpenAI has stalled, WSJ reports · Reuters

David Silver left Google DeepMind to found Ineffable Intelligence.

The well-known AlphaGo, AlphaZero and MuZero architect, and one of DeepMind’s first employees, is building a London startup around reinforcement learning (RL), aiming for an endlessly learning superintelligence that discovers knowledge for itself.

In what he calls an “era of experience”, Silver argues LLMs remain constrained by human knowledge, including through post-training based on human feedback. His overriding thesis is that, to reach superintelligence, AI will not just have to move beyond human knowledge. It will need to discard it and learn to achieve goals from scratch, working from first principles.

• Longtime DeepMind researcher David Silver leaves to found AI startup · Fortune

ALETH · OPEN ACCESS RESEARCH

aleth.co

The Aleth Briefs trace each story to its original source and show how the week unfolded.

Top five stories:

• GRAIL filed Galleri for FDA approval.

• AstraZeneca committed $15bn to China.

• Roche reported 22.5% placebo-adjusted weight loss for CT-388.

• Medicare picked 15 more drugs for price talks.

• FDA lifted Intellia’s phase 3 CRISPR trial hold.

Browse by day:

• Weekend: NHS cancer · Guardant injunction · Merck/Revolution talks end

• Monday: UK biotech IPOs · AZ Cambridge · Genmab halt · Elevidys follow-up

• Tuesday: Roche obesity · Waters/BD · Intellia lift · EU/India deal · Medicare · J&J

• Wednesday: Lilly/Seamless · REGENXBIO · Cellares · Danaher · newborns · Yuvezzi

• Thursday: AZ China · Roche · Thermo Fisher · mRNA flu · Galleri · Repertoire/Lilly

• Friday: AstraZeneca/CSPC deal

Weekend catch-up

NHS England launched a national register for people carrying inherited variants that increase cancer risk.

The register covers >100 genes and gives the NHS a route to monitor and recall people for tests.

• Inherited cancer checks programme · NHS England

Patent Court rejects Guardant’s injunction request against Sophia Genetics.

The Paris Local Division refused provisional measures over Sophia’s liquid-biopsy test. It found two patents more likely than not invalid for added matter and said infringement of the third had not been shown with sufficient certainty.

• Final Order, Guardant Health v. Sophia · Unified Patent Court

Merck was no longer in talks to buy Revolution Medicines, The Wall Street Journal reported.

• Merck No Longer in Talks to Buy Revolution · The Wall Street Journal

Monday 26 January

UK drug developers considering IPOs after a four-year domestic biotech drought.

The BioIndustry Association (BIA) told Fierce Biotech that companies were looking at Nasdaq. Baker McKenzie lawyers expected at least two possible London biotech listings in 2026.

• ‘Things are looking up’: British biotechs · Fierce Biotech

AstraZeneca kept its planned £200m Cambridge expansion on hold.

The company said its planning application preserved the option to build rather than restarting the project. The proposed site would employ about 1,000 people.

• AstraZeneca keeps UK research site · Fierce Biotech

Genmab stopped trial enrolment of cancer candidate acquired in $1.8bn ProfoundBio acquisition.

Endpoints reported that the halt affected an early-stage programme. Genmab bought ProfoundBio in 2024 to acquire its antibody-drug conjugate pipeline.

• Genmab halts enrollment · Endpoints

Sarepta said three-year data showed Elevidys slowed the loss of motor function in ambulatory Duchenne patients.

Elevidys (delandistrogene moxeparvovec) produced at least 70% less decline than a propensity-weighted external control on time to rise and the 10-metre walk or run. The follow-up covered 52 patients from EMBARK.

• Sarepta Announces Positive Topline Results · Sarepta

Tuesday 27 January

Roche’s CT-388 produced 22.5% placebo-adjusted weight loss.

The highest once-weekly dose had not reached a weight-loss plateau at 48 weeks. Some 54% of recipients ended below the obesity threshold, against 13% on placebo, and Roche said phase 3 was expected to begin in Q1.

• Roche announces positive Phase II results · Roche

Waters shareholders approved the combination with BD’s Biosciences.

99% of shares represented at the meeting voted in favour. Waters said regulatory approvals were in place and expected the transaction to close on 9 February.

• Shareholders approve combination with BD’s Biosciences · Waters

The FDA lifted the hold on Intellia’s phase 3 MAGNITUDE-2 CRISPR trial.

The decision restarts enrolment of patients with hereditary transthyretin amyloidosis with polyneuropathy. The MAGNITUDE cardiomyopathy trial remained paused.

• Lift of FDA hold on MAGNITUDE-2 Ph3 trial in ATTRv-PN · Intellia

The EU and India concluded negotiations on a free-trade agreement.

Once signed, ratified and in force, the agreement would eliminate or reduce tariffs on >96% of EU goods exports into India, including 11% tariffs on pharmaceuticals.

• EU and India conclude landmark Free Trade Agreement · European Commission

CMS selected 15 medicines for the third Medicare price-negotiation cycle.

The round includes Part B medicines for the first time. Negotiations run through 2026 and the resulting prices take effect on 1 January 2028.

• 15 drugs selected for third Medicare price-negotiation cycle · CMS

The FDA approved J&J’s Darzalex Faspro quadruplet for multiple myeloma.

Darzalex Faspro (daratumumab and hyaluronidase) can now be combined with bortezomib, lenalidomide and dexamethasone in adults ineligible for an autologous stem-cell transplant.

• DARZALEX FASPRO quadruplet approved for transplant-ineligible myeloma · J&J

Wednesday 28 January

Eli Lilly signed a hearing-loss gene-editing deal with Seamless Therapeutics.

Seamless will design programmable recombinases that can make large, precise DNA changes without relying on the cell’s repair machinery. Lilly receives rights to develop the resulting therapies. Potential payments exceed $1.1bn.

• Lilly collaboration · Seamless Therapeutics

The FDA placed two REGENXBIO gene therapies on clinical hold after a brain tumour was found in a treated child.

The five-year-old had received RGX-111 four years earlier. Preliminary analysis found AAV integration associated with PLAG1 overexpression. RGX-121 was also held because the programmes share relevant risks.

• Regulatory update on ultra-rare MPS programmes · REGENXBIO

Cellares raised $257m to expand automated cell-therapy manufacturing.

BlackRock and Eclipse co-led the Series D, taking total capital raised to $612m. Cellares expects clinical manufacturing in H1 2026 and commercial-scale in 2027.

• $257m Series D led by BlackRock and Eclipse · Cellares

Danaher’s Q4 revenue rose 4.5% to $6.8bn.

Full-year revenue increased 3% to $24.6bn. The life-science tools group guided to 3% to 6% core revenue growth for 2026.

• Q4 and full-year 2025 results · Danaher

An NIH-funded study selected seven programmes to assess integration of whole genome sequencing into public health newborn screening.

BEACONS chose Iowa, Minnesota, New York, Oregon, Puerto Rico, South Carolina and Texas. Its gene list targets conditions that can be acted on during a child’s first year.

• Seven sites and final gene list for genomic newborn screening · Ariadne Labs

The FDA approved Tenpoint’s combination eye drop Yuvezzi for presbyopia.

Yuvezzi (carbachol and brimonidine) combines two existing agents in a formulation for adults with blurry close-up vision due to age. Tenpoint plans a Q2 US launch.

• FDA approval of YUVEZZI, 1st combo presbyopia eye drop · Tenpoint Therapeutics

Thursday 29 January

AstraZeneca committed $15bn to China through 2030.

The investment covers research and manufacturing, including cell therapy and radioconjugates. AstraZeneca said it would expand its existing R&D centres in Beijing and Shanghai and increase its Chinese workforce beyond 20,000.

• AstraZeneca invests $15bn in China through 2030 · AstraZeneca

Roche reported 2025 sales growth of 7%

Sales reached CHF 61.5bn +7% CER, or 2% in CHF. Roche forecast mid-single-digit sales growth at constant currencies for 2026.

• 2025 results: sales up 7% · Roche

Thermo Fisher Scientific’s 2025 revenue rose 4% to $44.6bn.

Q4 revenue increased 7% to $12.2bn. Adjusted earnings per share rose 5% for the year. Thermo guided 2026 revenue of $46.0-$47.2bn, representing growth of 4%-6%.

• Q4 and full-year 2025 results · Thermo Fisher

• TMO Q4 2025 earnings call transcript · The Motley Fool

Sanofi deprioritised its next-generation mRNA seasonal flu vaccine programme, Fierce Biotech reported.

Sanofi said it did not anticipate a near-term launch. Its existing protein-based influenza portfolio remains in development and on the market.

• Sanofi scraps attempt to develop mRNA seasonal flu vaccine · Fierce Biotech

GRAIL submitted Galleri for FDA premarket approval.

The final module completes the application for its multi-cancer early-detection (MCED) blood test. The filing draws on PATHFINDER 2 and the NHS-Galleri trial.

• FDA PMA application for the Galleri multi-cancer early detection test · GRAIL

Repertoire and Eli Lilly signed an autoimmune collaboration worth up to $1.9bn plus royalties.

Repertoire receives $85m upfront and up to $1.84bn in milestones. It will use its DECODE platform to nominate tolerising therapies before Lilly takes over clinical development and commercialisation.

• Lilly collaboration on tolerizing therapies for autoimmune diseases · Repertoire

Friday 30 January

AstraZeneca agreed to pay CSPC $1.2bn upfront for eight long-acting obesity and diabetes programmes.

AstraZeneca would receive ex-China rights to the portfolio, led by once-monthly GLP-1/GIP candidate SYH2082. Closing was expected in Q2. CSPC can receive up to $3.5bn in development and regulatory milestones, plus sales payments and royalties.

• AstraZeneca agrees obesity and T2D deal with CSPC · AstraZeneca

ALETH · OPEN ACCESS RESEARCH

aleth.co

The Aleth Briefs trace each story to its original source and show how the week unfolded.

The week in five lines:

• South Korea formally enacts world’s first comprehensive AI safety law

• Elon Musk filed for damages of $79-$134bn from OpenAI.

• Beijing told its tech giants to prepare H200 orders.

• OpenAI courted Gulf funds for $50bn.

• Anthropic reported to be raising $25bn at a $350bn valuation.

Browse by day:

• Weekend: DeepSeek · Anthropic round · OpenAI compute

• Monday: UK Treasury Committee

• Tuesday: ChatGPT age prediction · China algorithm registry

• Wednesday: OpenAI $50bn · US chip-export bill · Stargate energy

• Thursday: Claude constitution · Grok images · South Korea AI law

• Friday: H200 orders

Weekend (17-18 January)

Elon Musk filed for damages of $79-$134bn from OpenAI, Microsoft.

The claim, made ahead of the jury trial set for 27 April, alleges OpenAI defrauded him by abandoning its nonprofit roots and partnering with Microsoft. It is the largest figure yet attached to the dispute over the restructuring.

• Musk notice of remedies · Court Listener

• Musk seeks up to $134 billion damages from OpenAI, Microsoft · Bloomberg

DeepSeek reportedly used smuggled Nvidia chips to train its next model.

According to the report, Huawei and other domestic chips did not deliver sufficient performance, forcing DeepSeek back onto Nvidia hardware despite US export controls. The model is expected within weeks.

• Chinese AI developers can’t beat America without better chips · Wall Street Journal

Anthropic reported to target a $25bn round at a $350bn valuation.

The FT reported that Sequoia is preparing a large investment in a round led by GIC and Coatue, each putting in $1.5bn, with Anthropic targeting $25bn. Sequoia had sat out every previous Anthropic round. Its new leadership has now backed one, at $350bn, against the $183bn post-money Anthropic announced in September.

• Sequoia plans investment in Anthropic round targeting $25bn · Financial Times

• Anthropic raises Series F at $183bn post-money valuation · Anthropic

OpenAI projected roughly 1.9 GW of compute and >$20bn of revenue for 2025, against 0.2 GW and $2bn in 2023.

CFO Sarah Friar’s Sunday post suggests a tenfold rise on both measures in two years, and more compute would have meant faster customer adoption and monetisation.

• A business that scales with the value of intelligence · OpenAI

Monday 19 January

The UK Treasury Committee said regulators’ wait-and-see approach to AI in financial services risks serious harm.

The criticism is directed at the Bank of England, FCA and Treasury: evidence to the committee suggested >75% of UK financial services firms already use AI, with adoption highest among insurers and international banks. The committee called for clearer regulatory oversight as AI becomes embedded across banking and markets.

• Approach to AI in financial services risks serious harm · UK Treasury Committee

Tuesday 20 January

OpenAI began rolling out age prediction in ChatGPT, applying content protections automatically to accounts it judges to belong to minors.

The classifier reads usage times, account age and the age entered at signup. Flagged accounts lose access to graphic and sexual content. Parents get separate controls, among them rest periods and notifications when the system detects acute distress.

• Our approach to age prediction · OpenAI

China’s Cyberspace Administration requires AI tools with public-opinion or social-mobilisation capabilities to be filed in a public algorithm registry.

The filings amount to a detailed public map of the country’s AI ecosystem - who is building what, and on which models - giving Beijing an inventory of deployed systems.

• How China’s AI boom has been mapped by its algorithm registry · Wired

Wednesday 21 January

OpenAI courted Gulf investors for a round of almost $50bn.

Bloomberg reported Sam Altman has been meeting Middle East investors - Abu Dhabi’s state-backed funds, MGX among them - to raise $50bn for OpenAI at a valuation of roughly $750bn to $830bn. The talks are early stage.

• OpenAI’s Altman meets Mideast investors for $50 billion round · Bloomberg

• OpenAI meets Middle East investors for $50bn fundraising · AGBI

The House Foreign Affairs Committee voted 42-2 to advance the AI OVERWATCH Act, applying arms-sale style congressional oversight to AI chip exports.

Chair Brian Mast’s bill would require Commerce Dept licences for advanced AI chip exports and let Congress block licences to countries of concern by joint resolution: “this is not about kids playing Halo”, “It is about the future of military warfare.” White House adviser David Sacks opposed it, and it now goes to the full House.

• Chip export bill advances in House Foreign Affairs · Roll Call

OpenAI committed to “paying our own way on energy“ so Stargate sites do not push up local electricity bills.

The pledge covers funding generation and grid upgrades its load requires, flexible loads that cut consumption during grid stress, and a tailored community plan for every Stargate site. It follows Trump’s call for AI companies to pay their own way.

• Stargate Community · OpenAI

• OpenAI commits to paying its own way on energy · Tom’s Hardware, via Yahoo

OpenEvidence raised a $250m Series D at a $12bn valuation, double its October 2025 value.

Thrive Capital and DSTco-led the round in the clinical answer engine, which served 18m clinical consultations from US clinicians in December and passed $100m revenue.

• Raised $250m to build medical superintelligence for doctors · OpenEvidence

Meta’s Superintelligence Labs delivered its first models internally, CTO Andrew Bosworth told Reuters at Davos.

He described the models as very good but said they still required “a tremendous amount of work” in post-training. He also said big capability leaps for everyday users are diminishing, tempering expectations for rapid step-changes from the new lab.

• Meta’s new AI team delivered first key models internally, CTO says · Reuters

GPTZero found 100 hallucinated citations in papers accepted to NeurIPS 2025.

The audit of 4,841 papers found invented authors, fake DOIs and journal details across 50 papers, all of which survived review by 3+ experts at the field’s largest conference.

• GPTZero finds 100 new hallucinations in NeurIPS 2025 accepted papers · GPTZero

Thursday 22 January

Anthropic rewrote Claude’s constitution so the model generalises from explained principles rather than following rules mechanically.

The document organises Claude’s behaviour around being safe, ethical, compliant with guidelines and genuinely helpful, on the argument that a model needs to understand why a behaviour is wanted to handle situations no rule anticipated. The constitution shapes the Claude models, though outputs may not always follow it.

• Claude’s new constitution · Anthropic

CCDH estimated that Grok generated 3m sexualised images in 11 days.

Center for Countering Digital Hate (CCDH) research, published alongside a New York Times analysis, sampled 20,000 of the 4.6m images Grok produced between 29 December and 8 January and estimated about 3m photorealistic sexualised images - 190 a minute - including roughly 23,000 sexualised images of children.

• Grok floods X with sexualized images of women and children · CCDH

South Korea’s AI Basic Act came into force.

The government describes the Act as the world’s first comprehensive body of law regulating AI. It requires labelling of AI-generated content and advance notification and human oversight for high-impact systems, with fines of KRW 30m ($20k) and a one-year grace period before penalties bite. Domestic startups have warned about the compliance burden. The law gives Asia its clearest counterpart yet to the EU AI Act.

• South Korea launches landmark laws to regulate AI · Reuters

• ‘Framework Act on AI’ takes effect on January 22 · Korea Policy Briefing

Friday 23 January

Beijing told Alibaba, Tencent and ByteDance to prepare H200 orders.

Bloomberg reported the companies were told they could begin preparing orders for Nvidia’s H200, suggesting import approval was close, allowing discussions over volumes and delivery. Regulators are expected to require purchases of domestic chips alongside Nvidia hardware. Approval would reopen the Chinese market for advanced Nvidia chips shortly after Washington shifted H200 exports to case-by-case licensing.

China tells Alibaba, top tech firms to prep Nvidia H200 orders · Bloomberg

ALETH · OPEN ACCESS RESEARCH

aleth.co

The Aleth Briefs trace each story to its original source and show how the week unfolded.

The week in five lines

• The US Supreme Court agreed to hear key Hikma v. Amarin case.

• GSK agreed to buy RAPT for an estimated $2.2bn.

• AstraZeneca will quit Nasdaq for the NYSE.

• Moderna pulled back from vaccine trials.

• J&J guided 2026 revenue to $100bn.

In this edition

• Weekend catch-up: SCOTUS skinny label; Cordis sale; biotech IPOs

• Monday: Europe pricing push; Valneva withdrawal

• Tuesday: GSK-RAPT deal; ViiV reshuffle; AZ NYSE; melanoma vaccine; Qiagen strategic review

• Wednesday: J&J $100bn; OpenEvidence raise; IntraBio approval

• Thursday: Abbott miss; Corcept ovarian win; Moderna vaccine retreat; Corxel raise; US-WHO exit

• Friday: Sanofi eczema

Weekend catch-up

The US Supreme Court agreed to hear Hikma’s challenge to Amarin over a generic’s “skinny label”.

The court granted certiorari on Friday in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (No. 24-889), taking up the Federal Circuit ruling that let Amarin’s induced-infringement claim proceed even though Hikma had carved the patented cardiovascular indication out of its generic Vascepa (icosapent ethyl) label. This case impacts branded drugs with secondary uses still under patent and could set how far generics can carve a patented use out of their labelling.

• Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889 - Supreme Court of the United States, docket entry of 16 January 2026

Hellman & Friedman is exploring the sale of med-device maker Cordis at >$9bn, Bloomberg reported.

The PE firm is working with advisers to gauge interest, with about half a dozen listed medtech companies weighing bids, according to the report; talks are early and no sale is assured. H&F bought Cordis, which makes stents and other cardiovascular devices, from Cardinal Health in 2021 for about $1bn.

• H&F Explores $9 Billion-Plus Sale of Medical Device Maker Cordis - Bloomberg

SpyGlass Pharma and Agomab Therapeutics filed Nasdaq IPOs

SpyGlass is an eye-disease company, whose lead asset is a drug-eluting intraocular lens in phase 3 for glaucoma. It filed its S-1 on Friday to trade under the ticker SGP. Immunology developer Agomab Therapeutics filed for its own Nasdaq listing in the same window. Only a handful of drug developers completed sizeable IPOs in 2025, and several 2026 biotech IPOs are taking shape a week after the JPM conference.

• SpyGlass Pharma, Inc. Form S-1

• Agomab Therapeutics NV Form F-1

Monday 19 January

US drugmakers are pressing European governments to accept higher prices

The push follows the MFN pricing deals US companies struck with the Trump administration, which they say force them to raise prices abroad to defend the $700bn US market. Pfizer chief executive Albert Bourla, the first to sign such a deal, told reporters at the JPM conference that faced with cutting the US price to France’s level or pulling out, the company would stop supplying France.

• Financial Times report, 19 January 2026 - Financial Times

Valneva withdrew its chikungunya vaccine after the FDA suspended the shot.

Valneva voluntarily withdrew the US BLA and IND application for Ixchiq, after the FDA suspended the licence in August 2025 following four new reports of serious adverse events; earlier safety concerns had centred mainly on older recipients. The agency has now also placed the IND on clinical hold to investigate a newly reported serious event in a younger adult. This was Valneva’s main commercial launch it its largest market.

• Valneva Provides Update on Chikungunya Vaccine IXCHIQ

• Valneva Announces FDA’s Decision to Suspend License of IXCHIQ In the U.S.

Tuesday 20 January

GSK agreed to buy US biotech RAPT Therapeutics for $2.2bn, its first major deal under new chief executive Luke Miels.

GSK will pay $58 a share in cash, an equity value of $2.2bn and about $1.9bn net of cash, for RAPT’s ozureprubart, a long-acting anti-IgE antibody in phase 2b for the prevention of food-allergy reactions. Its once-quarterly dosing would set it apart from Novartis and Roche’s Xolair (omalizumab), which dominates the anti-IgE class.

GSK enters agreement to acquire RAPT Therapeutics

Pfizer agreed to exit the HIV joint venture ViiV Healthcare as Shionogi committed $2.1bn to raise its holding.

GSK, Pfizer and Shionogi agreed to replace Pfizer’s 11.7% interest in ViiV with new shares issued to Shionogi. Pfizer receives $1.875bn and GSK a $250m special dividend, leaving GSK with 78.3% and Shionogi 21.7%. Pfizer, which warned in December that 2026 revenue will fall, exits a business it helped found while Shionogi doubles down.

• GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding

AstraZeneca will delist from Nasdaq and move its US listing to the NYSE.

AZ gave notice that it will withdraw its ADSs and debt from Nasdaq, effective after the close on 30 January, with its ordinary shares and debt starting to trade directly on the NYSE from 2 February. This will complete a shareholder-approved plan to harmonise its listing across London, Nasdaq Stockholm and New York.

• AstraZeneca to complete direct listing of shares and US debt securities on NYSE

Moderna and Merck’s personalised cancer vaccine sustained a 49% cut in the risk of melanoma recurrence or death at five years when added to Keytruda.

In the phase 2b KEYNOTE-942 trial, intismeran autogene (mRNA-4157) plus Keytruda reduced recurrence or death by 49% (hazard ratio 0.510) against Keytruda alone in resected high-risk stage III/IV melanoma, matching the benefit seen at three years.

• Moderna & Merck announce 5-yr data for intismeran autogene in melanoma

Qiagen is weighing strategic options, including sale, Bloomberg reported.

The molecular-testing company is working with advisers and has held talks with several possible buyers, including some US strategics, according to the report; its shares rose about 12%. A 2020 Thermo Fisher approach worth roughly $12bn collapsed after an activist opposed it, and the pending exit of chief executive Thierry Bernard is seen as clearing the way.

• Qiagen Is Said to Consider Strategic Options Amid Fresh Interest - Bloomberg

Wednesday 21 January

J&J guided to 2026 revenue of $100bn to $101bn, led by Darzalex.

FY2025 sales rose 6.0% to $94.2bn and Q4 sales 9.1% to $24.6bn. Darzalex, its multiple myeloma antibody, delivered $14.4bn in 2025, with $3.9bn in Q4. J&J said pharma sales topped $60bn for the first time and forecast double-digit growth by 2030.

• Johnson & Johnson reports Q4 and Full-Year 2025 results

Health-AI company OpenEvidence raised $250m, doubling its valuation to $12bn.

The Series D, co-led by Thrive Capital and DST Global, roughly doubled the valuation of three months earlier and takes total funding to c.$700m. OpenEvidence’s clinical-search tool, used widely by US physicians, joins the wave of capital chasing medical AI.

• OpenEvidence Raises $250 Million to Build Medical Superintelligence for Doctors

IntraBio won European approval for Aqneursa in Niemann-Pick type C and a phase 3 win in ataxia-telangiectasia.

The European Commission cleared Aqneursa for the neurological signs of Niemann-Pick type C in patients aged six and over weighing at least 20 kg. Separately, a phase 3 crossover trial in ataxia-telangiectasia, a rare neurodegenerative disease with no approved treatment, showed a statistically significant improvement on the SARA ataxia scale. IntraBio said it would advance regulatory submissions.

• IntraBio Receives EC Approval of AQNEURSA for Niemann-Pick Type C Disease

• IntraBio Announces Positive Pivotal Trial Results of Levacetylleucine for the Treatment of Ataxia-Telangiectasia

The FDA set out draft guidance on using minimal residual disease and complete response to support accelerated approval in multiple myeloma.

The draft recommends MRD negativity in the bone marrow, measured by flow cytometry or next-generation sequencing, and complete response as primary endpoints to support accelerated approval, with clinical benefit confirmed later on survival or progression. Because response rates in myeloma are now so high, traditional endpoints can no longer adequately differentiate between new therapies.

• Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints To Support Accelerated Approval - Federal Register

Thursday 22 January

Abbott’s Q4 sales were light and its shares fell sharply.

Q4 sales rose 4.4% to $11.46bn against a consensus of about $11.8bn, as nutrition fell 8.9% and diagnostics slipped 3.6% organically on China’s volume-based procurement. Devices grew 12.3% and pharma 7.0% organically. It guided to 2026 organic sales growth of 6.5-7.5%. Shares fell around 10% on the day.

• Abbott Reports Q4 and Full-Year 2025 Results; Issues 2026 Financial Outlook

Corcept’s relacorilant improved overall survival in a phase 3 ovarian cancer trial.

In the ROSELLA trial, relacorilant plus nab-paclitaxel cut the risk of death by 35% (hazard ratio 0.65, p=0.0004) against nab-paclitaxel alone in platinum-resistant ovarian cancer, with median survival of 16.0 months versus 11.9. The win follows the FDA’s rejection of relacorilant in Cushing’s syndrome; the agency has set a decision on the ovarian filing for 11 July, and Corcept has filed in Europe.

• Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Moderna will not fund new late-stage vaccine trials blaming US hostility.

Speaking to Bloomberg TV at Davos, Bancel said regulatory delays and shrinking official support had made the market too small: “You cannot make a return on investment if you don’t have access to the U.S. market.“ This retreat pulls late-stage funding from the core technology Moderna was built on, as U.S. vaccine policy undergoes a major overhaul under Health Secretary Robert F. Kennedy Jr.

• Moderna Curbs Investment in Vaccine Trials Due to US Backlash - Bloomberg

China-founded Corxel raised $287m to push an oral GLP-1 pill beyond China.

The Series D1, led by RTW Investments and SR One, funds an ongoing US phase 2 in obesity, a planned global phase 2 in type 2 diabetes and phase 3 preparations for CX11, an oral small-molecule GLP-1 receptor agonist Corxel licensed ex-China from Vincentage. It is one of the larger private rounds for an oral incretin as Eli Lilly, Novo Nordisk and several biotechs race into the pill market.

• CORXEL Announces $287 million Series D1 Financing

The United States formally left the World Health Organization.

The exit took effect on Thursday, a year after President Trump ordered it by executive order on his first day back in office and the required 12 months’ notice ran out. Critics warn the departure damages US and global health.

• Fact Sheet: U.S. Withdrawal from the World Health Organization - HHS

• Withdrawing the US From the World Health Organization - The White House

Friday 23 January

Sanofi will file eczema drug amlitelimab despite a mixed set of phase 3 readouts.

The SHORE study met all primary and key secondary endpoints in moderate-to-severe atopic dermatitis, but COAST 2 was mixed: it hit the US co-primary endpoint while missing statistical significance on its EU co-primaries. Sanofi, which has tipped the OX40-ligand antibody as an immunology blockbuster to follow Dupixent (dupilumab), said it will proceed with global submissions in H2 2026.

• Press Release: Sanofi’s amlitelimab confirms its potential in atopic dermatitis

ALETH · OPEN ACCESS RESEARCH

aleth.co

The Aleth Briefs trace each story to its original source and show how the week unfolded.

The week in five lines:

• Apple chose Gemini to underpin its next-generation Siri.

• Nvidia and Eli Lilly will invest $1bn in lab to push AI through drug discovery.

• Washington eased H200 licensing as Beijing restricted purchases.

• Taiwanese firms committed $250bn to US chip and AI capacity.

• OpenAI said it would test ads below ChatGPT replies.

Browse by day:

• Weekend: Grok blocked in Asia · Pax Silica · Anthropic healthcare

• Monday: Apple-Gemini · Nvidia-Lilly · UK Grok laws · Claude Cowork

• Tuesday: H200 licensing · DEFIANCE Act · Anthropic · Etched · MedGemma · Grok

• Wednesday: GLM-Image · OpenAI-Cerebras · Skild · Thinking Machines

• Thursday: Taiwan deal · TSMC · AWS sovereign cloud

• Friday: ChatGPT ads · Micron NY fab

Weekend (10-11 January)

Indonesia became the first country to block Grok, Malaysia followed a day later.

Indonesia cut access on Saturday over the risk of AI-generated sexual images, with a minister calling deepfakes “a serious violation of human rights, dignity, and the security of citizens in the digital space“. Malaysia imposed its own block on Sunday.

• Government cuts access to Grok to protect public in digital space · Komdigi

• X fails to implement safeguards, MCMC orders restrictions on Grok · MCMC

Anthropic launched Claude for Healthcare.

The release lets healthcare organisations run Claude on protected health information, with connectors into the US Centers for Medicare & Medicaid Services (CMS) coverage database for prior-authorisation and coding work, alongside an expansion of its life science products. It follows OpenAI’s healthcare push last week.

• Advancing Claude in healthcare and the life sciences · Anthropic

Monday 12 January

Apple picked Google’s Gemini to power a rebuilt Siri.

Apple and Google entered a multi-year collaboration for the next generation of Apple Foundation Models, which will be based on Gemini models and Google Cloud, helping power a more personalised Siri this year. The deal answers the long-running question of which external model provider Apple would use for Siri, while giving Google a major role in the AI infrastructure behind Apple’s default assistant.

• Joint statement from Google and Apple · Google

Nvidia and Eli Lilly committed up to $1bn over five years to a new San Francisco Bay Area AI lab focused on drug discovery.

The facility will bring Lilly biologists and chemists together with Nvidia researchers working on its BioNeMo platform, marking an unusually direct move by a chipmaker into pharmaceutical R&D. Work is due to begin this year.

• NVIDIA & Lilly announce AI Lab to reinvent drug discovery in age of AI · NVIDIA

The UK’s Ofcom opened an Online Safety Act investigation into X, and the government moved to criminalise creating non-consensual intimate images.

Ofcom is examining if X breached its duties by running a tool capable of generating image-based abuse and child sexual abuse material. Separately, science secretary Liz Kendall told the Commons the offence of creating such images, under the Data (Use and Access) Act 2025, would be brought into force under the Online Safety Act.

• Ofcom launches investigation into X over Grok sexualised imagery · Ofcom

• Secretary of State statement to the House of Commons: 12 January 2026 · GOV.UK

Anthropic opened a research preview of Cowork, extending its Claude Code agent from the terminal to general knowledge work.

Cowork gives Claude access to local files and lets it carry out multi-step tasks through the desktop app, moving the agent beyond coding into broader office and research workflows. Its main unresolved risk is prompt injection, where malicious instructions embedded in documents or other content could influence the agent’s actions.

• Cowork research preview · Anthropic · TechCrunch

Tuesday 13 January

The US eased H200 export licensing as Beijing reportedly restricted purchases.

The Bureau of Industry and Security (BIS) shifted H200 chip exports from denial to case-by-case review, on conditions that include independent security testing of each shipment and proof the sale will not cut US supply. Beijing pushed the other way: sources said China told domestic firms to buy the H200 only in special circumstances.

• License review policy for chips exported to China · US Bureau of Industry & Security

• China reportedly tightens H200 restrictions · Reuters

The US Senate passed the DEFIANCE Act, giving deepfake victims a right to sue.

Passed by unanimous consent, the bill lets people sue those who create or distribute non-consensual sexually explicit forgeries, with damages of up to $250,000. It moved amid the furore over images generated with Grok and now goes to the House.

• Durbin passes bill to combat non-consensual deepfake images · Dick Durbin

Anthropic expanded Labs into an incubator for experimental products at the frontier of Claude’s capabilities.

The team will prototype new ways of using rapidly improving models, test rough products with early users and pass successful ideas to Anthropic’s main Product organisation to scale. Anthropic says the same approach previously produced Claude Code, MCP, Skills, Claude in Chrome and Cowork.

• Introducing Labs · Anthropic

AI chip startup Etched reported to raise $500m at $5bn valuation led by Stripes.

Etched develops transformer-specific chips designed to outperform general-purpose GPUs on a defined class of AI workloads. Peter Thiel and Ribbit Capital also reportedly participated, taking total funding close to $1bn. Etched has not confirmed the round.

• Etched raises $500m for a $5bn valuation · Data Center Dynamics

Google released MedGemma 1.5, an open-weights medical model that reads 3D CT and MRI scans, alongside the MedASR speech model.

The 4bn-parameter model extends earlier 2D image work to volumetric scans and histopathology, published on Hugging Face/Vertex AI. Google reports MedASR making 82% less errors than OpenAI’s Whisper large-v3 on general medical dictation.

• Next-gen medical image interpretation with MedGemma 1.5 · Google Research

US defence secretary Pete Hegseth said Grok will be given access to classified Pentagon networks this month.

Putting a commercial frontier model into classified US defence systems would extend the Pentagon’s AI push into sensitive operational infrastructure, raising questions around security, procurement and dependence on private vendors.

• War Department launches AI acceleration strategy to secure… · Department of War

Wednesday 14 January

Z.ai released GLM-Image, an image-generation model trained on Huawei chips.

The roughly 16bn-parameter model combines an autoregressive generator with a diffusion decoder, and Z.ai released its weights publicly. The company says GLM-Image was trained entirely on domestic Huawei hardware, making it a notable test of how far Chinese AI developers can reduce their dependence on Nvidia.

• GLM-Image model card · Hugging Face

• Z.ai trained a model using only Huawei hardware · The Register

OpenAI and Cerebras signed a multi-year agreement to deploy 750 MW of Cerebras systems for OpenAI customers, beginning in 2026.

The deal gives the wafer-scale chipmaker an anchor customer at unprecedented scale and is focused on inference rather than model training. OpenAI is diversifying the hardware used to serve its models, and Cerebras has won a major role in inference by offering an architecture fundamentally different from Nvidia GPUs. According to Cerebras, this will become the world’s largest high-speed AI inference installation.

• OpenAI partners with Cerebras to bring hi-speed inference to mainstream · Cerebras

Skild AI raised $1.4bn at a valuation above $14bn, led by SoftBank.

NVentures, Macquarie and Bezos Expeditions joined the round with existing investors Lightspeed, Coatue and Sequoia. Skild is developing a general-purpose robotics foundation model, the Skild Brain, designed to work across different robot types and tasks rather than being built for a single machine. The company will use the new capital to expand training data, foundational research and real-world deployments.

• Announcing Series C · Skild AI

Three senior Thinking Machines researchers returned to OpenAI, including co-founder Barret Zoph.

Zoph, fellow co-founder Luke Metz and researcher Sam Schoenholz left Mira Murati’s heavily funded AI startup less than a year after its launch. Thinking Machines raised $2bn at a $12bn valuation in July 2025 and released its first product, the model fine-tuning platform Tinker, in October. The departures followed co-founder Andrew Tulloch’s move to Meta and represented a significant early loss of technical talent.

• Two Thinking Machines lab cofounders are leaving to rejoin OpenAI · Wiretd

• Simo tweet · Fidji Simo

Thursday 15 January

Qatar and UAE join US-led Pax Silica technology pact.

Qatar and the UAE joined the US-led Pax Silica initiative during the week, signing on Monday and Wednesday respectively. The non-binding pact aims to strengthen AI, semiconductor and other critical technology supply chains among aligned countries, bringing two major Gulf investors and data-centre markets into the US-led framework.

• US welcomes UAE and Qatar signing of Pax Silica · US Dept of State Qatar, UAE

The US and Taiwan struck a deal committing $250bn to US chip plants.

The Commerce Department said Taiwanese chip and technology firms would make at least $250bn of direct investment in US semiconductor, energy and AI capacity, backed by a further $250bn in credit guarantees, in exchange for reciprocal tariffs capped at 15%. The commitment covers semiconductor, energy and AI capacity.

• Restoring semiconductor manufacturing Taiwan agreement · US Dept of Commerce

TSMC reported record Q4 net income of NT$506bn, up 35% on AI chip demand.

The foundry’s highest-ever quarterly profit and an eighth straight quarter of growth, came on revenue up 20.5% YoY, with 7nm-and-below nodes at 77% of wafer sales. TSMC guided Q1 2026 revenue to $34.6-$35.8bn, with FY2026 capex $52-$56bn.

• TSMC reports fourth quarter EPS of NT$19.50 · TSMC

AWS launched its European Sovereign Cloud, opening in Brandenburg with more than €7.8bn of planned German investment

The structure uses dedicated European governance, a new parent company with three German subsidiaries, EU-resident operations and controls designed to keep data and control within the EU.

• AWS Launches European Sovereign Cloud and expansion across Europe · Amazon

Friday 16 January

OpenAI will test ads inside ChatGPT.

Arriving alongside the rollout of an $8-a-month ChatGPT Go tier, OpenAI will place sponsored results below replies for free- and Go-tier users in the US, matched to conversation topics, while pledging not to sell user data or expose chats to advertisers.

• Our approach to advertising and expanding access to ChatGPT · OpenAI

Micron broke ground in New York on what it says will be the largest semiconductor facility in the US.

The Clay megafab, first announced in 2022, is expected to involve up to $100bn of investment over two decades, moving a long-promised US memory project from announcement to construction as demand tightens across AI systems.

• Micron celebrates official groundbreaking at New York megafab site · Micron

ALETH · OPEN ACCESS RESEARCH

aleth.co

The Aleth Briefs trace each story to its original source and show how the week unfolded.

The week in five lines

• Execs at JPM Healthcare conference see biopharma mega-mergers in 2026

• Boston Scientific agreed to buy Penumbra at a $14.5bn enterprise value.

• Trump asked Congress to codify US drug-price deals.

• AbbVie signed a US pricing deal and pledged $100bn.

• EQT approached UK’s Oxford Biomedica for a buyout.

In this edition

• Weekend catch-up: JPM deals outlook

• Tuesday: GLP-1 suicide warnings; Novo deal hunt; Menkes approval; US probe

• Wednesday: UK OXB approach; Tecvayli phase 3; Jazz voucher sale

• Thursday: US pricing; Boston Scientific-Penumbra; Novo grant; NICE NHS prices

Weekend catch-up

Healthcare dealmakers arrived at the J.P. Morgan conference betting on a “new wave of mega-mergers in 2026”.

Bankers and executives gathering in San Francisco on Friday expected 2026 tie-ups to rival the peaks of 2019 and 2021, when deal values approached half a trillion dollars, after a thin 2024 and a partial 2025 rebound. More forgiving antitrust scrutiny under the Trump administration has given companies confidence to weigh acquisitions of $30bn or more. Jeremy Meilman, JP Morgan’s global co-head of healthcare banking, said deals “get approved... that could have had more regulatory risk in the past“, and a JP Morgan survey found 60% expecting biotech M&A to accelerate.

• US healthcare dealmakers hope for megamergers in 2026 - Reuters (RTÉ)

Monday 12 January

Abivax shares jumped 32% on report Lilly was weighing a EUR15bn takeover.

La Lettre reported Lilly was working towards a EUR15bn bid for the Paris-based biotech, whose obefazimod cleared a phase 3 trial in ulcerative colitis, and was seeking guidance if France’s foreign-investment screening would apply. France’s economy and finance ministry said it had received no formal request for approval and had had no contact with Lilly. Any acquisition of a strategic pharmaceutical company would fall under its screening regime. Neither company confirmed an approach.

• Ready to put €15 billion on the table for biotech firm Abivax - La Lettre

• Eli Lilly-Abivax rumour stirs markets, but no formal steps confirmed - Euro Biotech

AbbVie struck a drug-pricing deal with the US administration and pledged $100bn of US investment over ten years in exchange for tariff relief.

The company agreed to cut prices on certain Medicaid medicines and to sell Humira and other products direct to patients through TrumpRx, in return for exemption from branded-pharmaceutical import tariffs. It committed $100bn to US research, development and manufacturing over the next decade. Chairman and chief executive Robert Michael said the agreement let the company “move beyond policies that harm American innovation“. AbbVie was among the last of the large drugmakers to settle.

• AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans

AbbVie paid $650m upfront to license RemeGen’s PD-1/VEGF bispecific

The deal for RC148, worth up to about $5.6bn with milestones and tiered royalties, gives AbbVie rights outside Greater China to a clinical-stage bispecific for solid tumours including non-small cell lung and colorectal cancer. It is the latest large upfront Western for a Chinese-originated asset in the PD-1/VEGF class.

• AbbVie and RemeGen Announce Exclusive Licensing Agreement for a Novel Bispecific Antibody for Advanced Solid Tumors

Eli Lilly and Nvidia will build a $1bn AI drug-discovery lab in the Bay Area.

The co-innovation lab puts Lilly’s biologists alongside Nvidia’s model builders and runs on Nvidia’s BioNeMo software and Vera Rubin hardware. Its work is expected to begin in South San Francisco early this year. Unusually, the deal embeds a chipmaker inside drug discovery rather than merely selling compute into it.

• NVIDIA & Lilly Announce AI Lab to Reinvent Drug Discovery in Age of AI

The FDA rejected Atara and Pierre Fabre’s cell therapy Ebvallo a second time.

Announced on Monday, the complete response letter said the single-arm ALLELE trial the FDA had previously accepted is “no longer... adequate“ to support accelerated approval, citing confounded interpretability. Atara called it a “complete reversal of position“ by the FDA. Ebvallo (tabelecleucel) is already approved in Europe.

• Atara Biotherapeutics Provides Regulatory and Business Update on Ebvallo

Pharma leaders at JPM urged Washington to out-compete China on biotech not try to block its rise.

With a run of deals for Chinese-originated drugs framing the week, executives cast China’s advance as a “Sputnik moment“ and pressed for faster, cheaper US clinical development. John Maraganore said “innovation should come from anywhere in the world“ and warned against letting biotech “become like semiconductors“.

• JPM26: US biotech’s ‘Sputnik moment,’ - BioPharma Dive

Tuesday 13 January

The FDA asked drugmakers to strip the suicidal-behaviour warning from GLP-1 weight-loss drugs after a review found no increased risk.

The request covers Novo Nordisk’s Wegovy (semaglutide) and Saxenda (liraglutide) and Eli Lilly’s Zepbound (tirzepatide), removing a warning that has sat on the class since its move into obesity. The FDA’s review of 91 trials with 107,910 patients found no evidence of raised risk of suicidal thoughts, confirming a preliminary 2024 finding.

• FDA Requests Removal of Suicidal Behavior and Ideation Warning from GLP-1 Receptor Agonist Medications

Novo Nordisk said it was back in the market for obesity deals of any size, months after losing Metsera to Pfizer.

Chief executive Mike Doustdar told Bloomberg at the JPM conference that Novo was “in the market for big or small“ obesity deals and ready to go “very big“, as it works to rebuild an obesity pipeline after being outbid for Metsera last year.

• Novo’s CEO is ready to go ‘very big’ in hunt for obesity deals - Bloomberg

The FDA approved Sentynl’s Zycubo as the first treatment for Menkes disease, a rare and usually fatal copper-metabolism disorder in children.

The approval covers Zycubo (copper histidinate), a subcutaneous copper injection developed with Cyprium Therapeutics that bypasses the defective intestinal absorption caused by ATP7A mutations. In pooled single-arm data, early treatment cut the risk of death by nearly 80% against an untreated contemporaneous external-control cohort. The FDA had rejected the same application under four months earlier.

• Sentynl Therapeutics Announces FDA Approval of Zycubo (copper histidinate)

The Trump administration appears to have quietly closed its national-security investigation into pharmaceutical imports, according to Endpoints News.

Endpoints reported on Tuesday that the Commerce Department appeared to have concluded its Section 232 probe, leaving the president 90 days to decide on any action, which could include tariffs, and a further 15 days to act.

• Exclusive: Trump administration appears to have ended its US trade probe into pharma - Endpoints News

Wednesday 14 January

Oxford Biomedica confirmed an unsolicited takeover approach from private equity group EQT, having rejected earlier proposals as too low.

The UK-listed cell and gene therapy manufacturer said that EQT’s approach concerning a possible cash offer followed earlier proposals the board had turned down as undervaluing the business. Under the takeover code EQT has until 5pm on 11 February to announce a firm intention to bid or walk away. This adds Oxford Biomedica to a run of private equity interest in London-listed companies.

• Response to press speculation - Oxford Biomedica

J&J bispecific Tecvayli cut the risk of progression or death by 71% as a single agent in earlier-line multiple myeloma.

At the first pre-specified interim analysis of the phase 3 MajesTEC-9 trial, Tecvayli (teclistamab) monotherapy also reduced the risk of death by 40% against standard care in patients who had received one to three prior lines of therapy and were predominantly refractory to anti-CD38 therapy and Revlimid (lenalidomide). It is the second phase 3 win supporting a move of the drug out of late-line myeloma.

• Tecvayli monotherapy demonstrates superior progression-free and overall survival as early as first relapse in multiple myeloma - Johnson & Johnson

Jazz Pharmaceuticals agreed to sell a priority review voucher for $200m, the highest price in a decade.

CEO Renee Gala disclosed the agreement at the JPM conference without naming the buyer. Voucher prices have been rising and a figure of $200m is a new benchmark. Jazz earned the voucher on the FDA’s August approval of brain-tumour drug Modeyso.

• JPM26: Jazz inks $200M priority review voucher sale - Fierce Pharma

Thursday 15 January

Trump unveiled “The Great Healthcare Plan” and asked Congress to write his most-favoured-nation drug-pricing deals into law.

The four-part framework pairs the pricing codification with a shift of insurance subsidies into direct payments to consumers, an end to pharmacy-benefit-manager kickbacks and new price-transparency rules. Codifying the company-by-company deals would turn a set of executive-branch arrangements into a standing obligation that a later administration could not simply drop.

• The Great Healthcare Plan - The White House

Boston Scientific agreed to buy clot-removal specialist Penumbra at an enterprise value of about $14.5bn, its second acquisition of the week.

The cash-and-stock deal values Penumbra at $374 a share, paid roughly 73% in cash and 27% in stock, with Boston Scientific funding the about $11bn cash portion from cash and new debt. Penumbra’s mechanical thrombectomy devices pull blood clots from veins and arteries. It follows Boston Scientific’s purchase of Valencia Technologies days earlier and ranks as the period’s largest single transaction.

• Boston Scientific announces agreement to acquire Penumbra, Inc.

The Novo Nordisk Foundation committed up to DKK5.5bn, about EUR736m, to its BioInnovation Institute through 2035.

The ten-year grant announced during JPM week funds the Copenhagen incubator to back more start-ups and widen into fields including AI and quantum technology. The institute has helped create more than 130 companies since 2018 and is one of the largest private initiatives responding to Europe’s early-stage funding gap.

Novo Nordisk Foundation grants DKK5.5bn to elevate innovation in Denmark & Europe

The new chief executive of NICE said NHS drug prices should not rise for years, resisting the US pressure now heading to Congress.

The FT reported that NICE’s new chief said giving in to US demands for higher UK payments would be a backward step for the health system, putting the UK’s cost-effectiveness gatekeeper directly against the pricing efforts underway in Washington.

• NICE chief opposes higher NHS medicine prices - Financial Times

ALETH · OPEN ACCESS RESEARCH

aleth.co

The Aleth Briefs trace each story to its original source and show how the week unfolded.

The week in five lines:

• Zhipu and MiniMax took China’s AI labs public.

• Nvidia put its Vera Rubin platform into production.

• X faces four regulators over Grok’s sexual imagery.

• China said it will investigate Meta’s $2bn purchase of Manus.

• Anthropic is reportedly raising $10bn at a $350bn valuation.

Browse by day:

• Weekend: AWS GPU prices · FuriosaAI

• Monday: Vera Rubin · Grok probes · AMD MI500 · physical AI · Atlas-DeepMind

• Tuesday: xAI’s $20bn · Accenture buys UK’s Faculty · US FDA · Utah prescriptions

• Wednesday: Anthropic · GTR · PitchBook

• Thursday: HK IPOs · Manus · EU-Grok · OpenAI · Claude Code

• Friday: Meta nuclear · Erdős proof

Weekend (3-4 January)

AWS raised prices for EC2 Capacity Blocks for ML by about 15%, in a change posted quietly on Saturday.

The p5e.48xlarge rose from $34.61 to $39.80 an hour in most regions. AWS said the adjustment “reflects the supply/demand patterns we expect this quarter“. The move underscores hardware constraints in the AI ecosystem - specifically tight supply of H200 AI accelerators - and the reality that hyperscalers are passing downstream hardware cost increases directly onto enterprise AI budgets.

• AWS raises GPU prices 15% on a Saturday · The Register

Seoul-based FuriosaAI says its RNGD inference chip enters mass production this month, at a company valuation of about $700m.

The WSJ’s profile of founder June Paik reports the startup turned down an acquisition approach from Meta. Whether RNGD ships in volume, and who buys it, tests how much of the inference market is reachable by anyone other than Nvidia.

• Meet the ‘Mad Max’-loving CEO challenging Nvidia with a renegade chip · WSJ

Monday 5 January

Regulators moved on X after Grok generated sexual images of minors.

The European Commission said it is examining sexually explicit images of minors generated by Grok, with a spokesperson putting it plainly: “This is not ‘spicy’. This is illegal. This is appalling.” Investigations opened in France, Malaysia and India, and the UK asked for information. X’s response was to remove images, suspend the accounts involved and blame the users prompting the tool. It announced no product fixes.

• EC calls Grok’s sexualised AI photos ‘illegal,’ Britain demands answers · Reuters

Jerry Tworek, OpenAI’s VP of research and a central figure in its reasoning models, announced he is leaving after nearly seven years.

He said he will “try and explore types of research that are hard to do at OpenAI“. Wired linked the exit to a dispute on research direction with chief scientist Jakub Pachocki.

• OpenAI loses reasoning leader Tworek · TrendForce

• OpenAI Research VP Departs · Wired

Nvidia launched the Vera Rubin platform and physical AI models at CES

Rubin is six new chips, including the Vera CPU and Rubin GPU. Nvidia claims up to a 10x cut in inference token cost against Blackwell - which underpins most frontier training today - and that mixture-of-experts (MoE) models can be trained with a quarter of the GPUs. Jensen Huang said “Rubin arrives at exactly the right moment, as AI computing demand for both training and inference is going through the roof.”

Nvidia is expanding its physical AI stack with a suite of open-weight models and robotics. It released the Cosmos synthetic-data tools, Isaac GR00T vision-action model, and Jetson T4000 Blackwell module. Boston Dynamics, Caterpillar and LG showcased robots running the framework. For autonomous driving, Nvidia open-sourced Alpamayo a 10bn-parameter reasoning model with simulator and training dataset. Early partners backing the automotive push include Lucid, Jaguar and Uber.

• Nvidia Rubin: Six new chips, one incredible AI supercomputer · Nvidia

• New physical AI models as partners unveil next-generation robots · Nvidia

• Alpamayo open-source AI models to accelerate autonomous vehicles· Nvidia

AMD previewed its Instinct MI500 accelerators for 2027 at CES.

Lisa Su’s CES keynote gave an early look at Helios, a rack built on MI455X GPUs delivering up to 3 AI exaflops, projecting up to 1,000x the peak theoretical performance of a 2023 MI300X platform. AMD’s reponse to Nvidia’s Rubin roadmap.

• AMD’s vision for “AI Everywhere, for Everyone” at CES 2026 · AMD

Boston Dynamics and Google DeepMind formed a partnership to put Gemini Robotics models into Atlas, announced at CES.

The two will run joint research, which Boston Dynamics says is expected to begin in the coming months, aimed at industrial tasks: initially automotive manufacturing. The collaboration is spearheaded by Boston Dynamics’ director of robot behavior, Alberto Rodriguez, and DeepMind senior director of robotics, Carolina Parada.

• Bringing foundational intelligence to humanoid robots · Boston Dynamics

Tuesday 6 January

xAI closed a $20bn Series E and confirmed that Grok 5 is in training.

Participating investors include Valor Equity Partners, Fidelity, the Qatar Investment Authority, and Nvidia and Cisco - effectively supplying capital to a key GPU customer. The raise coincided with regulatory probes into Grok’s image generation.

• xAI raises $20B Series E · xAI

• xAI says it raised $20B in Series E funding · TechCrunch

Accenture agreed to buy Faculty, the UK applied-AI firm that supplies Whitehall

Founded in 2014, Faculty now employs >400 people and brings its Frontier decision-intelligence platform and AI safety capabilities. Terms were not disclosed. The deal gives Accenture ownership of one of the UK government’s main independent AI suppliers. Faculty CEO Marc Warner will become Accenture’s CTO on completion.

• Accenture to acquire Faculty to scale AI capabilities · Accenture

FDA eases oversight of wellness wearables and clinical decision-support software

Software giving a single clinical recommendation can now qualify for enforcement discretion, reversing the FDA’s 2022 position. Non-invasive consumer devices reporting blood pressure or glucose-related signals can also be treated as wellness products, provided they make no disease claims. These redrawn boundaries will determine how much consumer health AI can reach the market without FDA clearance.

• General wellness: policy for low-risk devices, guidance for industry & FDA staff · FDA

Utah authorises AI-assisted prescription renewals under regulatory sandbox.

Utah has authorised Doctronic to support routine prescription renewals for chronic conditions through the state’s regulatory sandbox. The Department of Commerce will assess safety protocols, refill timeliness, adherence, clinical outcomes and cost, and publish the results. A licensed physician will still review its recommendations, so describing this as autonomous prescribing is inaccurate.

• Doctronic partnership for AI prescription renewals · Utah Department of Commerce

A paper on arXiv pitted AI agents against professional penetration testers on a live university network of about 8,000 hosts across 12 subnets.

ARTEMIS, the agent framework the authors built, found nine valid vulnerabilities at an 82% valid submission rate, beat nine of the ten human professionals and placed second overall. Some variants ran at $18 an hour against $60 for a professional tester. The agents were strongest at systematic enumeration and parallel exploitation, and weakest on false positives and on anything with a graphical interface.

• Comparing AI Agents to Cybersecurity Professionals in Real-World Testing · arXiv

Wednesday 7 January

Anthropic reported to be raising $10bn at a $350bn valuation.

The WSJ reported the term sheet: $10bn at a $350bn pre-money valuation, led by Singapore’s sovereign fund GIC with Coatue Management, is expected to close in the coming weeks. The round would nearly doubles Anthropic’s $183bn valuation after its September round, four months ago.

• Anthropic raising $10 billion at $350 billion value · Wall Street Journal

London-based data centre developer Global Technical Realty secured nearly $2bn, with KKR committing a further $1.5bn and Oak Hill Capital about $400m.

The capital funds greenfield capacity and new European market entries - one of the larger single commitments to compute outside the US.

• KKR & Oak Hill commit nearly $2bn to data center platform GTR · GTR

The PitchBook-NVCA Venture Monitor put 2025 global venture investment at $512bn, with AI taking more than half of it.

AI accounted for a third of completed venture deals worldwide, and two thirds of the capital invested in the US. Venture funds raised $119bn, nearly $100bn below 2024 and the lowest in a decade. Exit value reached $549bn, >$200bn up on the year.

• PitchBook: AI dominates global VC as 2025 deal value nears record · SiliconANGLE

• PitchBook-NVCA Venture Monitor · NVCA

Thursday 8 January

Zhipu and MiniMax listed in Hong Kong within a day of each other.

Zhipu, listing as Z.ai, priced at HK$116.20 and opened at HK$120.00 under code 02513.HK, after a $558m IPO whose retail tranche was 1,159 times oversubscribed; the market capitalisation on debut was HK$53bn. Its chairman used the moment to warn that price competition is coming for US labs: its coding tool sells for about $3 a month.

MiniMax followed a day later and more than doubled, closing up 109% after a HK$4.8bn ($619m) IPO priced at HK$165: the top of the range. MiniMax’s prospectus disclosed an adjusted loss of about $186m for the first nine months of 2025.

• Z.ai listed on the Hong Kong Stock Exchange · PR Newswire

• Final offer price and allotment results · HKEX (Z.ai) · HKEX (MiniMax)

• MiniMax, China’s second ‘AI tiger’ to go public, doubles in value in debut · Reuters

China said it will investigate Meta’s $2bn purchase of Manus, and is reportedly drawing up an export control list for its own AI companies.

Ministry of Commerce spokesperson He Yadong said the deal will be assessed for compliance with Chinese rules on foreign investment, technology exports, overseas data transfers and acquisitions. The WSJ reported Beijing is separately identifying standout AI companies to place under export control. The offshore-then-sell route used by Chinese AI startups is now under direct scrutiny.

• Ministry comments on investigation of Meta acquisition of Manus · China SCIO

• Beijing warns AI startups against emulating the Meta deal · WSJ

OpenAI is rolling out ChatGPT for Health and OpenAI for Healthcare.

A free ChatGPT for Clinicians tier covers individually verified physicians, nurse practitioners, physician assistants and pharmacists with Cedars-Sinai, AdventHealth, HCA Healthcare and UCSF among the first deployments.

It follows ChatGPT Health on Wednesday, a consumer product that lets users import their medical records through b.well’s network of US providers, alongside Apple Health and others, initially for a waitlist. Over 230 million people ask ChatGPT health questions a week. Health chats are stored separately and not used to train its models.

• Introducing OpenAI for Healthcare · OpenAI

• Introducing ChatGPT Health · OpenAI

Microsoft put generative-AI use at about one in six of the world’s working-age population in the second half of 2025

The estimate comes from aggregated Microsoft telemetry, adjusted for OS share, device mix, internet access and population, and is up 1.2 points on H1. Adoption in the Global North grew twice as fast as the Global South, reaching 24.7% vs 14.1%. UAE leads at 64.0% of working-age adults, Singapore at 60.9%, and the US at 28.3%.

• Global AI adoption in 2025 · Microsoft

Friday 9 January

Terence Tao, one of the world’s foremost mathematicians, says AI solved a previously unsolved Erdős number-theory problem.

Problem #728 concerns when products of factorials divide one another and had not previously been solved. Tao said it was solved “more or less autonomously” by AI, describing the result as a milestone while qualifying how independently the system reached it, since humans selected the problem, operated the systems and subsequently checked and interpreted the proof.

• Tao on the Erdős #728 proof · Mathstodon

ALETH · OPEN ACCESS RESEARCH

aleth.co